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ABSTRACT 
 
I. Studies on the Metal-Catalyzed Cycloadditions of Isocyanates and Unsaturated Systems and II. 
Chromium-Catalyzed Synthesis of 1,3-Butadienes via (Silylmethyl)allenes. (August 2011) 
María Durán Galván, B.S., Instituto Tecnológico y de Estudios Superiores de Monterrey, 
Mexico 
Chair of Advisory Committee: Dr. Brian T. Connell 
 
 Metal-catalyzed cycloadditions of alkynes with isocyanates or nitriles are valuable tools 
for the synthesis of complex carbocycles and heterocycles. Although this transformation has 
been studied for over three decades, the cyclizations of disocyanates with 1,3-dienes or allenes 
are not known and the asymmetric cycloadditions of isocyanates are scarce. To expand the scope 
of these powerful reactions, we studied the semi-intramolecular metal-catalyzed cycloaddition of 
several unsaturated systems with isocyanates. Our results show that further work in this area is 
needed to suppress the formation of undesired homo-coupled adducts and obtain the bicyclic 
products in a more efficient manner. 
 1,3-butadienes are versatile building blocks in organic synthesis. Therefore, it is our 
interest to develop an efficient method for their preparation making 1,3-butadienes more 
available for the organic chemist. A number of methods are known for the synthesis of these 
compounds, but the majority of them present problems such as poor regioselectivity, low atom 
economy, or require the use of toxic or non-readily available reagents. In order to develop a 
more effective synthesis, we employed (allenylmethyl)silanes as intermediates for the 
preparation of 1,3-butadienes utilizing (4-bromobut-2-ynyl)trimethylsilane as a diene equivalent.  
 iv 
A Nozaki-Hiyama-Kishi type transformation was used for the highly regioselective preparation 
of (trimethylsilyl)methylallenic alcohols from aldehydes and ketones. In addition, several 
tridentate bis(oxazolinyl)carbazole ligands were synthesized and used for the enantioselective 
synthesis of allenic alcohols. Carbazole ligands synthesis was achieved by the Suzuki coupling 
of carbazoles with different boronic acids followed by carbonylative amidation and cyclization. 
We report an efficient new method for the desilylation of allenic alcohols providing a variety of 
secondary and tertiary 1,3-butadienylcarbinols. Furthermore, our interest in extending this 
methodology led us to the discovery of a novel synthesis of 2-aminomethyl-1,3-dienes from N-
tosyl imines.  
 v 
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1. INTRODUCTION TO THE METAL-CATALYZED CYCLOADDITIONS OF 
ISOCYANATES 
 
1.1.  Background 
 Metal-catalyzed cycloadditions have shown to posses immense value in the synthesis of 
complex carbocycles and heterocycles that can potencially be used in the total synthesis of 
natural products.1 Particularly, the cycloaddition of alkynes to isocyanates or nitriles can be a 
powerful tool in the synthesis of nitrogen containing heterocycles such as pyridines and 
pyridones.2 These atom economic transformations allow the formation of multiple carbon-carbon 
bonds in one step with high regio- and chemoselectivity.  
 Although Yamazaki and Hong reported the first example of a metal-mediated 
cycloaddition involving isocyanates in 1977,3 only few methodologies have thus far been 
developed. Moreover, the majority of the reports published to date include the inter- or 
intramolecular [2+2+2] cycloaddition of alkynes to isocyanates, and only two asymmetric 
cycloadditions of isocyanates have been reported. Some of the first transformations required 
high temperatures to give the desired product usually in low to moderate yields. These seminal 
reports are described below. 
 In the intermolecular cobalt(I)-mediated cycloaddition reported by Yamazaki and Hong3, 
cobalt cyclopentadiene complex 1.1 was reacted with an isocyanate species to produce pyridones 
1.3 in 37-81% yields. Temperatures as high as 130 °C were required for the cycloaddition to take 
place. (Scheme 1.1) 
 
 
 
 
This dissertation follows the style of the Journal of the American Chemical Society.1 
 
 2 
Scheme 1.1. Cobalt (I)-mediated synthesis of pyridones. 
 
  
 Yamazaki and Hong subsequently reported the first cobalt-catalyzed [2+2+2] 
cycloaddition of isocyanates with several acetylenes to obtain pyridones 1.6 and 1.7.3 As 
depicted in Scheme 1.2, a mixture of regioisomers was obtained when unsymmetrical alkynes 
were employed giving moderate yields.  
 
Scheme 1.2. Cobalt-catalyzed cycloaddition of phenylisocyanate with alkynes. 
 
 
 The cobalt-catalyzed [2+2+2] cycloaddition seems to follow the general mechanism 
shown in Scheme 1.3. First, the metal coordinates with two alkyne molecules or one diyne 
forming 1.9. Next metallacyclopentadiene 1.10 is formed via an oxidative coupling. In the 
following step, the intermediate coordinates to an isocyanate, and after a migratory insertion the 
seven-membered ring 1.11 is formed. Finally, a reductive elimination occurs to give the desired 
pyridone 1.12 and to regenerate the catalyst. This mechanism can be applied to [2+2+2] 
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cycloadditions catalyzed by other metals such as rhodium, ruthenium and nickel with the 
corresponding modifications depending on the reaction conditions.4 
 In addition to cobalt, nickel was also one of the first metals used in an isocyanate 
cycloaddition. Hoberg and Oster developed a nickel(0)-mediated [2+2+2] cycloaddition between 
phenyl isocyanate and different alkynes to afford the corresponding pyridones 1.14. (Scheme 
1.4)5 This cycloaddition required milder conditions than the work developed by Yamazaki et al.  
Unfortunately, the yields obtained were only in the range of 12 to 44%. 
 
Scheme 1.3. Mechasnim for the cobalt-catalyzed cyclization of isocyanates. 
 
 
Scheme 1.4. Nickel-catalyzed synthesis of pyridones. 
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 The first partially intramolecular [2+2+2] cycloaddition of 5-isocyanatoalkynes 1.15 to 
alkynes was achieved by Vollhardt and Earl6 using CpCo(CO)2 as a catalyst. High 
regeoselectivity is observed during this transformation due to the preference of the silyl group in 
the alkyne to be located adjacent to the carbonyl group. Vollhardt and Earl applied this 
methodology in a formal total synthesis of the antitumor agent camptothencin 1.18 (Scheme 
1.5).7 
 
Scheme 1.5. Cycloaddition of 5-isocyanatoalkynes with alkynes  
 
 
 Pioneering work of Yamazaki, Hong and Vollhardt established the foundation for the 
development of different methodologies for the metal-catalyzed cyclization of isocyanates. 
Recently, the scope of the metal-catalyzed cycloadditions of isocyanates has expanded and 
procedures utilizing milder conditions while obtaining higher yields and better regioselectivity 
have been reported. The cycloaddition of symmetric 1,6-diynes 1.19 with isocyanates has 
become one of the most extensively studied transformations in this area, since the utilization of 
diynes allows the reduction in the regioselectivity problems plaguing intermolecular 
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cycloadditions. (Scheme 1.6) Itoh, Maryanoff, Loui and Tanaka have independently 
accomplished these novel cycloadditions by using ruthenium, nickel, cobalt and rhodium 
catalysts.  
 
Scheme 1.6. General scheme for the metal-catalyzed synthesis of pyridones. 
 
 
 In 2001, Itho and co-workers reported the cycloaddition of !,!-diynes 1.19 (R1=H) with 
isocyanates to produce bicyclic pyridones 1.21. This transformation was accomplished in the 
presence of a catalytic amount of Cp*Ru(COD)Cl8 in 1,2-Dichloroethane under reflux. (COD = 
1,5cyclooctadiene, Cp*=n5-C5Me5) The use of this ruthenium catalyst allowed the formation of 
pyridones under mild conditions and with good yields (58-93%) following the mechanism 
depicted in Scheme 1.3. However, the competing dimerization of the diyne 1.19 to form the 
aromatic compound 1.22 was also observed. This side reaction was suppressed by dropwise 
addition of the diyne to a solution of the catalyst and the corresponding isocyanate in 1,2-
dichloroethane. Similarly, Marianoff reported the CpCo(CO)2 catalyzed cyclization of !,!-
diynes with isocyanates to form macrocylic pyridones in 30-65% yields. 9   
 Louie et al. developed the nickel(0)-catalyzed partially intramolecular cycloadditions. In 
this report, internal 1,6-diynes were coupled with aryl and alkyl isocyanates to produce the 
desired pyridones 1.21 in 61-99% yield.10 The reaction conditions were optimized using 
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Ni(COD)2 as a source of nickel(0) in toluene at room temperature and N-heterocyclic carbenes, 
such as SIPr, as ligands. In this case, the undesired dimerization reaction that leads to 1.22 was 
not observed under the optimized reaction conditions. In addition to the intramolecular reaction 
described above, Louie and co-workers achieved the intermolecular cyclization of isocyanates 
and alkynes. As shown in Scheme 1.7, when 3-hexyne was mixed with phenyl isocyanate in the 
presence of Ni(COD)2/SIPr, the corresponding pyridone 1.24 was obtained in 90% yield.10 
Nevertheless, when a large excess of phenyl isocyanate is used, a mixture of products is 
observed. In this case, pyrimidine-diones 1.26 are obtained as the minor product. Furthermore, 
when more hindered alkynes are used (such as 1-trimethylsylil-1-propine 1.25) pyrimidine-
diones are obtained as a single product.11 
 
Scheme 1.7. Nickel-catalyzed cycloadditions of phenylisocyanate and alkynes. 
 
 
 
  These observations concur with the mechanism previously proposed by Hoberg and 
Oster,5 in which the nickel catalyst reacts with one molecule of isocyanate and one alkyne to 
form intermediate 1.27, instead of the proposed metallacycle for the cobalt or ruthenium 
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catalyzed reactions. (Scheme 1.3).  Such an intermediate can follow two different paths reacting 
either with an isocyanate or with an alkyne moiety. When the isocyanate is present in excess and 
the substituents in the alkyne are bulky, the insertion of another molecule of isocyanate is 
favored versus the insertion of the alkyne and dione 1.26 is formed. Steric effects have an 
important role in this transformation due to the presence of bulky ligands such as SIPr.11  
 Tanaka and co-workers have developed a number of [2+2+2] cycloadditions catalyzed 
by the cationic rhodium complex [Rh(COD)2]BF4 and BINAP-type ligands such as H8-BINAP 
(Figure 1.1). Although the main focus of this research group has been the development of 
enantionselective [2+2+2] cycloadditions of alkynes they have also reported 
heterocycloadditions with nitriles, isocyanates and thioisocyanates.12 One of these examples 
involves the [2+2+2] cycloaddition of 1,6-diynes with isocyanates catalyzed by [Rh(COD)2]BF4/ 
H8-BINAP in dichloromethane at room temperature.13 Similar to the methodologies developed 
by Itoh and Louie, this reaction can take place with aryl, alkyl, or cyclohexyl isocyanates; 
additionally, terminal or internal diynes can be used for this transformation. (Scheme 1.6) 
 
 
 
Figure 1.1. Bidented phosphine ligands.  
 
  Tanaka et al. also developed the reaction of unsymmetrical diynes 1.28 with isocyanates 
to create axially chiral pyridones 1.30. The transformation was achieved in the presence of 
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[Rh(COD)2]BF4 and (R)-DTBM-SEGPHOS (Figure 1.1) in good yields and high 
enantionselectivity as shown in Scheme 1.8. This constitutes the first enantioselective 
cycloaddition of isocyanates. 
 
Scheme 1.8. Rhodium-catalyzed synthesis of axially chiral pyridones. 
 
 
  An additional report from Tanaka and co-workers describes the first semi-intramolecular 
[4+2] cycloaddition of 4-alkynals with isocyanates to form six-membered heterocycles.14 
(Scheme 1.9) This transformation was accomplished in the presence of [Rh(COD)2]BF4 as a 
catalyst and dppp (1,3-bis(diphenylphosphino)propane) as a ligand in dichlorometane at room 
temperature.  
 
Scheme 1.9. Cycloaddition of 4-alkynals with isocyanates.  
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  All the cycloadditions discussed thus far involve the cyclization of isocyanates with 
alkynes to give unsaturated products. Consequently, the formation of a sp3-chiral center was not 
observed. Nevertheless, Yu and Rovis were able to achieve the enantioselective [2+2+2] 
cycloaddition of alkenyl isocyanates with alkynes.15 The use of an olefin allows the formation of 
a stereogenic center resulting in an enantioselective transformation accomplished in the presence 
of [Rh(C2H4)2Cl2]2 and the chiral taddol derivate 1.37 as a ligand. Yet the expected lactam was 
observed only in small amount, or not at all. Instead, the vinilogous amide 1.36 was obtained. 
This methodology was successfully applied to the total synthesis of (+)-lasubine II (Scheme 
1.10). 
 
Scheme 1.10. Enantioselective rhodium-catalyzed cycloaddition of isocyanates and olefins. 
 
 
  The formation of amide 1.36 can be explained by the proposed mechanism depicted in 
Scheme 1.11. After formation of the rhodium methalacycle, a CO migration occurs to give the 
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intermediate 1.39, which after a migratory insertion and a reductive elimination gives the 
observed vinylogous amide.  
  It can be observed that many highly efficient methods for the cyclization of isocyanates 
have been developed. Most of the transformations reported to date involve the [2+2+2] 
cyclization of isocyanates to alkynes and, unfortunately, the employment of other pi-systems is 
reduced. Furthermore, only two enantioselective reactions have been achieved. It can also be 
noted that, in most cases, better selectivity and yields are obtained with semi-intramolecular 
cyclizations. Hence, in order to expand the scope and utility of isocyanate cycloadditions, it was 
envisioned that isocyanates could react with functional groups other than alkynes (such as 
dienes, allenes and vinyl cyclopropanes) to generate heterocyclic products containing at least one 
stereogenic center.  
 
Scheme 1.11. Mechanism for the synthesis of vinilogous amide 1.36. 
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1.2. Results and discussion 
 
1.2.1. Intramolecular  [4+2] cycloadditions of isocyanates with dienes 
 Our initial efforts were focused towards the intramolecular cycloaddition of dienes with 
isocyanates. Having in mind the well known metal-catalyzed [4+2] cyclization of dienes with 
alkynes and allenes16 it was pictured that, utilizing isocyanates, this process could lead to six-
membered heterocycles. It is anticipated that the resulting bicylic amides will contain bridgehead 
nitrogen and one chiral center. (Scheme 1.12) 
 
Scheme 1.12. Proposed synhtesis of bicyclic amides. 
 
 
 In order to explore this transformation, isocyanate 1.48 was synthesized from the known 
aldehyde 1.46. As described in Scheme 1.13, 2,4 pentadienoic acid was obtained by the reaction 
of malonic acid with acrolein following decarboxylation by the procedure reported by Liang et 
al.17 Esterification of 2,4-pentadienoic acid, followed by DIBAL reduction and bromination 
provided 5-bromopenta-1,3-diene 1.43.18 The bromide was then mixed with 1.4519 in the 
presence of sodium anhydride to afford the corresponding tert-butyl ester 1.47a in 77% yield 
(Scheme 1.14). Next, the tert-butyl protecting group was removed in the presence of 
trifluoroacetic acid to give the desired acid in 83% yield. Although this method afforded the 
desired compound in good yield, the acid was not obtained in high purity. An alternative route is 
described in Scheme 1.15. Dimethyl 2-(2,2-dimethoxyethyl)malonate 1.45, obtained from the 
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 12 
alkylation of dimethyl malonate with 2-bromo-dimethoxyethane,20 was alkylated with 5-
bromopenta-1,3-diene. The product of the alkylation was then deprotected with ferric trichloride 
to obtain the corresponding aldehyde.21 Subsequently, aldehyde 1.46 was successfully oxidized 
to the acid under Pinnick oxidation conditions in quantitative yield. Acid 1.47 was treated with 
ethyl chloroformate to form a mixed anhydride from which, upon treatment with sodium azide, 
the corresponding acyl azide was obtained. Finally, Curtius rearrangement of the generated acyl 
azide provided the desired isocyanate in 43% yield.  
 
Scheme 1.13. Synthesis of 5-bromopenta-1,3-diene. 
 
Scheme 1.14. Synthesis of 3,3-bis(methoxycarbonyl)octa-5,7-dienoic acid 
 
Scheme 1.15. Synthesis of dimethyl 2-(isocyanatomethyl)-2-(penta-2,4-dien-1-yl)malonate.  
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 With the desired isocyanate prepared, the intramolecular [4+2] cyclization was studied.  
Unfortunately, no cycloadduct was observed in presence of rhodium catalyst. Furthermore, 
catalytic systems known to be highly reactive towards isocyanates, such as Ni(COD)2/SIPr, 
[Rh(COD)2]BF4/H8-BINAP and Ru(COD)Cp*, did not afford the desired product (Scheme 
1.16). 
 
Scheme 1.16. Metal-catalyzed attempted synthesis of bicyclic amides. 
 
 
1.2.2. Attempted [2+2+2] cycloaddition of phenyl isocyanate with diallylmalonate 
 Aiming for a cyclization that could lead to saturated pyridones, it was envisioned that 
bicyclic amides containing two stereogenic centers could be prepared by a [2+2+2] cyclization 
of isocyanates with olefins. The use of symmetric substrates during a semi-intermolecular 
cycloaddition will eliminate possible regioselectivity problems. The required substrate was 
synthesized by the alkylation of dimethyl malonate with allyl bromide in the presence of sodium 
hydride.22 (Scheme 1.17) Unfortunately, malonate 1.51 proved to be unreactive toward 
cyclization with phenyl isocyanate under several conditions (Scheme 1.18).  
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Scheme 1.17. Synthesis of dimethyl 2,2-diallylmalonate. 
 
 
Scheme 1.18. Attempted cyclization of dimethyl 2,2-diallylmalonate with phenylisocyanate. 
 
  
 At this point, our attention was focused in finding more reactive substrates that could 
also lead to saturated amides such as 1.52. It was envisioned that allenes could be used for this 
transformation, expecting a higher reactivity than olefins under this conditions.  
 
1.2.3. Synthesis and [2+2+2] cycloaddition of allenes with isocyanates 
 Allenes are known to undergo [2+2+2] cycloaddition reactions with alkynes in the 
presence of nickel23 and cobalt-based24 catalysts.  In addition, the rhodium-catalyzed [2+2+1] 
cycloadditions of diene-allenes in CO atmosphere have been developed.25 Based on this 
precedent, it was considered that alkenes or alkynes tethered to allenes could undergo  [2+2+2] 
cycloadditions with isocyanates to yield the desired bicyclic amides and to form at least one 
stereogenic center, as depicted in Scheme 1.19. 
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Scheme 1.19. Proposed cyclization of allenes with isocyanates.  
 
 
 Allene 1.57 was synthesized following the procedures reported by Molander26 and Itoh.27 
The commercially available but-2-yne-1,4-diol 1.53 was treated with thionyl chloride in the 
presence of pyridine to afford 4-chlorobut-2-yn-1-ol 1.54 in 31% yield.  Compound 1.54 should 
be handled with caution since is a very strong irritant. Afterwards, 1.54 was reacted with lithium 
aluminum hydride and then phosphorus tribromide to provide 4-bromobuta-1,2-diene 1.55 in 
60% yield. Dimethyl 2-(2-propenyl)malonate 1.56 was obtained from the alkylation of malonate 
with allyl bromide. Finally, allene 1.55 was used to alkylate 1.56 and the desired allene was 
obtained in 54% yield (Scheme 1.20).  
 
Scheme 1.20. Synthesis of dimethyl 2-allyl-2-(buta-2,3-dien-1-yl)malonate 
 
 
 Once compound 1.57 was synthesized, it was mixed with phenyl and benzyl isocyanates 
under numerous conditions. In the presence of a catalytic amount of rhodium complexes, such as 
[Rh(COD)2]BF4, [Rh(COD)Cl2]2 or [Rh(C2H2)2Cl]2,  cyclopentane 1.58 was observed by 1H 
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NMR analysis instead of the desired cycloadduct. The observed compound results from the 
competing intramolecular cycloisomerization of allene 57 (Scheme 1.21). As shown in Scheme 
1.22, Makino and Itoh previously achieved this transformation in the presence of a catalytic 
amount of [RhCl(COD)]2.27  
 
Scheme 1.21. Attempted rhodum-catalyzed cyclization of dimethyl 2-allyl-2-(buta-2,3-dien-1-
yl)malonate with isocyanates. 
 
 
Scheme 1.22. Intramolecular rhodum-catalyzed cyclization of dimethyl 2-allyl-2-(buta-2,3-dien-
1-yl)malonate27 
 
 
 The formation of product 1.58 can be explained following the mechanism depicted in 
Scheme 1.23. To commence, a rhodium (I) complex coordinates at the allenic "-bond leading to 
the formation of intermediate 1.57a. Next, oxidative cyclization affords metallacycle 1.57b, 
which undergoes a #-hydride elimination of the hydrogen situated at the bridgehead position to 
afford the corresponding complex 1.57c. Finally, metallacycle 1.57c gives the desired compound 
by a reductive elimination process and the catalyst is regenerated.  
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Scheme 1.23. Mechanism for the rhodium-catalyzed cycloisomerization of allenes.27 
 
 
 
  Because the [2+2+2] cycloaddition of isocyanates with alkynes is very well documented, 
it was decided to exchange the olefin moiety in the substrate for an alkyne, This eliminates the 
possibility of an intramolecular cycloisomerization reaction due to the absence of a #-hydrogen 
in metallacycle 1.60b. Thus, impeding the formation of the corresponding cycloadduct.  (Scheme 
1.24)  
 
Scheme 1.24. Formation of metallacycle 1.60b. 
 
 
 As shown in Scheme 1.25, the synthesis of the terminal alkyne 1.61 was accomplished 
by alkyation of dimethyl malonate 1.44 with propargyl bromide, and a subsequent alkylation 
with 4-bromobuta-1,2-diene 1.55, which provided the desired tethered allene in 96% yield.  
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Scheme 1.25. Synthesis of dimethyl 2-(buta-2,3-dien-1-yl)-2-(prop-2-yn-1-yl)malonate. 
 
 
 Having prepared the tethered alkylallene 1.61, it was mixed with phenyl and benzyl 
isocyanates in the presence of different rhodium complexes. Although the starting material was 
consumed, the desired pyridone was not obtained. (Scheme 1.26) It is hypothesized that 
compound 1.61 could have dimerized. Homo-coupled products have been previously identified 
in  [2+2+2] cycloadditions with terminal alkynes (See Scheme 1.6).8b In addition, the formation 
of aromatic compounds resulting from the known alkyne cyclotrimerization is also possible 
(Scheme 1.27).28  
 
Scheme 1.26. Attempted cyclization of 1.61 with isocyanates.  
 
 
Scheme 1.27. Cyclotrimerization of alkynes. 28 
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 Previous reports of nickel-catalyzed cyclizations of isocyanates with internal 1,6-diynes 
describe the synthesis of 2-pyridones suppressing the formation of the undesired diyne dimer or 
trimer10. Therefore, it was speculated that a different outcome might be obtained by utilizing 
internal alkynes. In order to explore this possibility, internal alkyne 1.65 was synthesized by 
alkylation of dimethylmalonate giving the corresponding product 1.64 in 44% yield. To 
complete the synthesis malonate 1.64 was alkylated with allene bromide 1.55 in 92% (Scheme 
1.28).  
 
Scheme 1.28 Synthesis of dimethyl 2-(but-2-yn-1-yl)-2-(buta-2,3-dien-1-yl)malonate. 
 
 
 Interestingly, preliminary results show the cycloaddition of alkyne 1.65 to isocyanates in 
the presence of [Rh(COD)2]BF4 and BINAP, produced pyridone 1.67 whose can be explained by 
the isomerization of the expected product 1.66, as shown in Scheme 1.29. The synthesis of 
pyridone 1.67 was previously achieved by the nickel-catalyzed cyclization of diyne 1.19 with 
phenylisocyanate and described in Scheme 1.6. In addition, a major by-product was identified by 
mass spectroscopy as the homo-coupled adduct of 1.65. A plausible structure for this adduct is 
shown in Figure 1.2, anticipating the favored formation of an aromatic adduct as it as been 
observed in previous metal-catalyzed cyclization reactions involving alkynes.8b Pyridone 1.67 
and the homo-coupled product were isolated in a 1:1 ratio.  
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 With this promising result, it was decided to study the cycloaddition of disubstituted 
allenes, aiming to avoid the isomerization of the desired product and not to lose the sterogenic 
center in the pyridone.  To accomplish this, allene 1.70 was synthesized as described in Scheme 
1.30. First, following the procedure reported by Cook and Danishefsky,29 1-bromo-2-butyne was 
mixed with formaldehyde in the presence of indium to obtain the corresponding allenyl alcohol. 
After that, the alcohol was brominated with PBr3 to give allene bromide 1.69, which was utilized 
to alkylate malonate 1.64 and complete the synthesis of the desired disubstituted allene.  
 
Scheme 1.29. Rhodium-catalyzed cyclization of 1.61 with phenylisocyanate. 
 
 
Figure 1.2. Homo-coupled adduct of alkyne 1.65. 
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Scheme 1.30. Synthesis of dimethyl 2-(but-2-yn-1-yl)-2-(2-methylbuta-2,3-dien-1-yl)malonate. 
 
 
 Preliminary results showed that mixing 1.70 with phenyl isocyanate in presence of 
[Rh(COD)2]BF4/BINAP afford the desired amide 1.71 (Scheme 1.31). The presence of the amide 
was determined by crude 1H NMR and mass spectroscopy. The desired amide was also obtained 
using benzyl isocyanate. Formation of the desired adduct can be explained by the mechanism 
depicted in Scheme 1.32. After the rhodium catalyst coordinates to the p-system of the allene 
and alkyne, intermediate 1.72 undergoes an oxidative coupling to afford rhodium metallacycle 
1.74. Next, coordination to a molecule of isocyanate and migratory insertion give 1.75. Finally, a 
reductive elimination occurs to afford bicyclic amide 1.71 and regenerate the catalyst. 
Unfortunately, further optimization, including lowering the concentration of the starting material 
and reducing the temperature of the reaction, did not increase the yield of the desired product. It 
can be deduced that the main product remains to be a homo-coupled adduct of 1.70, identified by 
mass spectroscopy. 
 
Scheme 1.31. Synthesis of bicyclic amide 1.71. 
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Scheme 1.32. Pausible mechanism for the formation of 1.71. 
 
 
 
1.2.4. Enantioselective [2+2+2] cycloaddition allene-isocyanates with alkynes 
 Bicyclic compounds containing bridgehead nitrogen atoms are recurrent in numerous 
natural products such as alkaloids.1b Therefore, transformations capable to produce such moieties 
in an efficient manner have high synthetic value. It is our intention to develop a method from 
which six and seven-membered N-heterocycles can be obtained in an asymmetric fashion. The 
metal-catalyzed [2+2+2] cycloaddition of alkenylisocyanates and alkynylisocyanates with 
alkynes were independently achieved by Vollhardt6 and Rovis.15 These cyclizations provide 
bicyclic pyridones containing a bridgehead nitrogen which, as Vollhardt and Rovis have 
demonstrated, can be useful in the Total Synthesis of alkaloid Natural Products. Unfortunately, 
the methodology developed by Vollhardt only affords unsaturated pyridones (compound 1.17 in 
Scheme 1.5) and no chiral centers are generated. Considering these precedents and aiming to 
minimize possible regioselectivity problems in the cyclization of allenes with isocyanates we 
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became interested in the development of a rhodium-catalyzed [2+2+2] cycloaddition of 1,7-
alleneisocyanates with alkynes to yield bicyclic lactams. (Scheme 1.33)   
 
Scheme 1.33. Proposed synthesis of bicyclic lactams. 
 
 
 
 The synthetic strategy followed for the preparation of allene-isocyanates 1.74 was 
similar to that of isocyanate 1.48 (Scheme 1.34). First, malonate 1.6720 was alkylated with 4-
bromobuta-1,2-diene 1.47 to produce acetal 1.72. Unfortunately, the desired acid was not 
obtained under Pinnick oxidation conditions. Thus this cyclization reaction was not explored.  
 
Scheme 1.34. Towards the synthesis of 3,3-bis(methoxycarbonyl)hepta-5,6-dienoic acid. 
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1.3. Summary and conclusions  
 The metal-catalyzed [2+2+2] cycloaddition of alkynes and isocyanates is a powerful 
synthetic tool that has been extensively studied. Aiming to expand this methodology to the use of 
olefins and allenes, several cyclization substrates were synthetized.  
Although the cyclization reactions were attempted under numerous conditions for a variety of 
substrates, the desired adducts were not obtained or were synthetized in poor yields. Olefin-
containing substrates 1.48 and 1.51 proved to be unreactive towards cyclization in the presence 
of rhodium and, in the case of the latter, nickel and ruthenium catalyst.  
 On the other hand, cyclization reactions of allenes and alkynes were plagued with 
chemoselectivity problems. In the case of tethered alkene-allene 1.57, only the product of a 
cycloisomerization reaction 1.58 was obtained. Compound 1.61 containing a terminal alkyne 
moiety did not afford the desired product. Is hypothesized that the corresponding homo-coupled 
product of 1.61 was formed. 
 Interestingly, tethered alkyne-allene 1.65 afforded an unsaturated pyridone, product of 
the isomerization of the expected compound. In an attempt to minimize the formation of 
undesired byproducts, methylallene 1.70 was synthetized and submitted to the cyclization 
conditions with phenyl isocyanate to afford the corresponding cycloadduct in 23% yield. 
Although the desired product was obtained, we were not able to increase the percent yield and 
the homocoupled product remained as the major adduct. 
  Finally, aspiring to the synthesis of pyridones containing a bridgehead nitrogen, the 
synthesis of thetered allene-isocyanates was attempted. Unfortunately, Pinnick oxidation of 
aldehyde 1.76 did not afford the corresponding acid, thus the synthesis of the desired isocyanate 
was not completed. Other conditions for the oxidation of 1.76 remain to be explored. Having 
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isocyanate 1.72 available will offer an exciting opportunity to study the semi-intramolecular 
reaction of isocyanates with allene and alkynes.  
 While the cyclization of isocyanates with alkynes and olefins can be achieved using 
different types of catalyst and conditions, additional studies to expand the scope of these 
transformations are needed. Further improvements that allow the asymmetric synthesis of 
saturated pyridones will be necessary to achieve the synthesis of more complex organic 
compounds. Such studies will increment the value of this transformation as a tool for the 
synthesis of nitrogen-containing natural products.  
 
1.4. Experimental section 
 
1.4.1. General information 
 All reactions were performed under an argon atmosphere in oven-dried glassware with 
magnetic stirring. 1,2-dichloroethane was distilled from CaH2 under an argon atmosphere before 
use. THF, CH2Cl2 and Toluene were dried with a solvent purification system. Other 
commercially available reagents were used as received. Reactions were monitored by analytical 
thin layer chromatography using 0.25 mm glass-backed silica gel plates. Flash column 
chromatography was performed using silica gel (230-400 mesh). Visualization was 
accomplished by UV light and potassium permanganate.  
 1H NMR spectra were recorded at 300 MHz and referenced to CDCl3 (" 7.27). 1H NMR 
coupling constants (J) are reported in Hertz (Hz) and multiplicities are indicated by: s (singlet), d 
(doublet), t (triplet), q (quartet), m (multiplet), dt (doublet of triplets), dd (doublet of doublets), 
ddd (doublet of doublet of doublets). Proton-decoupled 13C NMR spectra were recorded at 75 
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MHz and reported relative to CDCl3 (" 77). Infrared Spectra were obtained as thin film on NaCl 
plates.  
 dimethyl-2-(2-oxoethyl)-2-(penta-2,4-dien-1-yl)malonate(1.46)21: 
Sodium hydride (72 mg of a 60% dispersion in mineral oil, 1.87 mmol) 
was added to a round bottom flask followed by addition of 150 mL of 
THF. Next, dimethyl 2-(2,2-dimethoxyethyl)malonate30 1.45 (330  mg, 1.5 mmol) was added 
slowly and the reaction mixture was stirred for 30 min. After this time, (E)-5-bromopenta-1,3-
diene31 (288 mg, 1.95 mmol) was added and the mixture was stirred at r.t for 2 h. A saturated 
solution of NH4Cl was added to the mixture followed by extractions with diethyl ether (three 
times). The combined organic phases were dried over Mg2SO4 and concentrated under reduced 
pressure. The residue was pufiried by column chromatography (15% ethyl acetate in hexanes) to 
give the corresponding acetal as a clear oil (299 mg, 1.048 mmol, 70%). Then, the pure acetal 
was dissolved in acetone (26 mL) and FeCl3·SiO2 (175 mg, 0.11 mmol) was added. The mixture 
was stirred for 1 h, filtrated though florisil and washed with ethyl acetate. The solvent was 
removed under recurred pressure and the residue was purified by column chromatography (15% 
ethyl acetate in hexanes) to give a clear oil (90 mg, 0.37, 70%). 1H NMR (CDCl3, 300 MHz) " 
9.7 (s, 1 H), 6.30 (ddd, J = 10.5, 10.5, 16.7 Hz, 1 H), 6.11 (dd, J = 10.5, 15.44 Hz, 1 H), 5.52 (dt, 
J = 7.58, 14.18 Hz, 1 H), 5.11 (d, J = 16.36 Hz, 1 H), 5.08 (d, J = 10.19 Hz, 1 H), 3.78 (s, 6 H), 
3.01 (s, 2 H), 2.83 (d, J = 8.00 Hz, 2 H); 13C NMR (75 MHz, CDCl3) " 198.9, 170.6, 135.4, 
136.1, 127.4, 117.5, 55.1, 53.2, 46.5, 37.4; IR (thin film) 2960.8, 1744.0, 1430.2, 1208.2 cm-1; 
MS (ESI) calcd for C12H16O5 (M + Li) 247.1158, found 247.1225. 
 
 (E)-1-tert-butyl 2,2-dimethyl hepta-4,6-diene-1,2,2-tricarboxylate 
(1.47a): Sodium hydride (2.1 g of 60% dispersion in mineral oil, 52.7 CO2t-BuMeO2C
MeO2C
MeO2C
MeO2C
O
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mmol) was added to a round bottom flask followed by addition of 150 mL of THF. Next, 2-tert-
butyl 1,1-dimethyl ethane-1,1,2-tricarboxylate19 (10.8 g, 44 mmol) was added slowly and the 
reaction mixture was stirred for 30 min. After this time, (E)-5-bromopenta-1,3-diene31 (11 g, 
81.8 mmol) was added and the mixture was stirred at 80 °C overnight. A saturated solution of 
NH4Cl was added to the yellow mixture followed by extractions with diethyl ether (three times). 
The combined organic phases were dried over Mg2SO4 and concentrated under reduced pressure. 
The residue was purified with column chromatography (8-15% ethyl acetate in hexanes) to 
afford the desired compound (6.02 g, 19.2 mmol, 77%). 1H NMR (CDCl3, 300 MHz) " 6.32 
(ddd, J = 10.4, 10.4 17.4 Hz, 1 H), 6.12 (dd, J =10.9, 14.9 Hz, 1 H), 5.57 (dt, J = 7.9, 14.9 Hz, 1 
H), 5.17 (d, J = 17.5 Hz, 1 H), 5.07 (d, J = 9.6 Hz, 1 H), 3.77 (s, 6 H), 2.9 (s, 2 H), 2.81 (d, J = 
7.7 Hz, 2 H), 1.46 (s, 9 H); 13C NMR (75 MHz, CDCl3) " 176.0, 170.5, 136.4, 135.5, 127.5, 
116.8, 81.2, 55.7, 52.7, 38.7, 36.6, 27.9; MS (ESI) calcd for C16H24O6  (M + H) 313.1651, found 
313.1756. 
 
 3,3-bis(methoxycarbonyl)octa-5,7-dienoic acid (1.47): Method 1: 1-
tert-butyl 2,2-dimethyl hepta-4,6-diene-1,2,2-tricarboxylate 1.47a (1.11 
g, 3.5 mmol) was dissolved in CH2Cl2, After addition of trifluoroacetic acid (0.3 mL, 3.9 mmol), 
the mixture was stirred at r.t. for 3 hours. After this time more trifloroacetic acid was added (10.5 
mmol) and the mixture was refluxed overnight. After cooling to room temperature, the solution 
was washed with brine and extracted with 3 portions of ethyl acetate. The combined organic 
phases were dried over Na2SO4 and concentrated under reduced pressure. The desired compound 
was obtained as a clear oil (0.76 g, 2.96 mmol, 84%).  
 Method 2: dimethyl 2-(2-oxoethyl)-2-(penta-2,4-dien-1-yl)malonate21 1.46 (90 mg, 0.37 
mmol), was dissolved in THF/tBuOH (2 mL). Then, 2-methyl-2-butene (1.15 mL, 11.07 mmol) 
MeO2C
MeO2C
O
OH
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and NaH2PO4 (0.4 g, 2.9 mmol) were added to the mixture followed by a solution of NaClO2 
(100 mg, 1.11 mmol) in water (1 mL). The slightly yellow solution was stirred at r.t. for 5 h. 
After this time, NaHCO3 was added and the mixture was acidified again with 1M HCl. Finally, 
the mixture was extracted with three portions of ethyl acetate, dried over Na2SO4 and 
concentrated under reduced pressure to afford a clear oil. The obtained product did not required 
further purification.  (94 mg, 2.96 mmol, 99%).  1H NMR (CDCl3, 300 MHz) " 6.28 (ddd, J = 
10.5, 16.7 Hz, 1 H), 6.11 (dd, J = 10.5, 15.44 Hz, 1 H), 5.52 (dt, J = 7.58, 14.18 Hz, 1 H), 5.11 
(dd, J = 1.56, 16.36 Hz, 1 H), 5.08 (dd, J = 1.49, 10.19 Hz, 1 H), 3.76 (s, 3 H), 3.01 (s, 2 H), 2.83 
(d, J = 8.00 Hz, 2 H); 13C NMR (75 MHz, CDCl3) " 175.7, 170.5, 136.5, 136.1, 127.3, 117.5, 
55.7, 53.2, 37.3, 37.0; IR (thin film) 2962.8, 1736.6, 1434.9 cm-1; MS (ESI) calcd for C12H16O6 
(M - H) 255.0874, found 255.0810. 
 
  dimethyl-2-(isocyanatomethyl)-2-(penta-2,4-dien-1-yl)malonate 
(1.48): Acid 1.47 (590 mg, 2.3 mmol) was dissolved in acetone (10 
mL) and cooled to 0 °C. Then, Et3N (0.35 mL, 2.5 mmol) is added to the solution and a white 
precipitate is formed. A solution of ethyl chloroformate (0.24 mL, 2.45 mmol) in acetone (1 mL) 
is added to the reaction solution dropwise. The mixture is stirred at 0°C for 45 minutes. After 
this time, a solution of sodium azide (0.3 g, 4.6 mmol) in H2O (1 mL) is added and the mixture is 
stirred for 3 hours. The pink mixture was poured into ice water (60 mL) and extracted with 
toluene (3 portions of 80 mL). The combined organic phases were dried over Na2SO4. The 
resulting yellow solution was heated to reflux, bubbling was observed starting at 80°C for at lest 
30 min. The mixture was refluxed for two hours and toluene was removed to afford a yellow oil 
90% pure (150 mg, 0.6 mmol, 45%). 1H NMR (CDCl3, 300 MHz) " 6.27 (ddd, J = 10.2, 10.2, 
16.8 Hz, 1 H), 6.11 (dd, J = 10.47, 14.5 Hz, 1 H), 5.54 (dt, J = 7.88, 14.75 Hz, 1 H), 5.11 (d, J = 
NMeO2C
MeO2C
O
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16.6 Hz, 1 H), 5.04 (d, J = 10.5 Hz, 1 H), 3.74 (s, 6 H), 3.64 (s, 2 H), 2.71 (d, J =7.57 Hz, 2 H); 
13C NMR (75 MHz, CDCl3) " 169.4, 136.4, 129.3, 128.4, 126.4, 117.7, 58.5, 53.2, 44.9, 34.8; IR 
(thin film) 3037.8, 2264.3, 1717.4, 1492 cm-1; MS (CI) calcd for C12H15NO5 (M + H) 254.10, 
found 254.2. 
 
dimethyl 2,2-diallylmalonate (1.51)22: Sodium hydride (2.2 g of 60% 
dispersion in mineral oil, 92 mmol) was dissolved in THF (100 mL). 
Dimethyl malonate (2.6 mL, 23 mmol) was added dropwise at 0 °C and the solution was stirred 
for 1hr.  Allyl bromide (8.8 mL, 103.5 mmol) was then added and the mixture was refluxed for 3 
h. After cooling to r.t., the mixture was poured into a saturate solution of NH4Cl and it was 
extracted with three portions of ether. The combined organic phases were dried over MgSO4 and 
concentrated under reduced pressure to afford a yellow oil. The residue was purified by column 
chromatography (15% ethyl acetate in hexanes) to afford the desired compound as a clear oil 
(2.72 g, 12.7 mmol, 56%). 1H NMR (CDCl3, 300 MHz) " 5.76-5.61 (m, 2 H), 5.17 (m, 2H), 5.12 
(m, 2 H), 3.75 (s, 6 H), 2.68 (dt, J = 1.25, 7.30 Hz, 4 H); 13C NMR (75 MHz, CDCl3) " 171.0, 
132.2, 119.0, 57.5, 52.2, 36.8; MS (CI) calcd for C11H16O4 (M + H) 213.1, found 213.0. 
 
dimethyl 2-allyl-2-(buta-2,3-dien-1-yl)malonate (1.57)27: Sodium 
hydride (0.66 g of a 60% dispersion in mineral oil, 16.5 mmol) was 
dissolved in THF (70 mL) and cooled to 0 °C. Then, dimethyl-2-allylmalonate32  1.56 (2.37 g, 
17.6 mmol) was added slowly via syringe. After stirring for 30 min a solution of 4-bromobuta-
1,2-diene26 1.55 in THF was added and the reaction mixture was stirred overnight at room 
temperature. A saturated solution of NH4Cl was added, and the mixture was extracted with three 
portions of diethylether.  The combined organic phases were washed with brine, dried over 
MeO2C
MeO2C
MeO2C
MeO2C
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MgSO4 and concentrated under reduced pressure. The residue was purified by column 
chromatography (5%-8% ethyl acetate in hexanes) to afford a clear oil (1.68 g, 7.32 mmol, 
55%). 1H NMR (CDCl3, 300 MHz) " 5.57 (m, 1 H), 5.16 (app d, J = 5.04 Hz, 1 H), 5.12 (s, 1 H), 
4.97 (m, 1H), 4.70 (dt, J = 2.53, 6.71 Hz, 2 H), 3.75 (s, 6 H), 2.71 (dt, J = 1.18, 7.48 Hz, 2 H), 
2.63 (dt, J =2.43, 8.00 Hz, 2 H); 13C NMR (75 MHz, CDCl3) " 210.1, 171.0, 132.2, 119.4, 84.1, 
74.6, 57.8, 52.4, 36.8, 31.8; MS (ESI) calcd for C12H16O4 (M + Li) 231.1249, found 231.1255. 
 
dimethyl 2-(prop-2-yn-1-yl)malonate (1.60):33  Sodium hydride (2.9 g of a 
60% dispersion in mineral oil, 72.8 mmol) was dissolved in THF and cooled 
to 0 °C. Then, dimethyl malonate (7.86 mL, 69.3 mmol) was added slowly via syringe. After 
stirring for 30 min, propargyl bromide (8.5 mL, 76.2 mmol) was added and the reaction mixture 
was refluxed overnight. A saturated solution of NH4Cl was added, and the mixture was extracted 
with three portions of ethyl acetate.  The combined organic phases were washed with brine, dried 
over MgSO4 and concentrated under reduced pressure. The residue was purified by column 
chromatography (4%-8% ethyl acetate in hexanes) to afford a clear oil (3.06 g, 18.0 mmol, 26 
%). 1H NMR (CDCl3, 300 MHz) " 3.81 (s, 6 H), 3.56 (t, J = 7.69 Hz, 1 H), 2.83 (app dd, J = 
2.67, 7.82 Hz, 2 H), 2.06 (t, J = 2.67 Hz, 1 H); 13C NMR (75 MHz, CDCl3) " 168.2, 78.9, 70.5, 
52.9, 50.8, 18.5; MS (ESI) calcd for C8H10O4 (M+Li) 177.0739 found 177.0751. 
 
 dimethyl 2-(buta-2,3-dien-1-yl)-2-(prop-2-yn-1-yl)malonate (1.61)34: 
Sodium hydride (0.16 g of a 60% dispersion in mineral oil, 4.1 mmol) was 
dissolved in THF (15 mL) and cooled to 0 °C. Then, dimethyl 2-(prop-2-yn-1-yl)malonate 1.6133 
(0.57 g, 3.4 mmol) was added slowly via syringe. After stirring for 30 min a solution of 4-
bromobuta-1,2-diene26 1.55 (0.5 g, 3.6 mmol) in THF was added and the white suspension was 
MeO2C
MeO2C
MeO2C
CO2Me
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stirred for 3 h. at room temperature. After this time, the mixture was poured into a saturated 
solution of NH4Cl, and extracted with three portions of ethyl acetate.  The combined organic 
phases were washed with brine, dried over MgSO4 and concentrated under reduced pressure. The 
residue was purified by column chromatography (25% ethyl acetate in hexanes) to afford a clear 
oil (0.71 g, 3.19 mmol, 94%). 1H NMR (CDCl3, 300 MHz) " 5.04-4.93 (m, 1 H), 4.72 (dt, J = 
2.37, 6.69 Hz, 2 H), 3.78 (s, 6 H), 2.89 (d, J = 2.74 Hz, 2 H), 2.81 (dt, J = 2.31, 7.96 Hz, 2 H), 
2.05 (t, J = 2.74 Hz, 1 H); 13C NMR (75 MHz, CDCl3) " 210.4, 170.2, 83.9, 78.9, 75.0, 71.7, 
57.4, 53.0, 31.8, 22.9; MS (ESI) calcd for C12H14NO4 (M+Li) 229.1052 found 220.1054. 
 
dimethyl 2-(but-2-yn-1-yl)-2-(buta-2,3-dien-1-yl)malonate (1.65)35: 
Sodium hydride (0.15 g of a 60% dispersion in mineral oil, 3.7 mmol) 
was dissolved in THF (30 mL) and cooled to 0 °C. Then, dimethyl 2-(but-2-yn-1-yl)malonate36 
1.64 (0.58 g, 3.1 mmol) was added slowly via syringe. After stirring for 30 min a solution of 4-
bromobuta-1,2-diene26 1.55 (0.46 g, 3.4 mmol) in THF was added and the suspension was stirred 
for 3 h. at room temperature. After this time, the mixture was poured into a saturated solution of 
NH4Cl, and extracted with three portions of ethyl acetate.  The combined organic phases were 
washed with brine, dried over MgSO4 and concentrated under reduced pressure. The residue was 
purified by column chromatography (15% ethyl acetate in hexanes) to afford a clear oil (0.71g, 
3.00 mmol, 95%). 1H NMR (CDCl3, 300 MHz) " 4.97 (m, 1H), 4.67 (m, 2 H), 3.7 (s, 6H), 2.80-
2.73 (m, 4H), 1.75 (s, 3 H); 13C NMR (75 MHz, CDCl3) " 210.3, 170.6, 100.2, 84.1, 74.8, 73.3, 
57.7, 52.9, 31.9, 23.2, 3.7. 
 
 
MeO2C
MeO2C
CH3
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dimethyl-1,4-dimethyl-3-oxo-2-phenyl-5,7-dihydro-2H-
cyclopenta[c]pyridine-6,6(3H)-dicarboxylate (1.67)10: The catalyst, 
[Rh(COD)2]BF4 (8.5 mg, 0.021 mmol) and BINAP (13.0 mg, 0.021 
mmol), were added to a 2-dram vial with a teflon cap inside a nitrogen drybox. Then, outside the 
drybox, degassed dry toluene (4 mL) was added by syringe. Allene 1.65 (100 mg, 0.42 mmol) 
and phenyl isocyanate (91 µL, 0.84 mmol) were sequentially added to the reaction mixture, 
which was stirred for 2 days. The solvent was removed under reduced pressure and the residue 
was purified by column chromatography (15% ethyl acetate in hexanes) to afford compound 
1.67 as a clear oil. 1H NMR (CDCl3, 300 MHz) " 7.51-7.43 (m, 4 H), 7.16 (m, 2H), 3.82 (s, 6 H), 
3.50 (s, 2 H), 3.42 (s, 2H), 2.09 (s, 3H), 1.81 (s, 3H); IR (thin film) 1733.8, 1669.6, 1616.5, 
1566.2 cm-1; MS (ESI) calcd for C20H21NO5 (M+H) 356.1498 found 356.1515. 
 A fraction obtained from the column chromatography 
was identified as the homo-coupled product of 1.65. MS 
(ESI) calcd for C26H32O8 (M+H) 473.2175 found 473.2131. 
 
 
dimethyl-2-(but-2-yn-1-yl)-2-(2-methylbuta-2,3-dien-1-yl)malonate 
(1.70): Sodium hydride (104 mg of a 60% dispersion in mineral oil, 
1.03 mmol) was dissolved in THF (15 mL) and cooled to 0 °C. Then, dimethyl 2-(but-2-yn-1-
yl)malonate 1.6436 (0.36 g, 1.99 mmol) was added slowly via syringe. After stirring for 15 min, 
4-bromo-3-methylbuta-1,2-diene 1.6929 (0.32 g, 2.19 mmol) was added slowly, The mixture was 
stirred for 2 h at room temperature. After this time, the mixture was poured into a saturated 
solution of NH4Cl, and extracted with three portions of ethyl acetate.  The combined organic 
phases were washed with brine, dried over MgSO4 and concentrated under reduced pressure. The 
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residue was obtained as a clear oil (300 mg, 1.19 mmol, 60%). 1H NMR (CDCl3, 300 MHz) " 
4.58 (m, 2H), 3.72 (s, 6 H), 2.87 (q, J = 2.61 Hz, 2 H), 2.75 (t, J = 2.55 Hz, 2 H), 1.76 (t, J = 
2.62 Hz, 3 H), 1.70 (t, J = 3.21 Hz, 3H); 13C NMR (75 MHz, CDCl3) " 207. 3, 170.7, 93.5, 79.2, 
75.0, 73.8, 57.3, 52.8, 35.2, 23.1, 20.6, 3.7; IR (thin film) 2212.3, 1960.1, 1733.8, 1434.4, 1194.7 
cm-1; MS (ESI) calcd for C14H18O4 (M+Li) 257.1365 found 257.1307.  
 
dimethyl-1,4a-dimethyl-4-methylene-3-oxo-2-phenyl-3,4,4a,5-
tetrahydro-2H-cyclopenta[c]pyridine-6,6(7H)-dicarboxylate 
(1.71a): The catalyst, [Rh(COD)2]BF4 (812 mg, 0.03 mmol) and 
BINAP (18.0 mg, 0.03 mmol), were added to a 2-dram vial with a teflon cap inside a nitrogen 
drybox. Then, outside the drybox, degassed dry 1,2-dichloroethane (30 mL) was added by 
syringe. Allene 1.70 (120 mg, 0.6 mmol) and phenyl isocyanate (130 µL, 1.2 mmol) were 
sequentially added to the reaction mixture, which was stirred under reflux for 16 hours. The 
solvent was removed under reduced pressure and the residue was purified by column 
chromatography  (5-20% ethyl acetate in hexanes) to afford the title compound (50 mg, 0.13 
mmol, 26 %). MS (ESI) calcd for C21H23NO5 (M+Li) 376.1736 found 376.1762. Homo-coupled 
product observed by mass spectroscopy. MS (ESI) calcd for C28H36O8 (M+Li) 507.2570 found 
507.2654. 
 
dimethyl 2-benzyl-1,4a-dimethyl-4-methylene-3-oxo-3,4,4a,5-
tetrahydro-2H-cyclopenta[c]pyridine-6,6(7H)-dicarboxylate 
(171b): Following the procedure described for 1.71a, using 
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benzylisocyanate 1H NMR (CDCl3, 300 MHz): = " 7.51-7.15 (m, 5 H, HAr), 4.83 (s, 2H, 
C=CH2), 4.27 (s, 2H, CH2Ph), 3.66 (s, 6 H, OCH3), 2.93 (s, 2H, CH2), 2.68 (s, 2H, CH2), 1.90 (s, 
3H, CH3), 1.76 (s, 3 H, CH3).  
 MS (ESI+): m/z [M + H]+ calcd for C22H25NO5: 384.1811; found: 384.1859. 
 
4-dimethyl 2-(buta-2,3-dien-1-yl)-2-(2,2-dimethoxyethyl)malonate 
1.75: Sodium hydride (290 mg of a 60% dispersion in mineral oil, 7.25  
mmol) was mixed with THF (25 mL) and cooled to 0 °C. Then, dimethyl 
2- (2,2-dimethoxyethyl)malonate30 1.45 (960 mg, 5.8 mmol) was added slowly via syringe. After 
stirring for 15 min, 4-bromobuta-1,2-diene26 1.55 (784 mg, 5.9 mmol) was added slowly, The 
mixture was stirred for 2 h at room temperature. After this time, the mixture was poured into a 
saturated solution of NH4Cl, and extracted with three portions of ethyl acetate.  The combined 
organic phases were washed with brine, dried over MgSO4 and concentrated under reduced 
pressure. The residue was purified by column chromatography (5-8% ethyl acetate in hexanes) to 
afford the desired compound as a clear oil (1.04 g, 3.82 mmol, 65%). 1H NMR (CDCl3, 300 
MHz) " 4.88-4.99 (m, 1 H), 4.68 (dt, J = 2.39, 6.62 Hz, 2 H), 4.45 (t, J = 5.59 Hz, 1 H), 3.72 (s, 
6 H), 3.31 (s, 6H), 2.67 (dt, J = 2.46, 8.10 Hz, 2 H), 2.26 (d, J = 5.72 Hz, 2 H); 13C NMR (75 
MHz, CDCl3) " 210.2, 171.4, 102.2, 84.4, 75.02, 55.6, 53.9, 52.7, 35.9, 33.0; IR (thin film) 
2951.9, 2836.5, 1741.1, 1439.1 cm-1; HRMS (ESI) calcd for C13H20O6  (M + Li) 279.1420 found 
279.1347. 
 
 dimethyl 2-(buta-2,3-dien-1-yl)-2-(2-oxoethyl)malonate 1.76: Acetal 
1.75 (104 mg, 0.38 mmol) was dissolved in acetone (15 mL) and 
FeCl3·SiO2 (175 mg, 0.11 mmol) was added. The mixture was stirred for 1 h, filtrated though 
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florisil and washed with ethyl acetate. The solvent was removed under recurred pressure to give 
a clear oil (83 mg, 0.37 mmol, 99%). 1H NMR (CDCl3, 300 MHz) " 9.73 (s, 1H), 4.97 (m, 1 H), 
4.69 (dt, J = 2.36, 6.7 Hz, 2 H), 3.76 (s, 6H), 3.05 (s, 2H), 2.73 (dt, J = 2.38, 7.98 Hz, 2H).  
 36 
2. CHROMIUM-CATALYZED SYNTHESIS OF (SILYLMETHYL)ALLENES AND 
1,3-BUTADIENES   
 
2.1. Introduction  
 1,3-butadien-2-ylcarbinols are highly functionalized molecules attractive to organic 
chemists due to their versatility as building blocks in organic synthesis37 and the abundance of 
this motif in natural products. As an example, 1,3-butadien-2-ylcarbinol fragment is present in 
caseamembrol B and 12-(S)-hydroxylabda-8(17),13(16),14-trien-19-oic acid. (Figure 2.1) 
Caseamembrol shows significant cytotoxic activity against human prostate tumor cells and was 
isolated from extracts of Casearia membranacea.37j On the other hand, 12-(S)-hydroxylabda-
8(17),13(16),14-trien-19-oic acid is a terpenoid isolated from Thuja standishii that shows 
activity as a potential cancer preventive agent.37g  
 
 
Figure 2.1. 1,3-butadien-2-ylcarbinol fragments in natural products. 
 
 The usefulness of functionalized dienes in organic synthesis is illustrated in Scheme 2.1. 
Among the documented transformations of 1,3-butadien-2-ylcarbinols can be listed: Diels-Alder 
H CH3
OH
i-BuO2C
OHO
AcO
CH3
caseamembrol B
H
OH
OHHOOC CH3
12-(S)-hydroxylabda-8(17),13(16),14-trien-19-oic acid
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cycloadditions37a, allylation and ring closing metathesis to afford spirocyclic compounds38, 
gold37h and nickel37m catalyzed cyclizations to afford bicyclic compounds and oxidations to give 
vinylic epoxides.37e  
 
Scheme 2.1. Reactions of 1,2-butadien-2-ylcarbinols. 
 
 
 A number of methodologies have been developed for the synthesis of 1,3-butadien-2-
ylcarbinols. Early protocols include addition of Grignard39 and lithium40 reagents to aldehydes or 
epoxides (Scheme 2.2). The majority of these methods gave low regioselectivity, providing 
mixtures of 1,3-butadien-2-ylcarbinols and allenic alcohols. Therefore, methodologies involving 
the use of different organometallic reagents, such as tin41, boron42 and silicon37d,37e compounds, 
were developed to overcome regioselectivity problems and achieve modest to high 
enantioselectivities. 
R2
OHR1
N
Me
O
O
N
O
O
Me
H
H
R2 OH
R1
DA
R2
OH
O
TBSO
H3C
Ni cat. Ox.
O
R2
R1
RCM
Bri.
ii.
O
i-Pr
Pt cat.
i-PrR2=
R1= H
H3C
R2=
R1= H
 38 
Scheme 2.2. Addition of homoallenic organometallic reagents to aldehydes. 
 
 
 Unfortunately, the above-mentioned procedures require the preparation of non-readily 
available organometallic starting materials as well as the use of considerable amounts of toxic 
reagents. Recently, new approaches have emerged to avoid these drawbacks. (Scheme 2.3) 37a, 38, 
43 For instance, Chan et al. developed an indium-mediated coupling in aqueous media where the 
active organoindium intermediate is formed in situ.43c In more distinctive approaches, Alcaraz et 
al reported the homologation of chiral epoxy bromides while Diver and co-workers developed an 
alkyne-ethylene cross-methatesis protocol to provide the corresponding 1,3-butadien-2-
ylcarbinols.43a, 43b More recently, Yamamoto et al. reported an enantioselective protocol which 
allows the formation of 1,3-butadien-2-ylcarbinols with high enantioselectivity and moderate 
yields by directly coupling aldehydes with 4-bromobuta-1,2-diene.43d 
 Although the methods recently developed have overcome many of the limitations 
presented by early approaches, only a few enantioselective synthetic procedures are known and 
which present various drawbacks including limited functional group tolerance or low reactivity 
that results in modest yields. Hence, there is an interest in developing an alternate method for the 
synthesis of 1,3-butadien-2-ylcarbinols.  
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 39 
2.2. Asymmetric synthesis of butadienylcarbinols via (silyl)allenic alcohols from chromium-
catalyzed additions to aldehydes 
 
2.2.1. Background 
 (Allenylmethyl)silanes are powerful synthetic reagents capable of reacting with a wide 
variety of electrophiles to afford 1,3-dienyl-2-yl compounds.41d, 44 It is known that 
(trimethylsilyl)methyl allenic alcohols provide the corresponding 1,3-butadien-2-ylcarbinols by 
treatment with hydrofluoric acid.41d Previous synthesis of (trimethylsilyl)methyl allenic alcohols 
have a limited substrate scope and require the use of a propargylic stannane which is prepared by 
a lengthy 4-step synthesis (Scheme 2.4).41d, 45 Consequently, a novel, efficient method for the 
preparation of (trimethylsilyl)methyl allenic alcohols is desirable. 
 
Scheme 2.3. Syntheses of 4-bromobuta-1,2-dienes. 
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Scheme 2.3. Continued. 
 
 
 
Scheme 2.4. Titanium-catalyzed synthesis of (trimethylsilyl)methyl allenic alcohols.41d 
 
 
 Among the synthesis for allenic alcohols, Cr/Mn redox system catalyses the 
enantioselective allenylation of aldehydes with propargyl bromides or 4-bromobuta-1,2-diene 
(Scheme 2.5).46 The asymmetric allenylation utilizing tridentate bis(oxazoline) carbazole ligands 
2.4 developed by Nakada and co-workers is among these reports. These carbazole ligands 
attracted our attention because they proved to be an excellent source of chirality for these 
asymmetric Nozaki-Hiyama-Kishi type reactions.46c, 47 
 We envisioned that the chiral (trimethylsilyl)methyl allenic alcohols 2.2 can be prepared 
regioselectively by the chromium catalyzed allenylation of aldehydes with (4-bromobut-2-
ynyl)trimethylsilane 2.5 as a diene equivalent and utilizing the bis-oxazoline carbazole ligands 
2.4 (Scheme 2.6). Herein, we describe the racemic and enantioselective synthesis of 
(trimethylsilyl)methyl allenic alcohols and its transformation to 1,3-butadien-2-ylcarbinols. 
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Scheme 2.5. Asymmetric Nozaki-Hiyama-Kishi allenylation.46c  
 
 
Scheme 2.6.  Strategy towards 1,3-butadien-2-ylcarbinols. 
 
 
2.2.2. Synthesis of butadienylcarbinols via (silyl)allenic alcohols from chromium catalyzed 
additions to aldehydes 
 Initial studies focused on the synthesis of (trimethylsilyl)methyl allenic alcohols from 
aldehdyes. The propargylic bromide (4-bromobut-2-ynyl) trimethylsilane 2.5 was prepared from 
but-2-yn-1-ol by a two step procedure (Scheme 2.7).48  
 
Scheme 2.7.  Synthesis of (4-bromobut-2-ynyl) trimethylsilane 
 
 
 Benzaldehyde was combined with 2.5 in the presence of a catalytic amount of CrCl3, 2 
equiv Mn0 and 1.1 equiv TMSCl in THF. The desired allenic alcohol 2.2a was formed in 75% 
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yield after 16 h with excellent regioselectivity. More significantly, the corresponding 
regioisomer was not observed (Table 2.1, entry 1). To explore the scope of the reaction, various 
aldehydes were examined as substrates. Aromatic aldehydes containing meta substituents are 
excellent substrates for this reaction and afford the corresponding product in good yields (entry 
2). However, more sterically hindered aldehydes required a longer reaction time, but the desired 
product was obtained in good yield after 48 h (entries 3 and 9). Allenic alcohol 2.2d was 
obtained after only 16 hours despite the presence of an o-bromo substituent (entry 4). The 
formation of allenic alcohols proceeded rapidly with good yields with aromatic aldehydes 
containing electron-withdrawing substituents (entries 4, 5 and 6) and aliphatic aldehydes (entry 
7). When meta substituted aldehydes are used, the product is obtained with 59% yield (entry 8). 
In the case of p-methoxybenzaldeyde only, the desired product is obtained when CrCl2 is utilized 
for the allenylation reaction (entry 10). 
 A pausible mechanism for this allenylation reaction is described in Scheme 2.8.  Based 
on the mechanism for the catalytic redox Cr(II)/Cr(III) proposed by Fürstner et al.,46b a 
chromium II species inserts into the C-Br bond of 2.5 forming CrX3 and the corresponding 
organochromium nucleophile, which exist as a mixture of proparylic 2.10 and allenic 2.11 
species.. The organochromium nucleophile then reacts with the aldehyde, presumably via a 6-
membered transition state, forming chromium alcoxide 2.12, which reacts with TMSCl to 
liberate a second molecule of CrX3 and form silyl ether 2.13. Chromium (III) salts are reduced by 
manganese to CrX2, which starts again the catalytic cycle. The steric properties of the substrate 
are one of the factors that strongly influence the equilibrium between the propargylic 2.10a and 
allenylic 2.11a chromium species (See Table 2.2).49 The regioselectivity of this transformation 
can be explained by the formation of organochromium 2.10 over 2.11 avoiding unfavorable 
steric interactions between chromium and the silicon moiety.  
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Table 2.1. Scope of the chromium-catalyzed allenylation reaction.a 
 
a Reaction conditions: (4-bromobut-2-ynyl)trimethylsilane (2.5) (1.1 equiv), CrCl3 (20 mol%), 
Mn0 (2 equiv), TMSCl (1.1 equiv), THF, 16 h; 2 mL of 1 M HCl.  Isolated yields. b Reaction 
time: 48 h. c Reaction time: 12 h. d CrCl2 (10 mol%).   
 
 Encouraged by these results, we directed our attention to the development of a method 
for the asymmetric synthesis of (trimethylsilyl)methyl allenic alcohols. For this purpose, 
bis(oxazoline)carbazole 2.4b was prepared.47b, 50 Suzuki coupling of 2.14 with phenyl boronic 
acid afforded carbazole 2.16b. Then iodination, palladium-catalyzed carbonylative amidation 
and BF3·Et2O mediated cyclization afforded the corresponding carbazole. To confirm the 
enantiopurity, 2.4b was employed in the chromium-catalyzed allylation of benzaldehyde 
following the known procedure (Scheme 2.9).47b 
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Scheme 2.8. Proposed mechanism for the synthesis of allenic alcohols 2.2a. 
 
 
Table 2.2. Effect of propargyl bromide substitution on the regioselectivy of chromium-catalyzed 
allenylation.49 
 
entry R yield (%) acetylenic:allenic alcohols 
1 H 68 65:35 
2 C5H11 78 0:100 
3 Ph 77 0:100 
4 C6H11 75 0:100 
2 CrX2 CrX3
SiMe3
Br
SiMe3
X2Cr
Me3Si
R
OCrX2
MnMnX2
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Scheme 2.9. Synthesis of bis(oxazolike)carbazole 2.4b.47b, 50 
 
 
 
 When ligand 2.4b was utilized in THF (Table 2.3, entry 1), the desired alcohol (–)-2.2a 
was obtained after 20 h in 31 % ee. The ee value increased to 46% when CrCl2 was used (entry 
2). To optimize the reaction conditions, different solvents were explored (entries 3 to 6). No 
product was observed when 1,2-dimethoxyethane was used, while DMF and EtCN46c afforded 
the desired product with poor to moderate enantiomeric excess (entries 4 and 5). MeCN became 
the solvent of choice, increasing the ee value to 73%. Next, the effect of catalyst loading was 
studied (entries 7 and 8). Decreasing the amount of CrCl2 and ligand to 5 mol% had virtually no 
effect on the ee value (entries 6 and 7) but, when the amount was further reduced to 2.5 mol% 
the %ee decreased considerably (entry 8). A slight increase in the %ee value was observed with 
5 mol% of the catalyst and 2 equiv Mn0 (entry 9). Under these conditions, the starting material 
was completely consumed after 36 h (entry 10). Additional Mn0 (5 equiv) reduced the %ee 
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H Br
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H2SO4, H2O 2.17b; X=I, 34%
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(entry 11). When a bulkier silyl group such as DMPS was used as a substituent on the propargyl 
bromide, a decrease in the product yield and %ee was observed.   
 
Table 2.3. Optimization of enantioselective reaction conditions.a 
 
entry CrCl2(%) Mn0(equiv) solvent yield(%) ee(%)b 
1 10% CrCl3 1.5 THF 99 31 
2 10 1.5 THF 99 46 
3 10 1.5 DME 0 0 
4 10 1.5 DMF 74 8 
5 10 1.5 EtCN 95 48 
6 10 1.5 CH3CN 99 73 
7 5 1.5 CH3CN -- 72 
8 2.5 1.5 CH3CN -- 51 
9 5 2 CH3CN 91 75 
10c 5 2 CH3CN 99 78 
11 5 5 CH3CN -- 21 
a Reaction Conditions: (4-bromobut-2-ynyl)trimethylsilane (2.5) (1.5 equiv), 
CrCl2 (5 mol%), ligand 2.4b (5 mol%), Mn0 (2 equiv), TMSCl (1.1 equiv), 
i-Pr2NEt (0.3 equiv), 20 h; 2 mL of 1 M HCl. b Enantiomeric excess 
determined by chiral HPLC. c Reaction time: 36 h. 
 
 The reaction rate is not dependent on the base employed. On the other hand, the %ee is 
higher when i-Pr2NEt, 2,6-lutidine or pyridine is used (Table 2.4, entries 1 to 3). Bases with 
more steric hindrance such as 2,6-di-tert-butylpyridine, DBU or DABCO decreased the %ee 
value (entries 5, 9, and 10).  
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OO N
i-Pr i-Pr
2.4b
OH
TMS
O
H
Br
TMS
CrCl2, (5 mol%), 2.4b, Mn0
i-Pr2NEt, TMSCl, r.t., 20 h;
then 1 M HCl, 30 min
2.5
(–)-2.2a2.8
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Table 2.4. Screening of bases.a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.3. Synthesis of chiral bis(oxazoline)carbazole  ligands 
 After the reaction conditions were optimized with respect to solvent, catalyst loading, 
Mn0 and base, our aim was to explore the effects of carbazole ligands substitution on reaction 
yield and enantioselectivity. The general strategy for the synthesis of 2.4 was pictured as a 
coupling of di-halocarbazoles and a variety of boronic acids, followed by halogenation, 
carbonylative amidation and cyclization following Scheme 2.9. 
 First, we focused in the variation of the substituent on the oxazoline group of ligand 2.4. 
For this purpose, amides 2.19 were obtained from the palladium-catalyzed carbonylative 
N
H
PhPh
N
OO N
i-Pr i-Pr
2.4b
2.8a 2.5
(–)-2.2a
OH
TMS
O
H
Br
TMS
CrCl2, (5 mol%),2.4b, Mn0
base, TMSCl MeCN, r.t.
20 h; then 1 M HCl, 30 min
entry base %conversion ee(%)b 
1 i-Pr2NEt 91 78 
2 2,6-lutidine 97 74 
3 pyridine 99 68 
4 4-t-Bupyridine 85 26 
5 2,6-t-Bupyridine 99 40 
6 2-chloropyridine 86 52 
7 2-bromopyridine 95 52 
8 1,8-bis(dimethylamino)naphthalene 99 45 
9 DBU 99 29 
10c DABCO 98 24 
11 K2CO3 95 11 
a Reaction Conditions: (4-bromobut-2-ynyl)trimethylsilane 2.5 (1.5 
equiv), CrCl2 (5 mol%), ligand 2.4b (5 mol%), Mn0 (2 equiv), TMSCl 
(1.1 equiv), i-Pr2NEt (0.3 equiv), 20 h 2 mL of 1 M HCl. b 
Enantiomeric excess and conversion determined by chiral HPLC. 
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coupling of diiodocarbazole 2.17 and different aminoalcohols, derived by reduction of the 
corresponding chiral amino acids. (Table 2.5) Bis-oxazoline 2.4a was isolated in 48% yield after 
two steps when subjected to MeSO2Cl mediated cyclization (entry 1). As it was mentioned 
before, compounds 2.4b and 2.4c were obtained following literature procedures.47b, 50 
Bis(oxazolinyl)carabazoles 2.4d and 2.4e were obtained in 27% and 25% respectively (entries 4 
and 5) after BF3•OEt2 mediated cyclization. Carbonylative amidation of 2.17 with amino alcohol 
2.18f51 provided the corresponding amide which gave the desired ligand in 61% yield after 
MeSO2Cl cyclization. (entry 4). 
 
Table 2.5. Synthesis of bis(oxazolinyl)carbazoles  from 2.17.a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
R
OH
NH2
Pd(PPh3)4 (20 mol%)
CO (1 atm), Et3N, DMF
N
H
Ph Ph
O
N N O
R R
N
H
Ph Ph
I I
N
H
Ph Ph
O
HN
HO R
O NH
OHR
BF3·Et2O
2.17 2.19 2.4
2.18
or
MeSO2Cl, NEt3
entry R product yield (%)b 
1c CH3 2.4a 48 
2 i-Pr 2.4b 57 
3 t-Bu 2.4c 4  
4 Ph 2.4d 27 
5 Bn 2.4e 25 
6c CH(OCH3)CH3 2.4f 61 
a Aminoalcohol  (2.5 equiv) CO (1 atm), Pd(PPh3)4 (20 mol%), NEt3 (4.0 
equiv), DMF, 60 °C, 8 h. Then BF3•Et2O, 120 °C, 6 h. Absolute 
configuration is as indicated, except for compounds 2.4d and 2.4f, for 
which the absolute configuration is (R). b Isolated yields.  c (i) MeSO2Cl 
(2.5 equiv), NEt3 (2.0 equiv), CH2Cl2, 0 °C to rt, 12 h. (ii) 5% alc KOH, 
reflux, 4 h.    
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 Next, we turned our attention to the synthesis of ligands with different substituents in the 
carabazole nucleous. Thus, 3,6–disubstituted carbazoles 4.16a-c were prepared by Suzuki 
coupling of 3,6-diiodo-9H-carbazole with the corresponding boronic acid 2.15 in the presence of 
Pd(OAc)2 catalyst (Table 2.6). While carbazoles 2.16a and 2.16b were obtained with excellent 
yield, carbazole 2.16c was prepared with moderate yield. 
 
Table 2.6. Suzuki coupling of 3,6-diiodo-9H-carbazole with boronic acids 2.15.a 
 
entry R product yield (%)b 
1 Ph 2.16a 65 
2 $-naphthyl 2.16b 79 
3 #-naphthyl 2.16c 23 
a R1B(OH)2 2.15 (3.0 equiv), Pd(OAc)2 (5 
mol%), P(o-tol)3 (10 mol%), Ba(OH)2·8H2O (3.0 
equiv), DME/H2O, 80 °C, 8 h. b Isolated yields. 
 
 Substituted carbazoles 2.16 were then halogenated to complete the preparation of the 
carbonylative amidation substrates. (Table 2.7) Carbazole 2.16a was prepared by the known 
procedure in 38% yield.47b Iodination of carbazole 4b with benzyltrimethylammonium 
tetrachloroiodate (BTMA•ICl2) afforded 3,6-di-!-naphtyl carbazole 5b in 40% yield (entry 2). 
Finally, carbazole 2.16c was obtained in 80% crude yield after iodination of with a KI/KIO4 
mixture. Unfortunately, the yield decreases considerably after recrystallization from toluene 
when the pure compound is obtained in only 18% yield (entry 3).  
 
2.14NH
I I
 Pd(OAc)2, P(o-tol)3,RB(OH)2
N
H
R R
Ba(OH)2·8H2O
DME/H2O 2.162.15
 50 
Table 2.7. Iodination of 3,6-disubstituted carbazoles. 
 
entry R conditions product yield (%)c 
1 Ph a 2.17a 34 
2 !-naphthyl b 2.17b 40 
3 #-naphthyl a 2.17c 18 
a) KI, KIO4‚·2H2O, AcOH, H2SO4, H2O, 5 h. b) BnMe3N·ICl2 
(2.2 equiv), AcOH, H2SO4, 60 °C, overnight c Isolated yields. 
 
 To complete the synthesis of bis(ozaxoline)carbazoles, halogenated carbazoles 2.17 
were subjected to carbonylative amidation with aminoalcohol 2.18b followed by cyclization 
under the corresponding reaction conditions (Table 2.8). Carbazoles 2.17a, 2.17b and 2.17c gave 
the corresponding ligands in 57%, 35% and 25% yields respectively by BF3·OEt2 mediated 
cyclization. (entries 1, 2 and 3). Ligand 2.4i was isolated 51% when MeSO2Cl was used for the 
dehydrative oxazoline formation (entry 4).  
 For the preparation of ligand 2.4g, 1,8-dibromo-3,6-di-tert-butyl-9H-carbazole 2.17d 
was prepared by the Friedel-Crafts alkylation of carbazole 2.20 and bromination following the 
procedure reported by Gibson et al. (Scheme 2.10)52 Chiral amino alcohol 4f was obtained in 
semipure form as a yellow oil in 55% by LAH reduction of (2S, 3R)-2-amino-3-
methoxybutanoin acid and used without further purification. 
 
Scheme 2.10. Synthesis of carbazole 2.17b.52 
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Table 2.8. Synthesis of bis(oxazolinyl)carbazoles  by coupling with aminoalcohol 2.18b.a 
 
 
entry R Carbazole  X cyclization conditions product yield (%)
d 
1 Ph 2.17a  I b 2.4b 57 
2 !-naphthyl 2.17b  I b 2.4g 35 
3 #-naphthyl 2.17c  I b 2.4h 25 
4 t-butyl 2.17d  Br c 2.4i 51 
a Aminoalcohol 2.18 (2.5 equiv) CO (1 atm), Pd(PPh3)4 (20 mol%), NEt3 (4.0 equiv), 
DMF, 60 °C, 8 h. b) BF3•Et2O, 120 °C, 6 h c) (i) MeSO2Cl (2.5 equiv), NEt3 (2.0 
equiv), CH2Cl2, 0 °C to rt, 12 h. (ii) 5% alc KOH, reflux, 4 h.  d Isolated yields. Dr. 
Worlikar is thanked for the synthesis of compounds 2.4h and 2.4i and their 
intermediates  
 
2.2.4. Asymmetric synthesis of (silylmethyl)allenic alcohols and 1,3-butadieny-2-ylcarbinols 
utilizing chiral carbazole ligands  
 After several bis(oxazolinyl)carbazoles were synthesized, their effect in the allenylation 
reaction was examined. It was observed that the substituent R1 plays an important role in the %ee 
of the reaction. Smaller R1 substituents such as Me and i-Pr afforded the product with higher %ee 
values (Table 2.9, entries 1 and 2), while the bulkier t-Bu decreased the %ee value and 
considerably slowed the reaction rate (entry 3). Likewise, the presence of a small R1 substituent 
such as a benzyl group afforded allene (–)-2a with higher enantiomeric excess than when a 
phenyl group was used (entries 4 and 5). The %ee of the product decreased slightly with R1= 
(R)-1-methoxyethyl, which is not as bulky as a Ph or a t-Bu group (entry 6). Phenyl was the best 
substutient at the R2 position, other aliphatic or aromatic R2 substituents, including t-Bu, !-
naphthyl and #-naphthyl, did not increase the %ee observed (entries 7 to 9).  
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Table 2.9. Effect of ligand substituent on enantiomeric excess.a 
 
entry ligand  %conversion ee(%)b 
1  (R1=Me, R2= Ph) 2.4a 92 74 
2  (R1=i-Pr, R2= Ph) 2.4b 91 78 
3  (R1=t-Bu, R2= Ph) 2.4c 86 20 
4  (R1=Ph, R2= Ph) 2.4d 99 31 
5  (R1=Bn, R2= Ph) 2.5e 68 75 
6  (R1= (R)-1-methoxyethyl, R2=Ph) 2.4f 32 68 
7  (R1=i-Pr, R2=!-naphthyl) 2.4g 99 57 
8 c  (R1=i-Pr, R2=#-naphthyl) 2.4h 99 21 
9  (R1=i-Pr, R2=t-Bu) 2.4i 86 20 
a Reaction Conditions: (4-bromobut-2-ynyl)trimethylsilane (2.5) (1.5 equiv), 
CrCl2 (5 mol%), ligand (5 mol%), Mn0 (2 equiv), TMSCl (1.1 equiv), i-
Pr2NEt (0.3 equiv), 20 h; 2 mL of 1 M HCl. b Enantiomeric excess and 
conversion determined by chiral HPLC. c CrCl2 (3 mol%), 2.4h (3 mol%). 
 
 Interestingly, a decrease in the reaction temperature from rt to 10 °C results in a slight 
decrease in the %ee observed from 75% ee to 70% ee (Table 2.10, entries 1 and 2). However, 
%ee was drastically reduced to 30% ee when the reaction temperature was further lowered to 0 
°C. The same effect was observed when ligands 2.4b or 2.4e were utilized for the reaction. A 
similar effect was observed by Nakada et al.53 for the chromium-catalyzed allylation of 
aldehydes using ligand 2.23 (Scheme 1.11). These results can be explained by a decrement on 
the solubility of the chiral chromium complex at low temperature, which makes the catalyst less 
available for the reaction while manganese reacts to give a racemic alcohol. Furthermore, when 
allenic alcohol (–)-2.2a is resubmitted to the reaction conditions at 0 °C a decrease in the ee 
value from 72% to 62% ee occurs. This indicates that a racemization process takes place under 
N
H
R2 R2
O
N N O
R1 R1
Ph
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TMS
CrCl2, (5 mol%), Ligand, Mn0
i-Pr2NEt, TMSCl, CH3CN r.t.,
then 1 M HCl, 30 min2.8 2.5 (–)-2.2a
O
HPh
Br
TMS
2.4
 53 
the reaction conditions at low temperature. On the contrary, when (–)-2.2a is resubmitted to the 
reaction conditions at room temperature, no racemization is observed.  
 
Table 2.10. Effect of temperature on enantiomeric excess.a 
 
entry Temperature (°C) ee(%)b 
1 rt 75 
2 10 70 
3 0 30 
a Reaction Conditions: (4-bromobut-2-
ynyl)trimethylsilane (2.5) (1.5 equiv), CrCl2 (5 
mol%), ligand 2.4e (5 mol%), Mn0 (2 equiv), TMSCl 
(1.1 equiv), i-Pr2NEt (0.3 equiv), 20 h; 2 mL of 1 M 
HCl. b Enantiomeric excess determined by chiral 
HPLC. 
 
Scheme. 2.11. Effect of temperature in the allylation of benzaldehyde.53 
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 After optimizing the reaction conditions, the scope of the asymmetric reaction was 
examined by studying a variety of aldehydes as electrophiles (Table 2.11). Para-substituted or 
unsubstituted aromatic aldehydes are excellent substrates and afforded the desired product in 
high yields and good enantioselectivities (Table 2.11, compounds 1 and 2). When more sterically 
hindered o-methyl benzaldehyde was used, the reaction is slower and the enantiomeric excess 
dropped to 59%. Electron deficient aldehydes gave the desired product with good ee values 
(entries 4, 5, and 6). As is the case with no chiral ligands present, aliphatic aldehydes undergo 
reaction more quickly than aromatic aldehydes. The products derived from addition to aliphatic 
aldehydes afford the corresponding allenes in good yields and modest enantioselectivities. The 
absolute configuration of all products in Table 2.11 was established after conversion of the 
(trimethylsilyl)methyl allenic alcohols to the corresponding dienes and comparison of the sign of 
optical rotation to the known compounds. 
 Having the (trimethylsilyl)methyl allenic alcohols in hand, we focused on the synthesis 
of 1,3-butadien-2-ylcarbinols. It is known that treatment of (trimethylsilyl)methyl allenic 
alcohols with a mixture of hydrofluoric acid and hydrochloric acid affords the desired diene.41d 
In search of milder reaction conditions that would allow the use of this methodology in sensitive 
substrates, we explored the use of various fluoride sources. We found TBAF could be utilized 
for the clean desilylation of the (silylmethyl)allenic alcohols to afford the corresponding dienes. 
When (–)-2.2a was treated with TBAF in THF for 36 h, diene 2.3a was obtained in 54% yield 
(Table 2.12, entry 1). These reaction conditions were tolerant of several functional groups and 
the (silylallenic)allenic alcohols synthesized were successfully transformed to 1,3-butadien-2-
ylcarbinols in good to excellent yields. For most of the substrates, no regioselectivity problems 
were encountered and enantiopurity was retained. However, for the synthesis of compound (–)-
2.2c, byproduct vinylsilane 2.24 was obtained, albeit in less than 5% yield (Scheme 2.12). The 
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vinylsilane was also observed as a minor byproduct in the synthesis of compounds 2.3a, 2.3b, 
and 2.3d (Table 2.12, entries 1, 2, and 4). 
 
Table 2.11. Scope of the asymmetric chromium-catalyzed allenylation reaction.a 
 
 
a Reaction Conditions: (4-bromobut-2-ynyl)trimethylsilane (2.5) (1.5 equiv), CrCl2 (5 
mol%), 2.4b (5 mol%), Mn0 (2 equiv), TMSCl (1.1 equiv), i-Pr2NEt (0.3 equiv), 48 h; 2 
mL of 1 M HCl. Isolated yields. Enantiomeric excess determined by chiral HPLC. b (4-
bromobut-2-ynyl)trimethylsilane (3 equiv), 50 h. c Reaction time: 36 h. 
 
Scheme 2.12. Synthesis of diene 2.3c. 
 
 
 
N
H
Ph Ph
O
N N O
i-Pr i-Pr
Ph
OH
TMS
CrCl2, (5 mol%), 2.4b, Mn0
i-Pr2NEt, TMSCl, CH3CN r.t.,
then 1 M HCl, 30 min2.8 2.5 (–)-2.2a
O
HPh
Br
TMS
2.4b
OH
TMS
OH
TMSH3C
88%, 78% ee 75%, 70% ee
OH
TMS
CH3
77%, 59% eeb
OH
TMS
Br
82%, 68% ee
OH
TMSF3C
OH
TMSBr
OH
TMS
88%, 72% ee 60%, 74% ee 67%, 68% eec
Ph
OH
TMS
58%, 55% eec
(–)-2.2a (–)-2.2b (–)-2.2c (–)-2.2d
(–)-2.2e (–)-2.2f (–)-2.2g (–)-2.2h
OH
TMS
TBAF, THF
84%
OHCH3 CH3 OHCH3
TMS(–)-2.2c 2.3c 2.24
 56 
 The !,#-Unsaturated aldehyde cinnamaldehyde affords TMS-protected allenic alcohols 
(Scheme 2.13). Bisdesilylation with TBAF in THF affords the desired adduct 2.3l in 35% yield. 
 
Table 2.12. Conversion of allenic alcohols to 1,3-butadien-2-ylcarbinols.a 
 
 
a Reaction Conditions: TBAF (1 equiv), THF, rt, 36 h. Isolated yields. 
 
Scheme 2.13. Synthesis of 2.2I from cinnamaldehyde. 
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 The synthesis of 1,3-butadien-2-ylcarbinols can be achieved under basic conditions but 
also under acidic conditions. When aliphatic allenic alcohols are treated with HCl, desilylation 
occurs and the corresponding dienes are obtained. The formation of 1,3-butadien-2-ylcarbinol 
2.2h from 3-phenylpropionaldehyde in one pot is illustrated in Scheme 2.14. After the aldehyde 
was treated with 2.5 under our reaction conditions, 2 M HCl was added to the reaction mixture 
and 2.3h was obtained after 5 h in 56% yield. 
 
Scheme 2.14. One-pot synthesis of 2.3h from 3-phenylpropionaldehyde. 
 
 
 To illustrate the versatility of (trimethylsilyl)methyl allenic alcohols, (–)-2.2g was 
treated with NIS to give the iodinated adduct 2.25 in 60% yield (Scheme 2.15). During this 
process, the alcohol was protected in situ and a 1:1 mixture of the free alcohol and the silyl ether 
was obtained.41d TBAF was added after 1 h and the free alcohol 2.25 was obtained in 60% yield. 
The synthesis of 2-iodo-1,3-dienes can also be accomplished by treatment with I2.44c 
Furthermore, (trimethylsilyl)methyl allenic alcohols may also be reacted with other electrophiles 
including Br241d and Selectfluor44e to afford the corresponding halogenated derivates. 
 
Ph
O Br
TMS
CrCl2, (5 mol%), 2.4b, Mn0
i-Pr2NEt, TMSCl, CH3CN r.t.;
then 2 M HCl, 5 h, r.t.
H Ph
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56% 44%ee
2.3h2.52.8h
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Scheme 2.15. Iodination of (trimethylsilyl)methyl allenic alcohol (–)-2.2g. 
 
 
 The absolute configuration of the chiral alcohols was assigned by comparing the optical 
rotations of known compounds 2.3a, 2.3g and 2.3h with the values reported in the literature.37d, 42a 
The absolute configuration of 2.3f was established by debromination to afford 2.3a and 
comparison with the known compound (Scheme 2.16). 
 
Scheme 2.16. Debromination of 1,3-butadien-2-ylcarbinol 2.3f 
 
 
 A plausible transition state that rationalizes the observed stereochemical outcome is 
depicted in Figure 2.2. The propargyl moiety is in the apical, less hindered position, avoiding 
steric interactions with the oxazoline substituents. The aldehyde coordinates to chromium with a 
trans geometry and occupies the less encumbered equatorial position. Addition to the aldehyde 
takes place from the Si-face, affording the R-alcohol. This is comparable with the observations 
made by Nakada and Inoue.46c Nonetheless, as previously discussed,46a, 46c the formation of a 
dinuclear complex or an intermolecular mechanism cannot be ruled out at this time.54 
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Figure 2.2. Proposed transition state for the allenylation reaction of aldehydes. 
 
2.3. Synthesis of tertiary 1,3-butadien-2-ylcarbinols from chromium-catalyzed addition of 
(4-bromobut-2-ynyl)trimethylsilane to ketones 
 
2.3.1. Introduction 
 Several strategies for the synthesis of 1,3-butadien-2-ylcarbinols from additions to 
aldehydes to afford secondary alcohols have been developed.41a, 42a, 43c-e However, methodologies 
for the synthesis of tertiary 1,3-butadien-2-ylcarbinols from ketones are scarce, regardless of 
their significance. Although the addition of a nucleophilic organometallic reagent to a carbonyl 
group is a common approach for the formation of new carbon–carbon bonds,55 aldehydes are 
used for this purpose much more regularly than ketones56, presumably due to the lower 
electrophilicity of ketones toward nucleophilic additions which also increases the possibility of 
competitive proton transfer. Among the examples of organometallic additions to ketones, the use 
of magnesium39a, 39b and lithium40b reagents derived from organostannanes for the synthesis of 
1,3-butadien-2-ylcarbinols can be highlighted. Unfortunately, these early methods present low 
regioselectivity and afford mixtures of the desired diene 2.28 and the corresponding homoallenic 
alcohol 2.29 (Scheme 2.17). 
 Due to this difficulty, alternative strategies have been developed. Tertiary 1,3-butadien-
2-ylcarbinols can be obtained by thermal ring opening of cyclobutenyl alcohols. (Scheme 2.18)57 
I
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R
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N
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O N N O
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i-Pr
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Although this method provides the desired alcohols with good yields, the required starting 
materials are not readily available and the substrate scope is limited. More recently, Alcaraz et 
al. reported the homologation of chiral epoxy bromides with dimethylsulfonium methylide for 
the synthesis of seconday and tertiary 1,3-butadien-2-ylcarbinols.58 (See Scheme 2.3, page 38) 
This method provides alkyl or aryl 1,3-butadien-2-ylcarbinols with good yields. Nevertheless the 
substrates are not commercially available. 
 
Scheme 2.17. Mixture of regioisomers obtained from the addition of 1,3-butadien-2-
ylmagnesium chloride to 3,3-dimethylbutan-2-one 39a. 
 
 
Scheme 2.18. Thermal ring opening of cyclobutenyl alcohols.57 
 
 
2.3.2. Results and discussion 
   In an effort to overcome some of the drawbacks presented by the existing procedures, 
we aimed for the synthesis of tertiary 1,3-butadien-2-ylcarbinols utilizing the methodology 
described in previous sections. Even though chromium-catalyzed additions to ketones are not 
common,59 it was envisioned that the allenylation of ketones and subsequent desilylation of the 
tertiary allenic alcohols could provide a useful approach for the regioselective synthesis tertiary 
1,3-butadien-2-ylcarbinols. 
O
t-BuH3C
ClMg
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H3C OH
t-Bu
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1   :   1.5
68%
THF, reflux
1 equiv 1 equiv
2.282.27 2.292.26
HO
C9H19
CH3 HO
C9H19
CH3
2.30 2.31
85%
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   The reactivity of ketones towards the chromium-catalyzed allenylation was explored. 4-
phenylbutan-2-one 2.32a was combined with 1.1 equiv of 2.5 in the presence of a catalytic 
amount of CrCl3 and 2 equiv of Mn0 and TMSCl in THF. After quenching with 1 M HCl the 
deprotected 3° allenic alcohol 2.33a was obtained with 51% conversion (Table 2.13, entry 1). No 
regioisomers such as the corresponding propargylic alcohol 2.34 were observed. This is 
complementary to prior methods in which the formation of propargylic alcohol is favored 
(Scheme 2.19).60 Increasing the equivalents of 2.5 results in an increase in conversion (entries 1 
and 3) until 4 equivalents is reached, at which point a notable decrease in conversion is observed 
(entry 4). 
 
Table 2.13. Optimization of the allenylation reaction.a 
 
 
2.32a
O
CH3 Br
TMS
CrCl3 (30 mol%)
Ph Mn0, Et3N, TMSCl;
then 1 M  HCl 2.33a2.5
H3C OH
Ph
TMS
entry TBAF (equiv) conversion(%b)  
1 1.1 51 
 
2 2.2 61 
3 3.0 80 
4 4.0 50 
a CrCl3 (30 mol%), Mn0 (2 equiv), TMSCl 
(2 equiv), rt. 24h. Then 1M HCl, rt, 30 
min. b Determined by 1H NMR. 
 
OH
Ph
H3C TMS
2.34 Not observed
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Scheme 2.19. Synthesis of propargylic alcohols from ketones.60a, 60b 
 
  
 The desired 1,3-butadien-2-ylcarbinol 2.41a was prepared in situ from the unpurified 
allene by direct treated with TBAF. Use of 2 equiv of TBAF resulted in only 25% conversion to 
the desired dienylalcohol (Table 2.14, entry 1). Use of excess TBAF greatly increased the 
product yield. The required excess can be explained by the presence of excess (4-bromobut-2-
ynyl)trimethylsilane 2.5 in the reaction mixture, which competitively consumes the fluoride. 
 After obtaining these optimized reaction conditions for ketone addition followed by 
diene formation, the substrate scope was evaluated. Aliphatic methyl ketone 2.32a is an excellent 
substrate for this reaction (Table 2.15). Ketone 2.32b, which is more sterically hindered due to 
the presence of a secondary carbon a to the carbonyl group, is somewhat less reactive, but 
afforded the desired product 2.41b in 41% yield. Cyclohexanone gave the corresponding diene 
2.41c, albeit in poor yield. Aromatic ketones including acetophenone and p-methylacetophenone 
afford the desired diene 2.41d and 2.41e in 45% and 53% yield, respectively. It was observed 
that the nature of the substituent in the aromatic group affects the rate of the reaction. 
Allenylation of 4-bromoacetophenone containing a slightly electron-withdrawing group in the 
para position afforded diene 2.41f in 67% after the starting material was consumed (48 h). 
Reactions involving electron-rich 4-mehotoxyacetophenone did not go to completion after 48 h. 
94      :      6
Br
Zn (5 equiv), (CH2I)2
THF, sonication
O
97     :      3
Br
In(5 mol%),Ga (1 equiv)
Ph CH3
80%
THF
95%
O
Ph CH3
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H3C OH
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H3C OH
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H3C OH
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H3C OHCH3
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2.35 2.36 2.37
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Although a 51% yield of product 2.41g was obtained, 40% of the starting material was also 
recovered. 
 
Table 2.14. Optimization of desilylation conditions.a 
 
entry TBAF (equiv) conversion (%)b 
1 2 25 
2 3 45 
3 5 68 
4 8 88 
a CrCl3 (30 mol%), Mn0 (2 equiv), Et3N (1 equiv) 
TMSCl (2 equiv), rt. 24h. Then 1 M TBAF in THF, 
rt, 16 h.  b Determined by 1H NMR Spectroscopy. 
 
 In an attempt at the asymmetric synthesis of 3° butadienylcarbinols, ketone 2.32d was 
submitted to the reaction conditions that we had previously developed for the enantioselective 
synthesis of 2° 1,3-butadien-2-ylcarbinols from aldehydes. As shown in Scheme 2.20, a racemic 
mixture of 2d was obtained with 17% conversion under our standard conditions. Further 
optimization of the reaction conditions increased the conversion to 90% when 2,6-lutidine was 
used as the base, when only 1.2 equiv of 2.5 were utilized. This represents a substantial increase 
over the yield observed in the absence of ligand (Table 15, entry 4), but no enantioselectivity 
was observed in the product mixture. Although this is a disappointing result on the surface, it 
does demonstrate that a bulky ligand does not inhibit this already hindered C–C bond forming 
reaction. 
O
CH2
Br
TMS
Ph
CrCl3 (30 mol%)
Mn0, Et3N, TMSCl;
then TBAF
OH
Ph
H3C
2.32a 2.5 2.41a
 64 
Table 2.15. Scope of the reactiona. 
 
 
a CrCl3 (30 mol%), Mn0 (2 equiv), Et3N (1 equiv) TMSCl (2 equiv), rt. 24h. Then 1 M 
TBAF in THF, rt, 16 h.  b Isolated yield. cReaction time: 48 h. 
  
Scheme 2.20. Attempted asymmetric synthesis of 2.33d. 
 
 
2.4. Synthesis of 2-aminomethyl-1,3-dienes from chromium-catalyzed addition of 4-
bromobut-2-yn-1-yl)trimethylsilane to imines 
 
2.4.1. Introduction and background 
 The addition of carbon nucleophiles to imines is a powerful and well-studied 
transformation for the preparation of nitrogen-containing organic compounds61 and the synthesis 
of  biologically active natural products. However, methods for the preparation of 2-
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aminomethyl-1,3-dienes are still uncommon. An early report describes the palladium-catalyzed 
coupling of amines with 2 equivalents of propadiene to afford 2-aminomethyl-1,3-dienes. 
(Scheme 2.21).62 Although the desired 1,3-dienes are obtained in moderate to good yields, the 
use of propadiene, a gas, is required and bis(dienyl)amines are also observed as a by-product of 
this palladium-catalyzed coupling. Hosomi et al.63 reported the Kumada cross coupling of 
Grignard reagents prepared from 2-bromo-3-aminopropene to vinyl halides for the synthesis of 
2-aminomethyl-1,-3dienes. This method proved to be efficient for the synthesis of the required 
1,3-dienes, which were further used in Diels-Alder cycloaddition reactions (Scheme 2.22). 
Unfortunately, the synthesis of starting materials 2-bromo-3-aminopropene is not convenient. 
Although both methods afford the desired products with moderate to good yield, the substrate 
scope is very limited. 
 
Scheme 2.21. Palladium coupling of allene with piperidine.62 
 
Scheme 2.22. Nickel-catalyzed synthesis of Diels-Alder reaction substrates.63  
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 More recently, metathesis of aryl propargylic amines with ethylene, in the presence of 
Grubb’s catalyst 2.51, was utilized for the synthesis of 2-aminomethyl-1,3-dienes.64 Although 
this method affords the desired products in moderate yields, the enantiomeric excess of the 
starting materials is conserved (Scheme 2.23). The adducts of interest can also be obtained by a 
regioselective titanium-mediated cross coupling of aryl imines with homoallenic alcohols 
(Scheme 2.24).65 One of the advantages of this method is the ability to use various protecting 
groups on nitrogen. Unfortunately, the use of excess titanium complex is required. Finally, 2-
aminomethyl-1,3-dienes were efficiently prepared by an indium mediated66 reaction of imines 
with 1,4-dibromo-2-butyne 2.56 (Scheme 2.25). The scope of this method is broad and, in the 
presence of acid, imines can be formed in situ from aniline and the corresponding aldehyde to 
afford the desired dienes in a three-component reaction.  
 In view of the limited number of methods for the synthesis of 2-aminomethyl-1,3-dienes 
and aiming to expand the scope of the chromium-catalyzed synthesis of 1,3-butadienes described 
in previous sections, we decided to study the reaction of imines with (4-bromobut-2-yn-1-
yl)trimethylsilane 2.5.  
 
Scheme 2.23. Synthesis of 2-aminomethyl-1,3-dienes by olefin cross-methatesis. 64 
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Scheme 2.24. Titanium mediated coupling of homoallenic alcohols with imines.65 
 
 
Scheme 2.25. Indium-mediated synthesis of 2-aminomethyl-1,3-dienes.66 
 
 
2.4.2. Chromium-catalyzed allylation of imines 
 Metal-catalyzed additions to imines are well-known transformations (e.g. allylation, 
alkylation, propargylation, etc.)61. Zinc, magnesium, tin, palladium67 and boron68 are examples of 
metals used for this purpose. However, only one example of a chromium-catalyzed addition to 
imines has been reported (Scheme 2.26).69 Therefore, prior to the synthesis of 2-aminomethyl-
1,3-dienes, we decided to use allyl bromide for a chromium-catalyzed synthesis of allylic imines.  
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Scheme 2.26. In situ formation of imines followed by CrCl2/BF3·OEt2 mediated allylation.69 
 
 
 When N-phenyl and N-benzyl imines were combined with allyl bromide in the presence 
of a catalytic amount of CrCl3, 2 equiv of Mn0 and TMSCl, the desired product was not 
observed, albeit the imines were consumed as indicated by TLC (Table 2.16, entries 1 and 2). On 
the contrary, when N-tosyl imine 2.60 was used, the desired product 2.62 was obtained in 80% 
conversion. It was suspected that the product from the allylation of imines 2.58 and 2.59 was 
being formed but may be coordinating to the chromium salts present in the reaction mixture. If 
this were the case, the product would be lost after filtration of the reaction mixture though silica. 
In order to recover the desired adducts 2.62, an excess of Et3N and DMF was added to the 
mixture prior to filtration, expecting the amines will coordinate to the chromium salts releasing 
the desired product. (entries 4 to 6). After the products were successfully recovered, it was 
observed that tosyl imine, activated by the presence of an electron-withdrawing group, afforded 
the corresponding adduct in higher yield than N-benzyl and N-phenyl imines (entry 7). 
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R
1. R'NH2, MS 4 Å, THF
2. 2.622.8
O
Br
CrCl2 (2.5 mmol)
, BF3·OEt2 (1 mmol)
45-75%
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Table 2.16. Chromium-catalyzed allylation of imines.a 
 
entry R additiveb yield (%)c 
1 Ph -- -- 
2 Bn -- -- 
3 Ts -- 80 
4 Ph DMF 46 
5 Bn DMF 36 
6 Bn Et3N 38 
7 Ts Et3N 88d 
aImine (1 equiv), allyl bromide (1.5 equiv), CrCl3 (10 
mol%), Mn (2 equiv), TMSCl (1.1 equiv), 16 h. b Added 
after 16 h; then TBAF(1 M in THF, 1 equiv). c Yield 
calculated by 1H NMR spectroscopy. d Isoated yield. 
 
 
2.4.3. Synthesis of  (silylmethyl)allenic amines and 2-aminomethyl-1,3-dienes 
 Encouraged by the results obtained with the allylation of imines, we directed our 
attention to the synthesis of (silylmethyl)allenic amines. After imines 2.59-2.60 were submitted 
to our reaction conditions. The corresponding imines were mixed with (4-bromobut-2-yn-1-
yl)trimethylsilane in the presence of CrCl2 (10 mol%), manganese (2 equiv) and TMSCl. After 
36 hours it was observed a considerable decrement on the reactivity of imines 2.58a and 2.59 
with respect to the allylation reaction (Table 2.17, entries 1 to 3). Only traces of product were 
observed when N-(4-(trifluoromethyl)benzylidene)aniline 2.58b was used. Albeit the presence of 
an electron withdrawing group in the substrate, the reactivity of imine 2.58b towards the 
allenylation reaction was poor. On the other hand, when activated tosyl imine 2.60 was used, the 
allenylated adduct was obtained in 64% conversion. Thus, confirming the presence of an 
electron withdrawing tosyl group is necessary to increase the electrophilicity of the substrate. 
N
R
H
HN
R
Br
CrCl3, Mn0, TMSCl
 THF, 16 h; then
 1 M TBAF, 10 min2.61 2.622.58-2.60
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The percent conversion of the reaction did not improve when the temperature of the reaction was 
increased to 60°C. The homo-coupled product of (4-bromobut-2-yn-1-yl)trimethylsilane 2.5b 
was observed when unreactive substrates 2.58-2.59 were used; addition of excess propargyl 
bromide 2.5 after 12 h did not improve the conversion of this reaction. 
  
Table 2.17. Allenylation of imines.a 
 
entry R1 R2  conversionb (%) 
1 Ph Ph 2.58a 10 
2 Ph 4-CF3C6H4 2.58b -- 
3 Bn Ph 2.59 8 
4 Ts Ph 2.60 64 
a Imine (1 equiv), propargyl bromide 2.5 (1.5 equiv), 
CrCl2 (10 mol%), Mn (2 equiv), TMSCl (1.1 equiv), 
36 h; then 1 M HCl (2 mL) b Determined by H1 NMR 
spectroscopy. 
  
 Interestingly, a by-product from the reaction of tosyl imine 2.60 and propargyl bromide 
2.5 was identified as the corresponding propargyl amine 2.64. The mixture of regioisomers was 
observed in a 2.5:1 ratio. It is known that propargylic organometallic reagents exist as an 
equilibrium mixture of allenic and propargylic species70. Hence, the use of metal-catalyzed 
additions of propargylic reagents to electrophiles for the synthesis of allenic compounds has 
been previously limited by low regioselectivity. A regioisomeric mixture was not observed 
previously for the allenylation of aldehydes or ketones.  
 The allenylation of aldehydes with (4-bromobut-2-yn-1-yl)trimethylsilane described in 
section 2.22 is a highly regioselective transformation due to the preferred formation of 
R2
N
R1
R2
HN
R1
TMS
H
CrCl2, Mn0
TMSCl, THF, 36 h;
1 M HClTMS
Br
2.58-2.60 2.5 2.63
TMS
TMS
2.5b
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propargylic chromium species 2.10 over allenic intermediate 2.11.  It has been observed that not 
only the propargyl halide, but also the electrophile present in the reaction affects the products 
ratio.49 For the synthesis of (silylmethyl)allenic amines 2.63, the presence of a bulky N-tosyl  
group on the substrate should be considered. As shown in Scheme 2.27, the attack of the 
preferred propargylic chromium species 2.10 to tosyl imine 2.60 results in a 6-membered chair-
like transition state 2.10b with unfavorable steric interactions between chromium and the tosyl 
group. On the contrary, reaction of allenic chromium 2.11 with tosyl imine occurs via transition 
state 2.11b, in which the corresponding steric interactions are minimized. Thus, resulting in the 
rapid formation of 2.64 even thought 2.11 is present as the minor organchromium regioisomer.  
 
Scheme 2.27. Proposed transition states leading to the formation of regioisomers 2.63 and 2.64. 
 
 
 To explain the product ratio in the context of the Curtin-Hammett principle, the reaction 
diagram for the allenylation reaction is depicted in Figure 3. The energy for the equilibration 
between organochromium species 2.10 and 2.11 (%G2.10—2.11) is greater than the activation energy 
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for the formation of the products (%G2.10—2.11 > %G2.10—2.63 and %G2.11—2.64,). The nucleophilic attack 
to the electrophile (imine or aldehyde) occurs faster than the interconvertion of the 
organometallic species thus the formation of allenes 2.64 and 2.2 from the attack of the more 
abundant chromium intermediate is favored. However, the products ratio is not only a reflection 
of the relative concentration of 2.10 and 2.11. Considering transition states 2.10b and 2.11b for 
the allenylatin of tosylimine, the first is higher in energy due to the presence of unfavorable 
steric interactions resulting is a slower formation of 2.63 with respect to 2.64. As a consequence 
of these two variables, a regioisomeric mixture is obtained where allene 2.63 is the major 
product. In the case for the chromium-catalyzed allenylation of aldehydes, the desired allenes 2.2 
are obtained as a single product. For this transformation it can be assume that, in the absence of a 
bulky tosyl group, the activation energy for the allenylation of aldehydes (shown in blue) is 
lower or equal in energy than for the formation of the propargylic amine 2.9. Thus, the formation 
of allene 2.2 is favored by both the abundance of organochorium 2.10 and a small %G2.10-2.2. 
 Aiming for an increment in the formation of the desired allene, the reaction conditions 
were optimized as described in Table 2.18. It was observed that increasing the amount of 
chromium catalyst accelerates the reaction rate and favors the formation of the desired allene 
2.63 (entries 1 to 4). However, if the catalyst is present in 30 or 50 mol% the regioisomer ratio 
does not change (entry 5). When the reaction is cooled to 0 °C, alkyne 2.64 is obtained as a 
single product albeit in low conversion (entry 6). Increasing the reaction temperature does not 
increment the formation of the corresponding allene (entry 7). A large excess of propargyl 
bromide reduces the reaction time to 16h yet affords a 1:1.6 mixture of regioisomers (entry 10). 
It was also observed that using CrCl3 or increasing the equivalents of TMSCl have no effect on 
the regioisomer ratio. Also, use of additives like Et3N or pyridine does not improve the ratio and 
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slow down the reaction. The use of propargyliodide 2.5c considerably decreases the yield of the 
reaction and does not improve the product ratio (Scheme 2.28).  
 
 
Figure 2.3. Reaction diagram for the chromium-catalyzed allenylation.  
 
Scheme 2.28. Allenylation of tosyl imine with propargyl iodine 2.5c. 
 
 
 To discard the possibility of an isomerization process occurring under the reaction 
conditions, pure allene 2.63 was stirred with propargyl bromide in the presence of the catalytic 
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Cr+1/Mn0 system followed by usual workup. After this process, the corresponding alkyne was not 
observed by 1H NMR spectroscopy. (Scheme 2.29).  
 
Table 2.18. Optimization of allenylation conditions.a 
 
 
 
 
Scheme 2.29. Treatment of allene 2.63 with propargyl bromide 2.5. 
 
 
 The reaction conditions can be tailored to afford propargylic amine 2.64 as the major 
product. The formation 2.64 is favored when the amount of catalyst if reduced. Absence of 
N
Ts
HN
TMS
Ts
HN
Ts
TMS
H
CrCl2, Mn0
TMSCl, THF, 48 h;
2 M HClTMS
Br
2.60 2.5 2.63 2.64
2.63
HN
Ts
TMS
HN
Ts
TMS
CrCl2, Mn0
TMSCl, THF, 20 h;
then 2 M HClMe3Si
Br
2.632.5
entry CrCl2 (%) temperature (°C) conversion (%)b ratio (2.63:2.64)b 
1 5 r.t. 87 1:1 
2 10 r.t. 99 2.5:1 
3 15 r.t. 91 2.6:1 
4c 30 r.t. 99 3.5:1 
5 50 r.t. 99 3.5:1 
6 10 0 27 0:1 
7 10 70 99 2:1 
8d 30 r.t. 23 2:1 
9e 30 r.t. 82 2.5:1 
10f 30 r.t 91 1:1.6 
a Imine (1 equiv), propargyl bromide 2.5 (1.5 equiv), CrCl3 (30 mol%), Mn 
(2 equiv), TMSCl (1.1 equiv), 48 h; then 1 M HCl (2 mL) b Determined by 
1H NMR Spectroscopy. c Propargyl bromide (2 equiv). d Solvent: CH3CN. e 
Mn (5 equiv). f Propargyl bromide (3 equiv), reaction time: 16 h. 
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TMSCl, use of TESCl or large excess of manganese also favor the formation of this regiosomer 
(Table 2.19). This effect is equally observed when propargyl bromide 2.65, containing a DMPS 
group is used. (Table 2.20) 
 
Table 2.19. Optimization towards the synthesis of propargylic amine.a 
 
entry CrCl2 (%) conversion (%)b ratio (2.63:2.64)b 
1c 10 95 1:2.5 
2 d 10 95 1:2.5 
3e 10 95 1:1.3 
4f 10 70 1:1.7 
a Imine (1 equiv), propargyl bromide 2.5 (1.5 equiv), CrCl3 (10 
mol%), Mn (2 equiv); then 1 M HCl (2 mL). b Determined by 
1H NMR Spectroscopy. c No TMSCl added. d TESCl (1.1 
equiv). e TESCl (4 equiv). f Mn (5 equiv), TMSCl (1.1 equiv). 
 
 
 
Table 2.20.  Use of (4-bromobut-2-yn-1-yl)dimethyl(phenyl)silane for the synthesis of allenic 
and propargylic amines.a 
 
entry CrCl2 (%) ratio (2.66:2.67) b yield (%)b 
1 30 3:1 52 
2c 10 1:3.3 42 
a Imine (1 equiv), propargyl bromide 2.65 (1.5 equiv), Mn 
(2 equiv), 16 h; then 2 M HCl (2 mL). b Determined by 1H 
NMR Spectroscopy. c No TMSCl added.  
 
N
Ts HN
TMS
TsHN
Ts
TMS
H
CrCl2, Mn0
TMSCl, THF, 48 h;
2 M HClMe3Si
Br
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 After optimizing the reaction conditions, different tosyl imines were prepared to 
examine the scope of the reaction. As described in Table 2.21, Lewis acid BF3·Et2O was used for 
the synthesis of p-toluenesulfonamides 2.60. This is an efficient procedure for the synthesis of 
variety of aromatic and $,#-unsaturated imines.  On the contrary, aliphatic imine 2.60f was not 
obtained, presumable due to the formation of the corresponding enol from 3-phenylpropanal. The 
hindered aldehyde p-methylbenzalhyde did not afford the desired product under these conditions, 
giving only a mixture of the imine and the corresponding starting material after several days.  
 
Table 2.21. Lewis acid mediated synthesis of N-tosyl imines.a 
 
entry R  yield (%)b 
 1c Ph 2.60a 90 
2 4-Br C6H4 2.60b 53 
3 4-CF3 C6H4 2.60c 31 
4 4-OMe C6H4 2.60d 85 
5 C6H5CHCH 2.60e 25 
6 PhCH2CH2 2.60f -- 
7 2-CH3C6H4 2.60g -- 
6 2-Br C6H4 2.60h 81 
aAldehyde (1 equiv), p-toluenesulfonamide (1 
equiv), BF3·OEt2 (20% wt). b Isolated yield. c 
No BF3·Et2O added. 
 
 Imines 2.60f and 2.60g were obtained from the reaction of sodium p-toluenesulfinate, p-
toluenesulfonamide and the corresponding aldehyde to give and intermediate sulfonamide 
sulfone that upon treatment with base afford the desired aducts. (Table 2.22)71 While aliphatic 
R
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S
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H2N
BF3·Et2O
Toluene, 110°C
2.8 2.68 2.60
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imine 2.60f was obtained after 16 hours, the formation of hindered imine 2.60f required several 
days.   
 In search of a more efficient procedure for the isolation of 2.63, the mixture of 
regioisomers was treated with TBAF. After 10 min, 2.64 reacted with TBAF to give the 
corresponding allene 2.69, while desilylation of more hindered allene 2.63 requires more than 20 
hours. The resulting mixture of allenes is easily separated with column chromatography (Scheme 
2.30).   
 
Table 2.22. Preparation of N-tosyl imines.a 
 
entry R  yield (%)b 
1c PhCH2CH2 2.60f 74 
2d 2-CH3C6H4 2.60g 49 
a Aldehyde (1 equiv), Sodium p-toluenesulfinate (1 equiv) p-
toluenesulfonamide (1 equiv), formic acid (15 mL), H2O (15 
mL) b Isolated yield. c Reaction time: 16 hours. d Reaction time: 
5 days. 
 
Scheme 2.30. Desilylation of propargyl amine. 
 
 
 The desired allenic amines were obtained from a variety of tosyl imines. Aromatic 
imines give the corresponding adducts in good yields (Table 2.23, entries 1 and 2). Imine 2.60c, 
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containing an electron-withdrawing group, is consumed after 16 hours under the reaction 
conditions albeit affording allene 2.63c in low yield (entry 3). The presence of an electron-
donating group in the substrate increases the reaction time, thus allene 2.63d was obtained in 
53% yield after 3 days (entry 4). $,#-unsaturated imine 2.63e is a poor substrate for the 
allenylation reaction giving the corresponding allene in only 16% yield (entry 5). On the 
contrary, aliphatic allene was obtained in excellent yield. The presence of an o-bromo 
substituend dramatically affects the outcome of the reaction. When imine 2.63h was used, only 
traces of the desired allene were observed by crude 1H NMR, the possibility of side reaction 
derived from the catalyst insertion to the arylhalide position is not discarded. 
 After screening several imines, it was confirmed that the nature of the substituent in the 
imine has a dramatic effect in the regioselectivity of the reaction (Scheme 2.27). When aliphatic 
tosyl imine 2.60f was used, allene 2.60f was obtained as the major isomer with a 10:1 ratio. On 
the contrary, sterically hindered imine 2.63g afforded a 1.3:1 mixture of regioisomers (Scheme 
2.31). 
 
Scheme 2.31. Poor regioselectivity in the synthesis of allene 2.63g. 
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Table 2.23. Synthesis of allenic sulfonamides.a 
 
entry substrate product conversion to 2.63(%)b yield (%)
c 
1 
  
2.63a 78 73 
2 
  
2.63b 73 56 
3 
  
2.63c 38 25 
4d 
  
2.63d 56 53 
5 
  
 
2.63e - 16 
6 
 
 
2.63f 91 84 
7 
  
2.63h -- -- 
a Imine (1 equiv), propargyl bromide 2.5 (2 equiv), CrCl3 (30 mol%), Mn (2 equiv), 
TMSCl (1.1 equiv), 48 h; then TBAF(1 M in THF, 1.5 equiv). b Determined by 1H NMR 
c Isolated yield. d Reaction time: 3 days, propargyl bromide (3 equiv), 1 equiv added 
after 48 hours. 
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 Having completed the synthesis of (silylmethyl)allenic amines, 2-aminomethyl-1,3-
dienes were successfully prepared using TBAF in good to excellent yields (Table 2.24).  This 
method was equally efficient for desilylation of aromatic an aliphatic allenic amines. 2-
aminomethyl-1,3-diene was obtained in 62% yield albeit a 74% conversion. This reaction was 
not allowed to go to completion to avoid decomposition of the product. Electron rich diene 2.70d 
was obtained in 84% yield. Finally, allenic imine 2.63g afforded the desired diene albeit the 
presence of an ortho-substituent. 
 
Table 2.24. Synthesis of 2-aminomethyl-1,3-dienes. a 
 
 
a Allene (1 equiv) TBAF (1M in THF, 1 equiv and one more equiv after 3 
h). Isolated yields 
 
 (silylmethyl)allenes are known to react with several electrophiles including acyl iminium 
ions44b, halogens41d, 72, aldehydes and acetals44d to afford highly functionalized dienes (Scheme 
2.32). To further illustrate the usefulness of (silylmethyl)allenes 2.63 for the synthesis of  highly 
functionalized 1,3-dienes, allenic amine 2.63a was mixed with different electrophiles in the 
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presence of a Lewis acid. (Table 2.25) The corresponding dienes were not obtained in the 
presence of benzaldehyde or 3-phenylpropanal. However, the desired product was formed in 
46% conversion using (dimethoxymethyl)benzene and TiCl4 as a Lewis acid. Under these 
conditions the cyclization product of 2.73a may be formed thus, a milder Lewis acid was used to 
promote the dienyllation reaction. To increase the yield of the reaction and avoid the formation 
of by-products, BF3·OEt2 was used to afford diene 2.73a in 100% conversion.  
 
Scheme 2.32. Versatility of allenylsilanes.41d, 44b, 44d, 72  
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Table 2.25. Synthesis of highly functionalized 1,3-dienes.a 
 
 
 To study the scope of this dienylation reaction, allenic sulfonamides were added to   
(dimethoxymethyl)benzene in the presence of one equivalent of BF3·OEt2 at – 78 °C. The desired 
products were obtained after 2-3 hours in excellent yields for aromatic or aliphatic substrates. A 
1:3 diasteromeric mixture was obtained for the aromatic substrates (Table 2.26, entries 1-3). 
While aliphatic substrate 2.63f afforded the desired diene in a 1:9 d.r. As shown in Scheme 33, 
addition of allylsilane to aldehydes in the presence of BF3·OEt2 favors the formation of 1,4-anti 
homoallylic alcohols as the major isomer.73 Thus, the anti diastereomer is expected to be the 
major product for this dienylation reaction. 
Ph
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CH2Cl2, – 78°C
electrophile Ph
TsHN
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entry Electrophile Lewis acid product conversion(%)
b 
1 
 
TiCl4 
 
2.71 !! - 
2 
 
TiCl4 
 
2.72 - 
3 
 
TiCl4 
 
2.73a 46 
4 
 
BF3·Et2O 
 
2.73a 100 
a Imine (1 equiv), aldehyde/acetal (1.6 equiv), Lewis acid (1.5 equiv), – 78°6. b 
Determined by 1H NMR Spectroscopy. 
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Table 2.26. Synthesis of highly functionalized 1,3-dienes.a 
 
 
 
Scheme 2.33. Diastereoselective addition of allylsilane 2.74 to aldehydes.73a 
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entry substrate product yield  (%)b d.r.c 
1 
  
2.73a 92 1:3 
2 
  
2.73b 93 1:3 
3 
  
2.73c 95 1:3 
4 
  
2.73d 78 1:9 
a Imine (1 equiv), aldehyde/acetal (1.6 equiv), BF3·OEt2 (1.5 equiv), – 78° C               
b Isolated yields. cDetermined by 1H NMR spectroscopy. 
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2.5 Experimental procedures and characterization data 
 
2.5.1 General information 
 All reactions were performed under an argon atmosphere in oven-dried glassware with 
magnetic stirring. Acetonitrile, propionitrile, DME, TMSCl and DIPEA were distilled from CaH2 
before use. THF, CH2Cl2 and Toluene were dried with a solvent purification system. Liquid 
aldehydes were distilled under reduced pressure and stored refrigerated. Other commercially 
available reagents were used as received. Reactions were monitored by analytical thin layer 
chromatography using 0.25 mm glass-backed silica gel plates. Flash column chromatography 
was performed using silica gel (230-400 mesh). Visualization was accomplished by UV light and 
potassium permanganate or p-anisaldehyde stains.  
 1H NMR spectra were recorded at 300 MHz and referenced to CDCl3 (" 7.27). 1H NMR 
coupling constants (J) are reported in Hertz (Hz) and multiplicities are indicated by: s (singlet), d 
(doublet), t (triplet), q (quartet), quint (quintet), oct (octet) m (multiplet), dt (doublet of triplets), 
td (triplet of doublets), tt(triplet of triplets), qd (doublet of quadruplets), br (broad), dd (doublet 
of doublets). Proton-decoupled 13C NMR spectra were recorded at 75 MHz and reported relative 
to CDCl3 (" 77). Infrared Spectra were obtained as thin film on NaCl plates. High performance 
liquid chromatography was performed on a system equipped with a wavelength detector and 
chiral stationary columns (0.46 cm x 25 cm). 
 
2.5.2  Synthesis of propargyl halides  
(4-bromobut-2-yn-1-yl)trimethylsilane (2.5): Prepared following the 
procedure reported by Tong et al.48 Obtained as a clear oil (2.7 g, 13.3 TMS
Br
 85 
mmol, 76%). 1H NMR (CDCl3, 300 MHz) " 3.99 (t, J = 2.71 Hz, 2H), 1.56 (t, J = 2.83 Hz, 2 H), 
0.14 (s, 9 H); 13C NMR (75 MHz, CDCl3) " 86.9, 74.2, 16.8, 7.5, -1.9.  
 
(4-iodobut-2-yn-1-yl)trimethylsilane (2.5c)74:  4-(trimethylsilyl)but-2-yn-1-
ol48 (460 mg, 3.23 mmol) was added to a solution of PPh3 (1.1 g, 4.2 mmol) 
in THF. The mixture was cooled to 0°C and NIS (0.87 g, 3.87 mmol) was added in small 
portions over 5 min. A yellow precipitate was formed immediately. The mixture was stirred at 0 
°C for 2 h. Then, hexanes were added (100 mL) and the yellowish solid formed was removed by 
filtration. The filtrate was passed though a path of silica to afford a pink solution. The solvent 
was removed under reduced pressure to give a clear oil (184 mg, 0.73 mmol, 22 %) 1H NMR 
(CDCl3, 300 MHz) " 3.96 (t, J = 2.95 Hz, 2H), 1.53 (t, J = 2.89 Hz, 2 H), 0.11(s, 9 H); 13C NMR 
(75 MHz, CDCl3) " 85.5, 75.07, 7.7, -1.8, -15.1. 
 
 (4-bromobut-2-yn-1-yl)dimethyl(phenyl)silane (2.65): Prepared 
following the procedure reported by Tong et al.48 Prepared following the 
procedure reported by Tong et al.48  Obtained as a clear oil (620 mg, 2.3 mmol, 23% over two 
steps). 1H NMR (CDCl3, 300 MHz) " 7.64-7.58 (m, 2H), 7.46-7.37 (m, 2H), 3.96 (t, J = 2.91 Hz, 
2H), 1.78 (t, J = 2.79 Hz, 2 H), 0.41 (s, 6 H); 13C NMR (75 MHz, CDCl3) " 137.2, 133.6, 129.5, 
127.9, 86.4, 74.7, 16.7, 7.1, -3.3; IR (thin film) 3435.7, 3069.7, 2892.9, 222.6 cm-1. MS (ESI) 
calcd for C12H15BrSi (M - H) 265.0054, found 265.1575. 
 
2.5.3 General method for the preparation of allenic alcohols  
 Inside a nitrogen atmosphere drybox, a mixture of CrCl3 (10 mg, 0.06 mmol) and Mn 
powder (325-mesh, 22 mg, 0.4 mmol) were added to a 2-dram vial. Then, the vial was capped 
SiMe2Ph
Br
TMS
I
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with a Teflon lid and it was removed from the drybox. THF (2 mL) was added via syringe and a 
purple suspension resulted. This was followed by addition of (4-bromo-2-butyn-1-
yl)trimethylsilane 2.5 (88 mg, 0.33 mmol), the aldehyde (0.3 mmol) and TMSCl (42 µL, 0.23 
mmol). The mixture was stirred at room temperature until the reaction was completed as judged 
by TLC.  HCl  (1 M) was added to the gray solution and it was stirred until the alcohol is 
completely deprotected as judged by TLC. The mixture was then extracted with EtOAc. The 
mixed organic phases were washed with brine, dried with Mg2SO4 and concentrated under 
reduced pressure to give dark yellow oil. The residue was purified by flash chromatography 
using ethyl acetate : hexanes (1 : 50 to 1:9) as eluent.  
 
1-(3,5-dimethylphenyl)-2-((trimethylsilyl)methyl)buta-2,3-dien-1-ol 
(2.2i): Obtained as a yellow oil (47 mg, 0.18 mmol, 59%). 1H NMR 
(CDCl3, 300 MHz) " 6.98 (s, 2 H), 6.94 (s, 1 H), 5.03 (q, J = 3.0 Hz, 2 
H), 4.90 (m, 1 H), 2.33 (s, 6 H), 2.21 (d, J = 4.8 Hz 1 H), 1.30-1.22 (dt, J = 23.0, 15.0 Hz, 1 H), 
1.04-0.96 (dt, J = 2.8, 14.8 Hz, 1 H), 0.02 (s, 9 H). 13C NMR (75 MHz, CDCl3) "  205.6, 142.9, 
139.0, 130.7, 126.0, 125.9, 106.3, 81.0, 75.9, 22.4, 18.0, -0.0. $R (thin film) 3417.37, 2953.26, 
1953.07, 1247.94 cm-1; HRMS (ESI) calcd for C16H24OSi (M + H) 261.1675, found 261.1668.  
 
1-(naphthalen-2-yl)-2-((trimethylsilyl)methyl)buta-2,3-dien-1-ol 
(2.2j): Obtained as a light yellow oil (51 mg, 0.18 mmol, 60%). 1H NMR 
(CDCl3, 300 MHz) " 8.24 (d, J = 8.3 Hz, 1 H), 7.88 (d, J = 8.3 Hz, 1 H), 
7.82 (d, J = 8.3 Hz, 1 H), 7.64 (d, J = 6.2 Hz, 1 H), 7.51 (m, 3 H), 5.78 (m, 1 H), 5.01 (q, J = 2.8, 
2.8 Hz, 2 H), 2.31 (d, J = 4.5 Hz 1 H), 1.43-1.36 (dt, J = 2.9, 15.1 Hz, 1 H), 1.13-1.05 (dt, J = 
2.9, 15.1 Hz, 1 H), 0.0 (s, 9 H). 13C NMR (75 MHz, CDCl3) "  207.0, 137.1, 134.2, 131.6, 128.9, 
OH
TMS
H3C
CH3
OH
TMS
 87 
128.8, 126.3, 125.8, 125.4, 125.1, 124.2, 104.8, 79.6, 73.0, 17.0, -0.8. IR (thin film) 3385.8, 
3060.91, 2953.19, 1952.50, 1247.59, 1056.43 cm-1; HRMS (ESI) calcd for C18H22OSi (M+ Li) 
289.1600, found 289.1594. 
 
1-(4-methoxyphenyl)-2-((trimethylsilyl)methyl)buta-2,3-dien-1-ol 
(2.2k): CrCl2 (2.5 mg, 0.02 mmol), Mn powder 325-mesh (22 mg, 
0.4 mmol), (4-bromo-2-butyn-1-yl)trimethylsilane (45 mg, 0.22 
mmol), aldehyde (27 mg, 0.2 mmol), TMSCl (24 mg, 0.22). Title compound was obtained as 
yellow oil (30 mg, 0.11 mmol, 56%). 1H NMR (CDCl3, 300 MHz) " 7.32%7.28 (d, J = 8.8 Hz, 2 
H), 6.91-6.87 (d, J = 8.8 Hz, 2 H), 5.01 (q, J = 2.8 Hz, 2 H), 4.94 (m, 1 H), 3.82 (s, 3 H), 2.23 (s 
br, 1 H), 1.31-1.23 (dt, J = 2.9, 15.0 Hz, 1 H), 1.06-0.98 (dt, J = 2.9, 15.0 Hz, 1 H), 0.02 (s, 9 H). 
13C NMR (75 MHz, CDCl3) " 204.6, 159.5, 134.3, 128.5, 113.9, 105.6, 80.1, 74.6, 55.5, 17.3, -
0.8; IR (thin film) 3427.97, 2954.02, 1952.94, 1248.11, 1117.7 cm-1; HRMS (ESI) calcd for 
C15H22O2Si (M+ Li) 269.1549, found 269.1543. 
 
2.5.4 General method for the preparation of enantioenriched allenic alcohols  
 Inside a nitrogen atmosphere drybox, a mixture of CrCl2 (1.2 mg, 0.01 mmol), Mn 
powder 325 mesh (22 mg, 0.4 mmol), and carbazole ligand 2.4b (5.5 mg, 0.01 mmol) were 
added to a 2-dram vial. Then, the vial was capped with a teflon lid and it was removed from the 
drybox. Freshly distilled CH3CN (2 mL) was added via syringe and a yellow suspension 
resulted. This was followed by addition of i-Pr2NEt (10 &L, 0.06 mmol) and the mixture was 
stirred for 5 min. After this time, (4-bromo-2-butyn-1-yl)trimethylsilane (61 mg, 0.3 mmol) was 
added and the solution was allowed to stir for 30 min. Next, the aldehyde (0.2 mmol) and 
TMSCl (28 &L, 0.22 mmol) were successively added at 0 °C. The mixture was stirred at room 
OH
TMSH3CO
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temperature for 48 h or until the reaction was completed as judged by TLC. 1 M HCl was added 
and the obtained green solution was stirred until the alcohol is completely deprotected as judged 
by TLC. The mixture was then extracted with EtOAc. The mixed organic phases were washed 
with brine, dried with Mg2SO4 and concentrated under reduced pressure to give a dark orange 
oil. The residue was purified by flash chromatography using EtOAc:hexanes (1:50 to 1:9) as 
eluent.  
 
  (R)-1-phenyl-2-((trimethylsilyl)methyl)buta-2,3-dien-1-ol ((–)-
2.2a)41d: Obtained as a clear oil (40 mg, 0.17 mmol, 88%, 78% ee) 1H 
NMR (CDCl3, 300 MHz) & 7.36-7.27 (m, 5 H), 4.98 (m, 3 H), 2.23 (d, J 
= 4.5 Hz 1 H), 1.30-1.23  (dt, J = 2.4, 15.3 Hz, 1 H), 1.07-0.94 (dt, J = 2.6, 14.2 Hz, 1 H),  0.0 (s, 
9H). 13C NMR (75 MHz, CDCl3) & 204.7, 141.9, 128.3, 127.8, 127.0, 105.1, 79.7, 74.9, 16.8, -
1.1.  IR (thin film) 3387, 3029, 2954, 1952, 1247 cm-1; HRMS (ESI) calcd for C14H20OSi (M–
OH) 215.1251, found 215.1252; Enantiomeric excess determined by HPLC (250 nm) using a 
ChiralPAK AD-H column (hexanes : isopropanol = 98:2, flow rate = 0.6 mL/min) retention 
time: = 14.3 min (major), 13.0 (minor). [$]D23  –107.2 (c 1.0, CHCl3). 
 
 (R)-1-p-tolyl-2-((trimethylsilyl)methyl)buta-2,3-dien-1-ol((–)-
2b): Obtained as a clear oil (27 mg, 0.17 mmol, 75%, 70% ee) 1H 
NMR (CDCl3, 300 MHz) & 7.29-7.24 (d, J = 8.0 Hz, 2 H), 7.19-7.14 
(d, J = 8.0 Hz, 2 H), 5.01 (q, J = 2.8 Hz, 2 H), 4.94 (m, 1 H), 2.36 (s, 3 H), 2.23 (d, J = 4.5 Hz 1 
H), 1.30-1.23 (dt, J = 2.7, 15.0 Hz, 1 H), 1.05-0.97 (dt, J = 2.8, 15.0 Hz, 1 H), 0.0 (s, 9 H). 13C 
NMR (75 MHz, CDCl3) & 204.6, 139.0, 137.5, 129.0, 126.9, 105.2, 79.7, 74.7, 21.2, 17.0, -
1.0. IR (thin film) 3408, 2953, 1953, 1247 cm-1; HRMS (ESI) calcd for C15H22OSi (M+Li) 
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253.1600, found 253.1596; Enantiomeric excess determined by HPLC (250 nm) using a 
ChiralPAK AD-H column (hexanes:isopropanol = 98:2, flow rate = 0.6 mL/min) retention time: 
= 17.8 min (major), 14.0 (minor). [$]D18 –106.7 (c 1.0, CHCl3). 
 
 (R)-1-o-tolyl-2-((trimethylsilyl)methyl)buta-2,3-dien-1-ol ((–)-
2c): Obtained as a clear oil (38 mg, 0.15 mmol, 77%, 59% ee) 1H NMR 
(CDCl3, 300 MHz) & 7.41 (m, 1 H), 7.18 (m, 3 H), 5.24 (m, 1 H), 4.94 (q, 
J = 3.0 Hz, 2 H), 2.37 (s, 3 H), 2.07 (d, J = 4.8 Hz 1 H), 1.36-1.28 (dt, J = 2.9, 15.1 Hz, 1 H), 
1.06-0.99 (dt, J = 2.9, 15.1 Hz, 1 H), 0.02 (s, 9 H). 13C NMR (75 MHz, CDCl3) &  205.4, 139.5, 
136.3, 130.5, 127.6, 126.7, 125.9, 104.1, 79.2, 72.1, 19.3, 16.5, -1.1  IR (thin film) 3358, 2953, 
1955, 1247 cm-1; HRMS (ESI) calcd for C15H22OSi (M+Li) 253.1600, found 253.1597; 
Enantiomeric excess determined by HPLC (210 nm) using a ChiralPAK AD-H column 
(hexanes:isopropanol = 98:2, flow rate = 0.6 mL/min) retention time: 12.8 min (major), 11.3 
(minor). [$]D19 –49.3 (c 1.0, CHCl3). 
 
 
 (S)-1-(2-bromophenyl)-2-((trimethylsilyl)methyl)buta-2,3-dien-1-ol 
((–)-2c): Obtained as a yellow oil (44 mg, 0.14 mmol, 82%, 68% ee) 1H 
NMR (CDCl3, 300 MHz) & 7.52-7.44 (m, 2 H), 7.33 (td, J = 1.57, 7.67 
Hz, 1 H), 7.33 (td, J = 1.92, 7.67 Hz, 1 H),  5.42 (m, 1 H), 4.94 (q, J = 3.09 Hz, 2 H), 2.29 (d, J = 
6.95 Hz 1 H), 1.39-1.33 (dt, J = 2.8, 15.0 Hz, 1 H), 1.16-1.08 (dt, J = 2.6, 15.0 Hz, 1 H), 0.0 (s, 9 
H). 13C NMR (75 MHz, CDCl3) & 205.4, 141.0, 132.8, 129.1, 128.8, 127.6, 123.7, 104.16, 79.7, 
73.7, 16.8, -1.1 . IR (thin film) 3384, 2953, 1953 cm-1; HRMS (ESI) calcd for C14H19BrOSi (M–
OH) 293.0356, found 293.0348; Enantiomeric excess determined by HPLC (250 nm) using a 
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ChiralPAK AD-H column (hexanes:isopropanol = 98:2, flow rate = 0.6 mL/min) retention time: 
= 15.5 min (major), 13.9 (minor). [$]D23 –74.5 (c 1.0, CHCl3). 
 
(R)-1-(4-(trifluoromethyl)phenyl)-2-((trimethylsilyl)methyl)-
buta-2,3-dien-1-ol ((–)-2e): Obtained as a yellow oil (53mg, 0.17 
mmol, 88%, 72% ee) 1H NMR (CDCl3, 300 MHz) & 7.64-7.58 (d, J 
= 8.4 Hz, 2 H), 7.52-7.46 (d, J = 8.4 Hz, 2 H), 5.06 (m, 1 H), 5.00 (q, J = 2.8, 2.9 Hz, 2 H), 2.31 
(d, J = 4.75 Hz, 1 H), 1.29-1.21 (dt, J = 2.9, 15.1 Hz, 1 H), 1.06-0.98 (dt, J = 2.9, 15.1 Hz, 1 H), 
0.02 (s, 9 H). 13C NMR (75 MHz, CDCl3) & 204.9, 146.06, 127.28, 125.22 (q, J = 3.72), 104.69, 
79.94, 74.63, 16.46, -1.15; IR (thin film) 3307, 2956, 2895, 1951, 1326, 1249 cm-1; HRMS (ESI) 
calcd for C15H19F3OSi (M+Li) 307.1317, found 307.1320; Enantiomeric excess determined by 
HPLC (250 nm) using a ChiralPAK AD-H column (hexanes:isopropanol = 98:2, flow rate = 0.6 
mL/min) retention time: = 13.55 min (major), 10.17 (minor). [$]D23 –101.9 (c 1.0, CHCl3). 
 
 (R)-1-(4-bromophenyl)-2-((trimethylsilyl)methyl)buta-2,3-dien-1-ol 
((–)-2f): Obtained as a clear oil (37 mg, 0.12 mmol, 60%, 74% ee) 1H 
NMR (CDCl3, 300 MHz) & 7.48-7.44 (d,  J= 8.559 Hz, 2 H), 7.25-7.21 
(d, J = 8.37 Hz, 2 H), 4.98 (q, J = 3.2 Hz, 2 H), 4.94 (m, 1 H), 2.21 (d, J = 4.4 Hz 1 H), 1.28-1.20 
(dt, J = 2.7, 15.1 Hz, 1 H), 1.04-0.96 (dt, J = 2.8, 15.0 Hz, 1 H), -0.03 (s, 9 H). 13C NMR (75 
MHz, CDCl3) & 204.6, 141.0, 131.3, 128.8, 121.6, 104.9, 80.1, 74.4, 16.6, -0.9 d. IR (thin film) 
3422, 2953, 1952, 1247 cm-1; HRMS (ESI) calcd for C14H19BrOSi (M–H) 309.0310, found 
309.0314; Enantiomeric excess determined by HPLC (250 nm) using a ChiralPAK AD-H 
column (hexanes:isopropanol = 98:2, flow rate = 0.6 mL/min) retention time: = 18.4 min 
(major), 14.6 (minor). [$]D20 –69.8 (c 1.0, CHCl3). 
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(R)-1-cyclohexyl-2-((trimethylsilyl)methyl)buta-2,3-dien-1-ol ((–)-2g): 
Obtained as a light yellow oil (32 mg, 0.14 mmol, 67%, 68% ee) 1H 
NMR (CDCl3, 300 MHz) & 4.80 (q, J = 2.8 Hz, 2 H), 3.67 (m, 1 H), 1.79-
0.81 (m, 13 H).  13C NMR (75 MHz, CDCl3) & 206.4, 104.5, 79.4, 77.6, 42.3, 31.1, 28.1, 27.5, 
27.4, 27.1, 17.7, 0.05 IR (thin film) 3415, 2925, 2852, 1952, 1247 cm-1; HRMS (ESI) calcd for 
C14H26OSi (M–OH) 221.1720 found 221.1725; Enantiomeric excess determined by HPLC (250 
nm) using a ChiralPAK AD-H column (hexanes:isopropanol = 98:2, flow rate = 0.6 mL/min) 
retention time: = 8.14 min (major), 8.7 (minor). [$]D20 –15.7 (c 1.0, CHCl3). 
 
(R)-1-phenyl-4-((trimethylsilyl)methyl)hexa-4,5-dien-3-ol ((–)-2h)41d: 
Obtained as a yellow oil (30 mg, 0.11 mmol, 58%, 55% ee) 1H NMR 
(CDCl3, 300 MHz) & 7.28-7.13 (m, 5 H), 4.83 (q, J = 2.7, 2.6 Hz, 2 H), 
3.89 (m, 1 H), 2.8-2.57 (m, 2 H), 2.00-1.87 (m, 1 H), 1.84-1.7 (m, 1 H), 1.57 (s br, 1 H), 1.42-
1.34 (dt, J = 2.8, 14.9 Hz, 1 H), 1.24-1.15 (dt, J = 2.9, 15.9 Hz, 1 H), 0.0 (s, 9 H). 13C NMR (75 
MHz, CDCl3) & 205.8, 142.36, 128.7, 128.62, 216.0, 104.8, 79.0, 72.2, 37.4, 32.1, 17.1, -0.8. IR 
(thin film) 3362, 2951, 1951, 1247 cm-1; HRMS (ESI) calcd for C16H24OSi (M+Li) 267.1756, 
found 267.1759; Enantiomeric excess determined by HPLC (250 nm) using a ChiralPAK AD-H 
column (hexanes:isopropanol = 98:2, flow rate = 0.6 mL/min) retention time: = 15.8 min 
(major), 14.38 (minor). [$]D20 –5.6 (c 1.0, CHCl3). 
 
2.5.5 General Method for the preparation of 1,3-butadien-2-ylcarbinols from allenic 
alcohols 
 Allene (0.11 mmol) was dissolved in dry THF (1.5 mL). TBAF (1 M wwwin THF, 0.1 
mL, 0.1 mmol) was added and the solution was stirred at rt for 36 h. After this time, a saturated 
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solution of NH4Cl (3 mL) was added and the mixture was extracted with three portions of ethyl 
acetate The combined organic fractions were washed with brine, dried over Mg2SO4 and 
concentrated under reduced pressure. The residue was purified by preparative TLC using (1:6) 
EtOAc:hexanes. 
 
 (S)-2-methylene-1-phenylbut-3-en-1-ol (2.3a)75: Allene (–)-2.2a (18 mg, 
0.11 mmol), 1 M TBAF in THF (0.1 mL, 0.1 mmol). Title compound was 
obtained as yellow oil (9 mg, 0.06 mmol, 54%, 70% ee). 1H NMR (CDCl3, 300 MHz) & 7.35-
7.21 (m, 5 H), 6.25 (dd, J = 11.5, 17.7 Hz, 1 H), 5.41 (s, 1 H), 5.35 (s, 1 H), 5.27 (s, 1 H), 5.15 
(d, J = 17.86 Hz, 1 H), 4.98 (d, J = 11.23 Hz, 1 H), 2.0 (s, 1 H); 13C NMR (75 MHz, CDCl3) & 
147.4, 141.8, 135.7, 128.4, 127.8, 126.8, 115.7, 115.4, 73.9; IR (thin film) 3362, 3084, 1954, 
1817, 1593; HRMS (ESI) calcd for C11H12O (M–OH) 143.0855, found 143.0802; Enantiomeric 
excess determined by HPLC (250 nm) using a ChiralPAK AS-H column (hexanes:isopropanol = 
98:2, flow rate = 0.6 mL/min) retention time: = 19.55 min (major), 17.87 (minor). [$]D17 –33.5 (c 
1.0, CHCl3). Reported value (98% ee) [$]D20 –93.2 (c 1.34, CHCl3)41c. 
 
 (S)-2-methylene-1-p-tolylbut-3-en-1-ol (2.3b)43d: Allene (–)-2.2b (14 
mg, 0.06 mmol), 1 M TBAF in THF (0.6 mL, 0.6 mmol). Title 
compound was obtained as yellow oil (9 mg, 0.051 mmol, 86%, 65% 
ee) 1H NMR (CDCl3, 300 MHz) & 7.30 (d, J = 7.90 Hz, 2 H), 7.17 (d, J = 7.90 Hz, 2 H), 6.33 
(dd, J = 10.91, 17.53 Hz, 1 H), 5.45 (s, 2 H), 5.34 (s, 1 H), 5.22 (d, J = 18.19 Hz, 1 H), 5.05 (d, J 
= 11.33 Hz, 1 H), 2.36 (s, 3 H), 1.97 (d J = 4.83, 1 H);  13C NMR (75 MHz, CDCl3) &  147.6, 
139.0, 137.6, 135.9, 129.2, 126.8, 115.5, 115.3, 73.7, 21.1; IR (thin film) 3363, 2922, 1956, 
1905, 1819, 1595 cm-1; HRMS (ESI) calcd for C12H14O (M+Li) 181.1205, found 181.1197; 
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Enantiomeric excess determined by HPLC (250 nm) using a ChiralPAK AS-H column 
(hexanes:isopropanol = 98:2, flow rate = 0.6 mL/min) retention time: = 21.17 min (major), 
16.7(minor). [$]D19 –51.1 (c 1.0, CHCl3). Reported value (89% ee) [$]D24 –69.2 (c 1.0, CHCl3).43d 
 
 (S)-2-methylene-1-o-tolylbut-3-en-1-ol (2.3c): Allene (–)-2.2d  (40 mg, 
0.16 mmol), 1 M TBAF in THF (0.16 mL, 0.16 mmol). Title compound was 
obtained as yellow oil (22 mg, 0.12 mmol, 79%, 68% ee.). 1H NMR (CDCl3, 
300 MHz) & 7.41 (m, 1 H), 7.21 (m, 3 H), 6.40 (dd, J = 11.33, 17.80 Hz, 1 H), 5.68 (d, J = 4.88 
Hz, 1 H), 5.36 (s, 1 H), 5.26 (s, 1 H), 5.21 (d, J = 17.55 Hz, 1 H), 5.09 (d, J = 11.22 Hz, 1 H), 
2.88 (s, 3 H), 1.86 (d, J = 4.86, 1 H);  13C NMR (75 MHz, CDCl3) & 147.1, 139.6, 136.3, 135.8, 
130.4, 127.7, 126.2, 126.1, 116.5, 114.9, 70.0, 18.9; IR (thin film) 3407, 2924, 1721, 1461 cm-1; 
HRMS (ESI) calcd for C12H14O (M+Li) 181.1205: found 181.1200. Enantiomeric excess 
determined by HPLC (250 nm) using a ChiralPAK AD-H column (hexanes:isopropanol = 98:2, 
flow rate = 0.6 mL/min) retention time: = 23.5 min (major), 21.6 (minor). [$]D19 – 16.5 (c 1.0, 
CHCl3). 
 
 (S)-1-(2-bromophenyl)-2-methylenebut-3-en-1-ol (2.3d)76: Allene (–)-2.2d 
(43 mg, 0.13 mmol), 1 M TBAF in THF (0.14 mL, 0.14 mmol). Title 
compound was obtained as yellow oil (27 mg, 0.11 mmol, 82%, 77% ee.). 1H 
NMR (CDCl3, 300 MHz) &  7.61 (dd, J = 1.22, 7.98 Hz, 1 H), 7.51 (dd, J = 1.79, 7.77 Hz, 1 H), 
7.35 (dt, J = 1.33, 7.42 Hz, 1H), 7.20 (dt, J = 1.79, 7.62 Hz, 1H), 6.42 (dd, J = 11.33, 18.21 Hz, 
1 H), 5.41 (m, 1 H), 5.36 (m, 1 H), 5.25 (dd, J = 0.78, 17.90 Hz 1 H), 5.12 (d, J = 11.18 Hz, 1 
H), 2.17 (d, J = 4.27, 1 H);  13C NMR (75 MHz, CDCl3) & 146.4, 140.7, 136.1, 132.8, 129.4, 
128.57, 127.7, 123.8, 116.8, 115.2, 71.9; IR (thin film) 3334, 3088, 2918, 1594 cm-1; MS (APCI) 
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calcd for C12H14O (M–OH) 221.00, found 221.40. Enantiomeric excess determined by HPLC 
(250 nm) using a ChiralPAK AD-H column (hexanes:isopropanol = 98:2, flow rate = 0.6 
mL/min) retention time: = 23.5 min (major), 21.6 (minor). [$]D17 –77.4 (c 1.0, CHCl3). 
 
 (S)-2-methylene-1-(4-(trifluoromethyl)phenyl)but-3-en-1-ol (2.3e): 
Allene (–)-2.2e (26 mg, 0.08 mmol), 1 M TBAF in THF (0.8 mL, 0.08 
mmol). Title compound was obtained as yellow oil (11 mg, 0.05 
mmol, 59%, 69% ee). 1H NMR (CDCl3, 300 MHz) & 7.26 (d, J = 8.39 Hz, 2 H), 7.53 (d, J = 8.39 
Hz, 2 H), 6.31 (dd, J = 11.56, 17.81 Hz, 1 H), 5.55 (d, J = 4.33 Hz, 1 H), 5.38 (s, 1 H), 5.27 (d, J 
= 18.31 Hz, 1 H), 5.10 (dd, J = 11.50 Hz, 1 H), 2.08 (d, J = 4.066 Hz, 1 H); 13C NMR (75 MHz, 
CDCl3) &  147.2, 145.7, 135.3, 127.0, 125.4 (q, J = 3.94), 116.7, 166.0, 73.6; IR (thin film) 3418, 
2923, 2951, 1619, 1325 cm-1; HRMS (ESI) calcd for C12H11F3O (M–H) 227.0654 found 
227.0690; Enantiomeric excess determined by HPLC (250 nm) using a ChiralPAK AD-H 
column (hexanes:isopropanol = 98:2, flow rate = 0.5 mL/min) retention time: = min 23.45 
(major), 19.18 (minor). [$]D19 –10.5 (c 1.0, CHCl3). 
 
(S)-1-(4-bromophenyl)-2-methylenebut-3-en-1-ol (2.3f)43d: Allene (–)-
2.2f  (36 mg, 0.11 mmol), 1 M TBAF in THF (0.1 mL, 0.11 mmol). 
Title compound was obtained as yellow oil (19 mg, 0.08 mmol, 72%, 
73% ee.). 1H NMR (CDCl3, 300 MHz) & 7.48 (d, J = 8.55 Hz, 2 H), 7.29 (d, J = 9.36 Hz, 2 H), 
6.30 (dd, J = 11.55, 17.80 Hz, 1 H), 5.45 (s, 1 H), 5.38 (s, 1 H), 5.35 (s, 1 H), 5.23 (d, J = 18.13 
Hz, 1 H), 5.08 (dd, J = 11.29 Hz, 1 H), 1.98 (s, 1 H); 13C NMR (75 MHz, CDCl3) 
& 147.3, 140.8, 135.5, 131.6, 128.6, 121.7, 116.2, 115.8, 73.4;  IR (thin film) 3356, 2922, 1634, 
1486, 1403, 1071 cm-1; HRMS (ESI) calcd for C11H11BrO (M–H) 236.9915, found 236.9916; 
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Enantiomeric excess determined by HPLC (250 nm) using a ChiralPAK AS-H column 
(hexanes:isopropanol = 98:2, flow rate = 0.6 mL/min) retention time: = 22.4 min (major), 19.34 
(minor). [$]D19 –24.3 (c 1.0, CHCl3). Reported value (86% ee) [$]D24  – 15.4 (c 1.0, CHCl3).43d 
 
 (R)-1-cyclohexyl-2-methylenebut-3-en-1-ol (2.3g)75: Allene (–)-2.2g (25 
mg, 0.1 mmol), 1 M TBAF in THF (0.1 mL, 0.1 mmol). Title compound was 
obtained as yellow oil (14 mg, 0.08 mmol, 84%, 64% ee.). 1H NMR (CDCl3, 
300 MHz) & 6.26 (dd, J = 11.06, 17.39 Hz, 1 H), 5.30 (d, J = 17.63 Hz 1 H), 5.13 (s, 1 H), 5.07 
(s, 1 H), 5.03 (d, J = 11.22 Hz, 1 H), 4.06 (d, J = 5.99 Hz, 1 H), 1.86-0.87 (m, 12 H).  13C NMR 
(75 MHz, CDCl3) & 148.1, 136.2, 114.7, 114.6, 76.9, 41.8, 30.0, 27.7, 26.4, 26.3, 26.1 IR (thin 
film) 3418, 2924, 2852, 1731 cm-1; HRMS (ESI) calcd for C11H18O (M–H) 165.1285, found 
165.1093; Enantiomeric excess determined by HPLC (250 nm) using a ChiralPAK AD-H 
column (hexanes:isopropanol = 99:1, flow rate = 0.5 mL/min) retention time: = 17.28 min 
(major), 18.3 (minor). [$]D19 – 2.8 (c 1.0, CHCl3). Reported value (89% ee) [$]D20 – 6.0 (c 3.25, 
CHCl3).42a 
 
 (R)-2-methylene-1-o-tolylbut-3-en-1-ol (2.3h)37d: Allene (–)-2.2h (26 mg, 
0.09 mmol), 1 M TBAF in THF (0.1 mL, 0.1 mmol). Title compound was 
obtained as yellow oil (8 mg, 0.04 mmol, 43%, 48% ee.). 1H NMR (CDCl3, 300 MHz) &  7.44-
7.28 (m, 5 H), 6.45 (dd, J = 11.6, 18.1 Hz, 1 H), 5.39 (s, 1 H), 5.33 (d, J = 18.24 Hz, 1 H), 5.29 
(s, 1 H), 5.19 (d, J = 11.52 Hz, 1 H), 4.17 (dd, J = 4.17, 8.33 Hz, 1 H), 2.48-2.77 (m, 2 H), 2.19-
2.07 (m, 1 H), 2.06-1.96 (m, 1 H), 1.76 (s br, 1 H); 13C NMR (75 MHz, CDCl3) &  149.0, 141.8, 
136.0, 128.5, 128.3, 125.8, 114.3, 114.2, 70.6, 37.9, 31.9;  IR (thin film) 3396.4, 3026.3, 2924.6, 
1713.8 cm-1; HRMS (ESI) calcd for C12H14O (M+Li) 195.1361, found 195.1245; Enantiomeric 
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excess determined by HPLC (250 nm) using a Chiralcel OB-H column (hexanes:isopropanol = 
99:1, flow rate = 0.5 mL/min) retention time: =  30.21 min (major), 27.46 (minor). [$]D19 + 14.3 
(c 1.0, CHCl3). Reported value (77% ee) [$]D29 + 36.4 (c 1, CHCl3).37d 
 
1-(3,5-dimethylphenyl)-2-methylenebut-3-en-1-ol (2.3i): Allene 2.2i 
(25 mg, 0.09 mmol), 1 M TBAF in THF (0.09 mL, 0.09 mmol). 
Compound was obtained as yellow oil (19 mg, 0.07 mmol, 81%). 1H 
NMR (CDCl3, 300 MHz) " 7.01 (s, 2 H), 6.94 (s, 1 H) 6.32 (dd, J = 11.38, 17.66 Hz, 1 H), 5.45 
(s, 1 H), 5.41 (s, 1 H), 5.35 (s, 1 H), 5.24 (d, J = 18.09 Hz, 1 H), 5.05 (dd, J = 11.30 Hz, 1 H), 
2.32 (s, 1 H), 1.94 (s br, 1H);  13C NMR (75 MHz, CDCl3) " 128.3, 141.8, 138.0, 135.9, 129.5, 
124.6, 115.3, 73.9, 21.3; IR (thin film) 3356.27, 3008.74, 2918.32, 1608.09 cm-1; HRMS (ESI) 
calcd for C13H16O (M+ Li) 195.1361, found 195.1448.  
 
2-methylene-1-(naphthalen-1-yl)but-3-en-1-ol (2.3j)6f: Allene 2.3j (25 
mg, 0.09 mmol), 1 M TBAF in THF (0.16 mL, 0.16 mmol). The title 
compound was obtained as yellow oil (28 mg, 0.13 mmol, 74%). 1H 
NMR (CDCl3, 300 MHz) " 8.13 (d, J = 8.97, 1 H), 7.89 (d, J = 7.29, 1 H), 7.83 (d, J = 8.41, 1 
H), 7.63 (d, J = 8.41, 1 H), 7.58-7.44 (m, 3 H), 6.47 (dd, J = 11.08, 18.20 Hz, 1 H), 6.27 (s, 1 H), 
5.43 (s, 1 H), 5.35 (s, 1 H), 5.24 (d, J = 19.05 Hz, 1 H), 5.10 (d, J = 11.72 Hz, 1 H); 13C NMR 
(75 MHz, CDCl3) " 147.3, 137.1, 136.4, 133.8, 131.0, 128.8, 128.6, 126.3, 125.6, 125.5, 125.3, 
124.4, 123.4, 117.3, 115.1. 69.6; MS (ESI) calcd for C15H14O (M+ Li) 217.1205, found 
217.1244. 
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1-(4-methoxyphenyl)-2-methylenebut-3-en-1-ol (2.3k)6f: Allene 2.2k 
(30 mg, 0.11 mmol), 1 M TBAF in THF (0.11 mL, 0.11 mmol). Title 
compound was obtained as yellow oil (16 mg, 0.082 mmol, 75%).  1H 
NMR (CDCl3, 300 MHz) " 7.32 (d, J = 8.86 Hz, 2 H), 6.89 (d, J = 8.86 Hz, 2 H), 6.32 (dd, J = 
11.89, 18.42 Hz, 1 H), 5.46 (s, 1 H), 5.44 (s, 1 H), 5.34 (s, 1 H), 5.19 (d, J = 18.12 Hz, 1 H), 5.04 
(d, J = 11.488 Hz, 1 H), 3.809 (s, 3 H), 1.93 (d J = 4.0, 1 H); 13C NMR (75 MHz, CDCl3) " 
159.2, 147.6, 135.9, 134.2, 123.2, 115.4, 115.3, 113.9, 73.4, 55.3; IR (thin film) 3416.87, 
3004.51, 2959.47, 1824.23, 1610.72, 1510.6, 1249.0, cm-1; HRMS (ESI) calcd for C12H14O2 (M+ 
Li) 197.1154, found 197.1154.  
 
4-methylene-1-phenylhexa-1,5-dien-3-ol (2.3i)43c: Inside a Nitrogen 
atmosphere drybox, CrCl2 (2.5 mg, 0.02 mmol) and Mn0 powder 325-mesh 
(22 mg, 0.4 mmol) were added to a 2-dram vial. Then, the vial was capped with a Teflon lid and 
it was removed from the drybox. Dry THF (2 mL) was added via syringe and a gray suspension 
was formed. This was followed by addition of 4-bromo-2-butyn-1-yl)trimethylsilane (45 mg, 
0.22 mmol), cinnamaldehyde (27 mg, 0.2 mmol) and TMSCl (24 mg, 0.22 mmol). The mixture 
was stirred at room temperature for 16 h. The mixture is then extracted with three portions of 
ethyl acetate. The mixed organic phases were washed with brine, dried with Mg2SO4 and 
concentrated under reduced pressure. The residue was redissolved in THF (1.5 mL) and, TBAF 
(1 M in THF, 0.4 mmol, 0.4 mL) is added. After 36h, a saturated solution of NH4Cl (3 mL) was 
added and the mixture was extracted with three portions of ethyl acetate. The combined organic 
fractions were washed with brine, dried over Mg2SO4 and concentrated under reduced pressure. 
The residue was purified by preparative thin layer chromatography using 1:6 
ethylacetate:hexanes and it was obtained as a clear oil (13 mg, 0.07 mmol, 35%). 1H NMR 
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(CDCl3, 300 MHz) &  7.43-7.25 (m, 5 H), 6.70 (d, J = 15.93 Hz, 1 H), 6.39 (dd, J = 11.36, 17.79 
Hz, 1 H), 6.32 (dd, J = 6.22, 15.86 Hz, 1 H), 5.46 (d, J = 18.33 Hz, 1 H), 5.39 (s, 1 H), 5.27 (s, 
1H), 5.17 (d, J = 11.25 Hz, 1 H), 5.10 (d, J = 6.11 Hz, 1 H), 1.81 (d J = 3.29, 1 H); 13C NMR (75 
MHz, CDCl3) & 147.3, 136.5, 135.8, 131.2, 130.2, 128.5, 127.8, 126.5, 115.3, 115.2, 72.2; IR 
(thin film) 3390, 3027, 2921, 2851, 1494 cm-1; HRMS (ESI) calcd for C12H14O2 (M+Li) 
193.1205, found 193.1202.  
 
Preparation of (R)-2-methylene-1-o-tolylbut-3-en-1-ol from 3-
phenylpropionaldehyde: Inside a Nitrogen atmosphere drybox, CrCl2 (1.2 
mg, 0.01 mmol), Mn0 powder 325-mesh (22mg, 0.4 mmol), and 2.4b (5.5mg, 0.01 mmol) were 
added to a 2-dram vial. Then, the vial was capped with a Teflon lid and it was removed from the 
drybox. Freshly distilled CH3CN (2 mL) was added via syringe and a yellow suspension was 
formed. This was followed by addition of N,N-diisopropylethylamine (7.5mg, 0.3 mmol) and the 
mixture was stirred for 5 min. After this time, (4-bromo-2-butyn-1-yl)trimethylsilane 2.5 (50mg, 
0.3 mmol) was added and the solution was allowed to stir for 30 min. Next, the aldehyde (0.2 
mmol) and TMSCl (24 mg, 0.22 mmol) were successively added at 0 °C. The mixture was 
stirred at room temperature for 36 h. 2 M HCl (2 mL) was added dropwise to the solution and the 
mixture was stirred for 5 h. The mixture is then extracted with three portions of EtOAc. The 
mixed organic phases were washed with brine, dried with Mg2SO4 and concentrated under 
reduced pressure. The residue was purified by preparative thin layer chromatography using 1:6 
EtOAc:hexanes and it was obtained as a yellow oil (22 mg, 0.11 mmol, 56%, 44% ee). 
Enantiomeric excess determined by HPLC (250 nm) using a Chiralcel OB-H column 
(hexanes:isopropanol = 99:1, flow rate = 0.5 mL/min) retention time: =  30.21 min (major), 
27.46 (minor).  
OH
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1-o-tolyl-2-((trimethylsilyl)methylene)but-3-en-1-ol (2.24): 1H NMR 
(CDCl3, 300 MHz) "  7.31-7.27 (m, 1 H), 7.09-7.00 (m, 3 H), 5.56 (d, J = 
2.87 Hz, 1 H), (s, 1 H), 5.37 (d, J = 2.87 Hz, 1 H), 4.93 (m, 2H), 2.37 (s, 3 
H), 1.76 (d, J = 3.76, 1 H), -0.13 (2, 9H). 13C NMR (75 MHz, CDCl3) " 152.7, 140.6, 136.6, 
131.1, 128.4, 128.1, 128.0, 127.5, 126.8, 13.4, 72.2, 20.1, 0.0 IR (thin film) 3374.3, 2955.9, 
1619.9, 1486.3, 1248.3 cm-1 HRMS (ESI) calcd for C15H22OSi (M + Na) 269.1338, found 
269.1334. 
 
1-cyclohexyl-3-iodo-2-methylenebut-3-en-1-ol (2.25): Allenic alcohol (–)-
2.2g (20 mg, 0.08 mmol) was dissolved in dry CH2Cl2 (1 mL). Then, at 0 °C, 
a solution of NIS (40 mg, 0.17 mmol) in CH2Cl2 (0.5 mL) was added via cannula. The pink 
solution was stirred at r.t. for 1 h. After this time, 0.16 mL of a TBAF (1 M in THF, 0.16 mmol) 
was added via syringe and the mixture was stirred for 2 h. After this time, a saturated solution of 
NH4Cl was added and the mixture was extracted with three portions of EtOAc. The combined 
organic phases were washed with brine, dried over Mg2SO4 and concentrated under reduced 
pressure. The residue was purified by flash chromatography using EtOAc:hexanes 1:6 as eluent. 
The title compound was obtained as a yellow oil (35 mg, 0.12 mmol, 60% yield). 1H NMR " 6.3 
(d, J = 1.67 H), 5.91 (d, J = 1.46 H), 5.42 (s, 1 H), 5.30 (s, 1 H), 4.28 (t, J = 4.75, 1H) 1.73-1.63 
(m, 3 H), 1.56 (d, J = 5.2, 2H), 1.23-0.89 (m, 6 H); 13C NMR (75 MHz, CDCl3) " 150.8, 127.8, 
118.9, 107.3, 76.3, 41.5, 30.1, 27.7, 26.36, 26.33, 26.0; IR (thin film) 3437, 1926, 2852, 1723, 
1260 cm-1; HRMS (ESI) calcd for C11H17IO (M–I) 265.1274, found 265.1274. 
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Preparation of (S)-2-methylene-1-phenylbut-3-en-1-ol (2.3a) from (S)-1-
(4-bromophenyl)-2-methylenebut-3-en-1-ol (2.3f): Compound 2.3f (16 mg, 
0.067 mmol) was dissolved in THF (2 mL) and cooled to –78 °C. Then n-
BuLi (0.53 mL of 2.5 M solution, 0.13 mmol) was added dropwise and the mixture was stirred 
for 15 minutes. Water (0.5 mL) was added dropwise and stirred for 5 minutes. The mixture was 
diluted with ethyl acetate, washed with brine, dried over Mg2SO4 and concentrated under 
reduced pressure. The residue was filtered through a short plug of silica. Compound 2.3a was 
obtained as a yellow oil (11 mg, 0.06 mmol, 93% yield, 69% ee). [!]D19 – 32.4 (c 1.0, CHCl3). 
 
2.5.6 Synthesis of aminoalcohols 2.18  
L-valinol (2.18b)77: Under argon atmosphere, THF (500 mL) was added to a 
round bottom flask containing lithium aluminum hydride  (15 g, 395 mmol) at 0 
°C. Then L-valine (30 g, 356 mmol) was added in small portions over 30 min. The mixture was 
then allowed to warm to r. t. follow by reflux for 16 h. After this time, the reaction mixture was 
cooled to 0 °C and diluted with diethyl ether (300 mL). Then 15 % NaOH (20 mL) and water 
where added slowly. The solution was stirred for 30 min and a white precipitate was formed, 
which was removed by filtration. The filter cake was washed with diethyl ether. Combined 
organic filtrates were dried over Na2SO4 and concentrated under reduced pressure. The residue 
was purified by distillation (80-90 °C at 10 Torr). Pure L-valinol was obtained as a clear oil 
(17.8 g, 172.6 mmol, 67%).  [!]D20 + 12.7 (neat).Literature value: [!]D20 + 14.6 (neat). 
 
 D-phenylglycinol (2.18d)77: Prepared following the procedure reported for L-
valinol. D-phenylglucine methyl ester (20g, 99 mmol), lithium aluminum hydride 
i-Pr
OH
NH2
Ph
OH
NH2
OH
 101 
(7.53g, 198 mmol). Compound obtained as white crystals (11.55 g, 84 mmol, 85%). [!]D19 – 
36.15 (c 0.76, 1 M HCl).  Literature value: [!]D25 – 32 (c 0.75, 1 M HCl). 78  
 
2.5.7 General procedure for synthesis of bis(oxazoline) carbazole ligand 2.4 from 1,8-
dihalocarbazole 2.17 via Pd–catalyzed carbonylative amidation followed by CH3SO2Cl 
induced cyclization 
 Modified procedures from the literature were used.50, 79 To a solution of 0.5 mmol of the 
1,8-diiodocarbazole and Pd(PPh3)4 (20 mol%) in 5 mL of dry, degassed DMF was added the 
corresponding amino alcohol (2.6 equiv) and Et3N  (4 equiv) via a syringe.  CO gas was then 
bubbled through the reaction mixture and a balloon of CO placed over the reaction flask.  The 
reaction mixture was stirred at 60 °C for 8 h.  After the mixture was cooled down it was diluted 
with CH2Cl2, washed with brine and 1 M CuSO4 several times.  The organic phase was dried 
over Na2SO4 and concentrated under reduced pressure to give the desired bisamide. The 
bisamide was partially purified by passing through a short silica bed and eluting with CH2Cl2 and 
methanol. The eluent was concentrated under reduced presusre, dried under vacuum and the 
bisamide thus obtained was dissolved in 3 mL CH2Cl2.  NEt3 (2 equiv) was added and the 
solution was cooled to 0 °C.  Methanesulfonyl chloride (2.5 equiv) was added and the reaction 
mixture was allowed to warm to room temperature and stirred overnight.  It was then poured into 
saturated aq. NH4Cl, the organic layer was separated and the aqueous layer extracted with 
CH2Cl2.  The combined organic layers were dried over Na2SO4 and concentrated under reduced 
pressure.  The residue was treated with 5% methanolic KOH soln. (3 mL) and heated under 
reflux for 3 h.  The solvent was evaporated, residue poured into H2O and extracted with CH2Cl2.  
The organic phase was dried over Na2SO4 and concentrated under reduced pressure to obtain 
desired product, which was purified by column chromatography. 
 102 
 (4S,4'S)-2,2'-(3,6-diphenyl-9H-carbazole-1,8-diyl)bis(4-methyl-4,5-
dihydrooxazole) (2.4a)47b: Purification by column chromatography (1:1 
CH2Cl2  in hexanes) and recrystallization (from hexanes/EtOAc) afforded 
the product as a yellow solid (121 mg, 0.25 mmol, 48%). 1H NMR (300 
MHz, CDCl3) ! 12.00 (s, 1H) 8.48 (d, J = 1.8 Hz, 2H), 8.22 (d, J = 1.8 Hz, 2H), 7.77-7.80 (m, 
4H), 7.49-7.54 (m, 4H), 7.36-7.41 (m, 2H), 4.61-4.70 (m, 4H), 4.05-4.09 (m, 2H), 1.55 (d, J = 
6.3 Hz, 6H); 13C NMR (75.4 MHz, CDCl3) " 162.6, 141.4, 138.8, 132.5, 128.8, 127.3, 126.7, 
125.2, 124.2, 121.9, 110.7, 73.6, 62.3, 21.7. 
 
 (4R,4'R)-2,2'-(3,6-diphenyl-9H-carbazole-1,8-diyl)bis(4-((R)-1-
methoxyethyl)-4,5-dihydrooxazole) (2.4f): Purification by column 
chromatography (1 to 3% MeOH in CH2Cl2) afforded 61% of the product 
as a yellow solid. Mp 147-148 °C; 1H NMR (300 MHz, CDCl3) "  8.43 (d, 
J = 1.5 Hz, 2H), 8.18 (d, J = 1.8 Hz, 2H), 7.71-7.74 (m, 4H), 7.42-7.47 (m, 4H), 7.29-7.35 (m, 
2H), 4.64-4.66 (m, 2H), 4.43-4.46 (m, 4H), 3.68-3.71 (m, 2H), 3.44 (s, 6H), 1.31 (d, J = 6.3 Hz, 
6H); 13C NMR (75.5 MHz, CDCl3) " 163.8, 141.5, 139.1, 132.7, 129.0, 127.5, 126.9, 125.6, 
124.4, 122.2, 110.8, 77.8, 70.4, 68.1, 57.3, 14.7; HRMS Calcd for C36H36N3O4: 574.2706 [M + 
H]+. Found: 574.2704; [!]D23 + 35.313; (c 1.0, CHCl3).  
 
 (4S,4'S)-2,2'-(3,6-di-tert-butyl-9H-carbazole-1,8-diyl)bis(4-isopropyl-
4,5-dihydrooxazole) (2.4i): Purification by flash chromatography (3:1 
CH2Cl2 in hexanes) afforded 51% of the product as a yellow solid. mp 
178-180 °C; 1H NMR (300 MHz, CDCl3) " 11.80 (s, 1H), 8.30 (d, J = 
N
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1.5 Hz, 2H), 8.03 (d, J = 1.8 Hz, 2H), 4.47-4.56 (m, 2H), 4.19-4.30 (m, 4H), 1.90-1.97 (m, 2H), 
1.54 (s, 18H), 1.20 (d, J = 6.6 Hz, 6H), 1.07 (d, J = 6.6 Hz, 6H); 13C NMR (75.4 MHz, CDCl3) !  
162.7, 141.5, 137.6, 123.4, 123.2, 119.7, 109.7, 72.9, 69.8, 34.8, 33.4, 32.1, 19.2, 18.7; IR 
3354.9, 2959.0, 1649.3, 1487.8, 1283.0 HRMS Calcd for C32H44N3O2: 502.3434 [M + H]+, 
found: 502.3427; [!]D18 = + 63.96 (c 1.0, CHCl3). 
 
2.5.8. General procedure for synthesis of bis(oxazoline) carbazole ligand 2.4 from 1,8-
dihalocarbazole 2.17 via Pd–catalyzed carbonylative amidation followed by BF3•OEt2 
induced cyclization 
 A modified procedure reported by Nakada et al was used.50  To a solution of 0.5 mmol 
of the 1,8-diiodocarbazole and Pd(PPh3)4 (20 mol%) in 5 mL of dry, degassed DMF was added 
the corresponding amino alcohol (2.6 equiv) and Et3N  (4 equiv) via a syringe.  CO gas was then 
bubbled through the reaction mixture and a balloon of CO placed over the reaction flask.  The 
reaction mixture was stirred at 60 °C for 8 h.  After the mixture was cooled down it was diluted 
with CH2Cl2, washed with brine and 1 M CuSO4 several times.  The organic phase was dried 
over Na2SO4 and concentrated under reduced pressure to give the desired bisamide 2.19.  The 
bisamide was partially purified by passing through a short silica bed and eluting with CH2Cl2 and 
methanol.  The eluent was concentrated under reduced pressure and the bisamide thus obtained 
was suspended in 15% w/v of BF3•Et2O.  The resulting suspension was stirred at 120 °C for 6 h. 
The red mixture was cooled to room temperature and poured into ice cold 2 M NaOH (5 mL), 
extracted with CH2Cl2, washed with a saturated solution of NaHCO3, dried over Na2SO4 and 
concentrated under reduced pressure.  The residue was purified by flash chromatography to 
afford the desired ligand.   
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 (4S,4'S)-2,2'-(3,6-diphenyl-9H-carbazole-1,8-diyl)bis(4-isopropyl-4,5-
dihydrooxazole)47b: Purification by flash chromatography (20%-50% 
CH2Cl2 in hexanes) afforded the product as a yellow solid (430 mg, 0.79  
mmol, 57%). 1H NMR (CDCl3, 300 MHz) " 8.48 (d, J = 1.44 Hz, 2 H), 
8.21(d, J = 1.69 Hz, 2 H), 7.77 (d, J = 7.80 H, 4 H), 7.53-7.46 (m, 4H), 7.37 (app t, J = 7.30 Hz, 
2H), 4.58-4.46 (m, 2H), 4.33-4.20 (m, 4H), 1.94 (oct, J = 6.58 Hz, 2H), 1.19 (d, J = 6.69 Hz, 6 
H), 1.06 (d, J = 6.69 Hz, 6 H); 13C NMR (75 MHz, CDCl3) " 162.3, 141.4, 138.8, 132.4, 128.8, 
127.3, 126.7, 125.2, 124.2, 121.8, 110.8, 72.9, 69.9, 33.4, 19.6, 18.6. 
 
 (4R,4'R)-2,2'-(3,6-diphenyl-9H-carbazole-1,8-diyl)bis(4-phenyl-4,5-
dihydrooxazole) (2.4d): Purification by flash chromatography (50% 
CH2Cl2 in hexanes) afforded the product as a bright yellow solid (164 mg, 
0.27 mmol, 27%).  1H NMR (CDCl3, 300 MHz) " 11.91 (s br, 1 H), 8.51 
(d, J = 1.23, 2 H), 8.29 (d, J = 1.67, 2 H), 7.8 (d, J = 8.7, 4 H), 7.53 (d, J = 7.4, 4 H), 7.45-7.28 
(m, 12 H), 5.55 (t, J = 9.43 2 H), 4.90 (dd, J = 8.52, 9.17, 2 H), 4.36 (t, J = 8.70 2 H); 13C NMR 
(75 MHz, CDCl3) " 163.9, 142.6, 141.5, 139.1, 132.7, 129.1, 128.8, 127.5, 127.0, 126.9, 125.5, 
124.5, 122.4, 110.7, 74.0, 70.1; IR (thin film) 3354.1, 3059.6, 2962.4, 1949.1, 1719.0. 1645.8, 
1478.8; HRMS (MALDI) calcd for C42H31N3O2 (M + H) 609.2416 found 609.9933 [!]D18 = –
135.6 (c 1.0, CHCl3). 
 
 (4S,4'S)-2,2'-(3,6-diphenyl-9H-carbazole-1,8-diyl)bis(4-benzyl-4,5-
dihydrooxazole) (2.4e): Purification by flash chromatography (50% 
CH2Cl2 in hexanes) affords the product as a bright yellow solid (159 mg, 
0.25 mmol, 25%). 1H NMR (CDCl3, 300 MHz)  & 11.91 (s br, 1 H), 8.41 
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(d, J = 1.84 Hz, 2 H), 8.12 (d, J = 1.67 Hz, 2 H), 7.68 (d, J = 8.0 Hz, 4 H), 7.41 (d, J = 7.1 Hz, 4 
H), 7.25 (m, 12 H), 4.7 (quint, J = 7.51 Hz, 2 H), 4.55-4.33 (m, 6 H), 4.12 (app t, J = 8.0 Hz, 2 
H), 3.22 (dd, J = 5.5, 13.79 Hz, 2 H), 2.82 (dd, J = 8.32, 13.7 Hz, 2 H); 13C NMR (75 MHz, 
CDCl3) & 163.0, 141.3, 138.8, 138.0, 132.5, 129.4, 128.8, 128.5, 127.3, 126.7, 126.4, 125.3, 
124.2, 122.0, 110.7, 71.3, 67.8, 42.0; IR (thin film) 3345.1, 2897.0, 1646.3, 1619.8, 1478.3, 
1265.6; HRMS (MALDI) calcd for C44H35N3O2 (M + H) 638.2802, found 638.2807 [$]D18 = + 
51.34 (c 1.0, CHCl3). 
 
 (4S,4'S)-2,2'-(3,6-di(naphthalen-1-yl)-9H-carbazole-1,8-
diyl)bis(4-isopropyl-4,5-dihydrooxazole) (2.4g): Purification 
by flash chromatography (4:1 hexanes/CH2Cl2) afforded 35% 
of the product as a yellow solid. mp 139-141 oC; 1H NMR (300 
MHz, CDCl3) " 1.06 (d, J = 6.3 Hz, 6H), 1.20 (d, J = 6.6 Hz, 6H), 1.91-1.95 (m, 2H), 4.18-4.29 
(m, 4H), 4.47-4.52 (m, 2H), 7.39-7.55 (m, 8H), 7.85-7.97 (m, 6H), 8.10 (d, J = 1.5 Hz, 2H), 8.31 
(d, J = 1.5 Hz, 2H), 12.20 (s, 1H); 13C NMR (75.4 MHz, CDCl3) " 18.9, 19.4, 33.7, 70.1, 73.1, 
110.6, 123.7, 125.0, 125.5, 125.9, 126.2, 126.3, 127.6, 127.7, 128.1, 128.4, 131.7, 132.3, 134.0, 
138.9, 140.4, 162.6; IR 3429.6, 1719.3, 1508.4; HRMS Calcd for C44H40N3O2: 642.3114 [M + 
H]+, found: 642.3123; [!]D18 = + 30.01 (c 1.0, CHCl3). 
 
  (4S,4'S)-2,2'-(3,6-di(naphthalen-2-yl)-9H-carbazole-1,8-
diyl)bis(4-isopropyl-4,5-dihydrooxazole) (2.4h): Prepared 
by a modification of previously reported procedures50. 
Compound 2.16c (470 mg, 1.12 mmol) was suspended in a 
mixture of AcOH, H2O and H2SO4 (1: 0.2: 0.03). After addition of I2 (142 mg, 1.12 mmol) and 
N
HO N N O
i-Pr i-Pr
N
HO N N O
i-Pr i-Pr
 106 
HIO4·2H2O (127 mg, 0.56 mmol), the pink suspension was stirred at 80 °C for 5 hours. The 
mixture was then cooled down to r.t. and poured into water. The solid was filtrated and dried 
under reduced pressure (600 mg, 0.89 mmol, 80% crude yield). After recrystallization from 
toluene pure 1,8-diiodo-3,6-di(naphthalen-2-yl)-9H-carbazole was obtained as a pink solid (130 
mg, 0.2 mmol, 18% yield. Next, the procedure described above for the synthesis of bis-oxazoline 
carbazoles was followed. Purification by flash chromatography (50 to 80% CH2Cl2 in hexanes) 
afforded the title compound as a yellow solid, more than 90% pure (32 mg, 0.05 mmol, 25% 
yield). 1H NMR (CDCl3, 300 MHz)  " 8.65 (s, 2 H), 8.35 (m, 2 H), 8.22 (m, 2 H), 7.99-7.88 (m, 
8 H), 7.58-7.46 (m, 4 H), 4.54 (m, 2 H), 4.28 (m, 4 H), 1.95 (m, 2 H), 1.22 (d, J = 6.17 Hz, 6 H), 
1.08 (d, J = 6.36 Hz, 6 H); 13C NMR (75 MHz, CDCl3) " 162.4, 138.9, 138.7, 133.8, 132.37, 
132.33, 128.4, 128.1, 127.6, 126.2, 125.9, 125.7, 125.6, 125.5, 124.3, 122.1, 110.9, 72.9, 70.0, 
33.4, 19.2, 18.6; IR (thin film) 3052.9, 2958.6, 1649.14, 1601.4, 1486.1, 14363.7; MS (APCI) 
calcd for C44H35N3O2 (M + H) 642.31, found 642.54. [!]D18 = + 55.6 (c 1.0, CHCl3). 
 
2.5.9 Representative procedure for the synthesis of carbazoles 2.16 
 Prepared by modification of the procedure reported by Nakada et al47b 3,6 
diiodocarbazole 2.14 (2 g, 4.84 mmol), boronic acid 2.15 (14.5 mmol) and Ba(OH)2·8H2O (4.5 g, 
14.5 mmol) weere dissolved in a 6:1 mixture of DME/H2O (60 mL).  A solution of Pd(OAc)2 
(54.3 mg, 0.24 mmol) and P(o-tol)3 (148 mg, 0.48 mmol) in DME (5mL) was then added via 
cannula.  The mixture was stirred at 80 °C for 18 h and then cooled to rt. The precipitate was 
removed by filtration and the filtrate was extracted with CH2Cl2. The organic phase was dried 
over Mg2SO4 and concentrated under reduced pressure.   
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 3,6-diphenyl-9H-carbazole (2.16a)47b: Purified by column 
chromatography  (25% CH2Cl2 in hexanes) to give a white solid  (4.1 g, 
12.8 mmol, 65%) 1H NMR (CDCl3, 300 MHz) " 8.36 (d, J = 2.90, 2 H), 
8.14 (s, 1 H), 7.73 (m, 4 H), 7.70 (d, J = 1.82 Hz, 2 H), 7.54 (d, J =0.52 Hz, 2 H), 7.52-7.46 (m, 
4 H), 7.36 (tt, J =1.20, 6.60 Hz, 2H);  13C NMR (75 MHz, CDCl3) " 142.0, 139.4, 133.2, 128.8, 
127.3, 126.3, 125.6, 124.0, 118.9, 110.9. 
 
3,6-di(naphthalen-2-yl)-9H-carbazole (2.16c): Purified by 
column chromatography (30% CH2Cl2 in hexanes) and then 
recrystallized from toluene. The product was obtained in 23% 
yield as a white solid. 1H NMR (CDCl3, 300 MHz)  "  8.53 (s, 2 H), 8.19 (s, 3 H), 8.01-7.83 (m, 
10 H), 7.61-7.47 (m, 6H); 13C NMR (75 MHz, CDCl3) " 139.7, 139.5, 134.1, 133.2, 132.5, 
128.6, 128.3, 127.9, 126.4, 126.3, 126.1, 125.9, 125.8, 124.3, 119.5, 111.3; HRMS (MALDI) 
calcd for C32H22N (M + H) 420.1752, found 420.5908.  
 
2.5.10 Synthesis of di-iodocarbazoles 2.17 
1,8-diiodo-3,6-diphenyl-9H-carbazole (2.17a)47b: Carbazole 2.17a 
(2.37 g, 7.42 mmol) was suspended in a mixture of AcOH, H2O and 
H2SO4 (1: 0.2: 0.03). After addition of I2 (0.94 g, 7.42 mmol) and 
HIO4·2H2O (0.85 g, 3.71 mmol), the pink suspension was stirred at 80 °C for 5 hours. The 
mixture was then cooled down to r.t. and poured into water. The solid was filtrated and washed 
with a saturated solution of NaS2O3, NaHCO3 and brine. After recrystallization from toluene the 
pure compound was obtained as a pink solid (1.42 g, 2.5 mmol, 34%). 1H NMR (CDCl3, 300 
MHz) " 8.23 (d, J = 1.22 Hz, 2 H), 8.16 (s, 1H), 8.07 (d, J = 1.47 Hz, 2H), 7.67 (d, J = 7.50 Hz, 
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4H), 7.52-7.45 (m 4 H), 7.38 (tt, J = 1.33, 3.79 Hz, 2 H); 13C NMR (75 MHz, CDCl3) " 140.4, 
140.3, 135.6, 134.4, 128.9, 127.3, 127.1, 124.6, 119.4, 76.4. 
 
1,8-diiodo-3,6-di(naphthalen-1-yl)-9H-carbazole (2.17b)50, 80: 
BnMe3NCl2I was added to a suspension of 2.16b in a mixture 
of AcOH (33 mL) and H2SO4 (1 mL). The mixture was stirred 
at 60 °C until the reaction was completed as judged by TLC. 
The mixture was cooled to rt and poured into 60 mL of water. The precipitate was filtered and 
partitioned between EtOAc (33 mL) and a saturated solution of NaHCO3 (10 mL). The organic 
layer was washed with a saturated solution of Na2S2O3 (20 mL) and brine (40 mL), dried over 
Na2SO4 and concentrated under reduced pressure. Flash chromatography (ethyl acetate:hexanes, 
1:50) afforded title compound, more than 90% pure, in 40% yield. 1H NMR (CDCl3, 300 MHz) 
"  8.32 (s, 1H), 8.11 (s, 2H), 7.99 (d, J = 1.39 Hz, 2H), 7.94-7.85 (m, 7H), 7.57-7.40 (m, 7H); 
13C NMR (75 MHz, CDCl3) " 140.3, 139.0, 136.9, 136.8, 134.7, 133.7, 131.8, 128.3, 127.8, 
127.4, 127.1, 126.2, 125.8, 125.3, 124.0, 122.3; IR 3429.9, 3054.3, 2924.4, 1722.1, 1508.4 
HRMS (MALDI) calcd for C32H19I2N (M - I) 544.0557, found 544.2573. 
 
2.5.11 Preparation of 3-methyl-1-phenyl-4-((trimethylsilyl)methyl)hexa-4,5-dien-3-ol 
(2.33a) under acidic conditions 
   Inside a nitrogen atmosphere drybox, a mixture of CrCl3 (17 mg, 0.1 mmol, 0.3 equiv), 
Mn powder 325-mesh (40 mg, 0.7 mmol, 2 equiv) were added to a 2-dram vial. Then, the vial 
was capped with a teflon lid and it was removed from the drybox. Dry THF (2.5 mL) was added 
by syringe and a suspension was formed. Then, TMSCl (93 µL, 0.7 mmol, 2 equiv) and Et3N (50 
µL, 0.3 mmol, 1 equiv) were added by syringe. The mixture is allowed to stir 20 minutes and (4-
N
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bromo-2-butyn-1-yl)trimethylsilane (222 mg, 1 mmol, 3 equiv) is added. After 30 min, the 
ketone (0.36 mmol, 1 equiv) is added and the mixture is stirred for 24 hours. 1 M HCl was added 
and the obtained green solution was stirred until the alcohol is completely deprotected as judged 
by TLC. A saturated solution of NH4Cl (2 mL) was added and the mixture was extracted with 
three portions of ethyl acetate. The combined organic fractions were washed with brine, dried 
over Mg2SO4 and concentrated under reduced pressure. The residue was purified by column 
chromatography or preparative thin layer chromatography (10% EtOAc in hexanes as eluent) 
and was obtained as a clear oil. 1H NMR (CDCl3, 300 MHz) &  7.23-7.17 (m, 2 H), 7.21-7.15 (m, 
3 H), 4.38 (t, J = 3.59 Hz, 2H), 2.65-2.44 (m, 2 H), 1.94-1.78 (m, 2 H), 1.74 (s, 1 H), 1.33-1.24 
(dt, J = 3.51, 15.6 Hz, 1 H), 1.27 (s, 3 H), 1.23-1.15 24 (dt, J = 3.30, 15.62 Hz, 1 H), 0.0 (s, 9 H); 
13C NMR (75 MHz, CDCl3) & 204.6, 142.5, 128.3, 128.3, 125.6, 107.5, 79.4, 27.9, 42.2, 30.4, 
27.1, 15.2, -0.8; IR (thin film) 3454.3, 3085.6, 2952.4, 1949.05, 1603.7, 1496.6 HRMS (ESI) 
calcd for C17H17OSi (M + H) 275.1831 found 275.1753.  
 
2.5.12 General method for the preparation of tertiary 1,3-butadien-2-ylcarbinols (2.41) 
 
 Inside a nitrogen atmosphere drybox, a mixture of CrCl3 (17 mg, 0.1 mmol, 0.3 equiv), 
Mn powder 325-mesh (40 mg, 0.7 mmol, 2 equiv) were added to a 2-dram vial. Then, the vial 
was capped with a teflon lid and it was removed from the drybox. Dry THF (2.5 mL) was added 
by syringe and a suspension was formed. Then, TMSCl (93 µL, 0.7 mmol, 2 equiv) and Et3N (50 
µL, 0.3 mmol, 1 equiv) were added by syringe. The mixture is allowed to stir 20 minutes and (4-
bromo-2-butyn-1-yl)trimethylsilane (222 mg, 1 mmol, 3 equiv) is added. After 30 min, the 
ketone (0.36 mmol, 1 equv) is added and the mixture is stirred for 24 hours. After this time the 
suspension is filtered through a path of silica gel and rinsed with ether. The solvent is removed 
and the residue is redisolved in THF (1 mL). TBAF (2.88 mL of a 1 M solution, 2.88 mmol, 8 
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equiv) is added and the solution is stirred for 20 hours or until the reaction is completed as 
judged by TLC. A saturated solution of NH4Cl (2 mL) was added and the mixture was extracted 
with three portions of ethyl acetate. The combined organic fractions were washed with brine, 
dried over Mg2SO4 and concentrated under reduced pressure. The residue was purified by 
column chromatography or preparative thin layer chromatography. 
 
3-methyl-4-methylene-1-phenylhex-5-en-3-ol (2.41a): Obtained as a clear 
yellow oil (25 mg, 0.12 mmol, 69%). 1H NMR (CDCl3, 300 MHz) &  7.31-
7.25 (m, 2 H), 7.21-7.15 (m, 3 H), 6.38 (dd, J = 10.9, 17.0 Hz, 1 H), 5.54 (dd, J = 1.84, 17.12 
Hz, 1 H), 5.35 (s, 1 H), 5.17 (d, J = 1.35 Hz, 1 H), 5.44 (dd, J = 1.97, 10.93 Hz, 1 H), 2.96-2.49 
(m, 2 H), 1.94 (d, J = 8.83 Hz, 1 H), 1.92 (d,  J = 10.2 Hz, 1 H), 1.56 (s br, 1 H), 1.42 (s, 3 H); 
13C NMR (75 MHz, CDCl3) & 152.7, 142.3, 135.4, 128.3, 128.3, 125.7, 115.9, 110.0, 74.6, 42.8, 
30.1, 28.2; IR (thin film) 3452.5, 3085.1, 2931.7, 1603.7 HRMS (ESI) calcd for C14H18O (M + 
Li) 209.1518, found 209.1577.  
 
2-cyclohexyl-3-methylenepent-4-en-2-ol (2.41b): Obtained as a tan oil (26 
mg, 0.14 mmol, 41%). 1H NMR (CDCl3, 300 MHz) &  6.27 (dd, J = 10.5, 
16.5 Hz, 1 H), 5.39 (dd, J = 2.1, 17.4 Hz, 1 H), 5.16 (t, J = 1.31 Hz, 1 H), 4.99 (dd, J = 2.9, 11.0 
Hz, 1H), 4.66 (dd, J = 1.66, 4.96 Hz, 1H), 1.76-1.58 (m, 5 H), 1.42-1.30 (m, 2H), 1.23 (s, 3 H), 
1.12-0.92 (m, 5 H); 13C NMR (75 MHz, CDCl3) & 153.4, 135.7, 115.5, 109.5, 76.5, 44.9, 26.7, 
26.6, 26.4, 24.6  IR (thin film) 3462.4, 2929.8, 2852.9, 1450.4, 1372.5 cm-1; GC/MS calcd for 
C12H20O (M) 181.1: found 181.1.  
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1-(buta-1,3-dien-2-yl)cyclohexanol (2.41c)58: Obtained as clear oil (9 mg, 
0.06 mmol, 23%). 1H NMR (CDCl3, 300 MHz) &  6.31 (dd, J = 11.9, 18.4 Hz, 
1 H), 5.46 (dd, J = 2.24, 17.45 Hz, 1 H), 5.14 (d, J = 1.37 Hz, 1 H), 5.08 (d, J = 1.38 Hz, 1H), 
5.08 (dd, J = 1.51, 11.18 Hz, 1H), 1.9-1.60 (m, 10 H). 1.31 (s, 1 H);  13C NMR (75 MHz, CDCl3) 
& 151.7, 135.9, 115.7, 109.9, 83.7, 39.1, 23.7, 23.7; IR (thin film) 3386.3, 2960.6, 2873.2, 
1630.1, 1422.4, 1377.2 cm-1; GC/MS calcd for C10H16O (M) 152.1, found 152.1.  
 
3-methylene-2-phenylpent-4-en-2-ol (2.41d)81: Obtained as a clear oil 
(28.5 mg, 0.16 mmol, 45%).1H NMR (CDCl3, 300 MHz)  & 7.48-7.43 (m, 
2 H), 7.37-7.23 (m, 3 H), 6.11 (dd, J = 11.4, 17.72 Hz, 1 H), 5.37 (d, J = 9.85 Hz, 2 H), 5.28 (dd, 
J = 1.69, 17.66 Hz, 1 H), 5.00 (dd, J = 1.53, 11.08 Hz, 1 H), 2.04 (s, 1 H), 1.71 (s, 3 H).  13C 
NMR (75 MHz, CDCl3) & 151.7, 146.0, 135.4, 128.2, 126.9, 125.2, 116.5, 112.0, 76.0, 29.5; IR 
(thin film) 3449.7, 3086.2, 2979.80 1632.0; HRMS (ESI) calcd for C12H14O (M+Li) 181.1205, 
found 181.1197. 
 
3-methylene-2-p-tolylpent-4-en-2-ol (2.41e): Obtained as a clear oil 
(35 mg, 0.18 mmol, 53%). 1H NMR (CDCl3, 300 MHz) &  7.37 (d, J = 
8.27 Hz, 2 H), 7.17 (d, J = 8.27 Hz, 2 H), 6.16 (dd, J = 11.11, 17.38 
Hz, 1 H), 5.39 (d, J = 9.05 Hz, 2 H), 5.32 (dd, J = 1.63, 17.58 Hz, 1 H), 5.03 (dd, J = 1.68, 11.23 
Hz, 1 H), 2.37 (s, 3 H), 2.02 (s, 1 H), 1.72 (s, 3 H); 13C NMR (75 MHz, CDCl3) & 151.9, 143.1, 
136.6, 135.5, 128.9, 125.2, 116.4, 111.7, 75.9, 29.4, 21.0; IR (thin film) 3450, 2979, 2924, 1955, 
1610 cm-1; HRMS (ESI) calcd for C13H16O (M+Li) 195.1361, found 195.1367. 
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2-(4-bromophenyl)-3-methylenepent-4-en-2-ol (2.41f): Obtained as a 
clear oil (59 mg, 0.23 mmol, 67%). 1H NMR (CDCl3, 300 MHz)  &  7.37 
(d, J = 8.6, Hz, 2 H), 7.25 (d, J = 8.6 Hz, 1 H), 6.02 (dd, J = 11.4, 17.8 Hz, 1H), 5.32 (s, 1 H), 
5.27 (s, 1 H), 5.20 (dd, J = 1.47, 17.42 Hz, 1 H), 4.95 (dd, J = 1.38, 11.15 Hz, 1 H), 1.95 (s, 1 H), 
1.60(s, 3H);  13C NMR (75 MHz, CDCl3) & 151.1, 145.2, 135.1, 131.2, 127.1, 120.9, 117.0, 
112.6, 75.8, 29.7 IR (thin film) cm-1; MS (APCI) calcd for C12H13BrO (M+Li) 251.0072, found 
251.0071.  
 
2-(4-methoxyphenyl)-3-methylenepent-4-en-2-ol (2.41g)81: Obtained 
as a clear oil (29 mg, 0.14 mmol, 51%).1H NMR (CDCl3, 300 
MHz)  &   7.36 (d, J = 9.42 Hz, 2 H), 6.86 (d, J = 9.42 Hz, 2 H) 6.11 
(dd, J = 11.35, 17.49 Hz, 1 H), 5.37 (s, 1 H), 5.35 (s, 1 H), 5.29 (d, J = 1.52, 17.4 Hz, 1 H), 5.01 
(dd, J = 1.71, 17.4 Hz, 1 H), 3.80 (s, 3 H), 1.99 (s, 1 H), 1.69 (s, 3 H);  13C NMR (75 MHz, 
CDCl3) &   158.5, 152.1, 138.1, 135.5, 126.5, 116.3, 113.5, 111.6, 75.7, 55.2, 19.3; IR (thin film) 
3473, 2977, 2934, 2836, 1955, 1610, 1510cm-1; MS (ESI) calcd for C13H16O2 (M-OH) 187.1117: 
found 187.1119.  
 
Preparation of 3-methylene-2-phenylpent-4-en-2-ol (3d)81 using ligand 2.4b 
 Inside a Nitrogen atmosphere drybox, CrCl3 (1.5 mg, 0.01 mmol), 2.4b47b (6 mg, 0.01 
mmol) and Mn0 powder 325-mesh (22 mg, 0.4 mmol) were added to a 2-dram vial. Then, the 
vial was capped with a Teflon lid and it was removed from the drybox. Dry THF (2 mL) was 
added via syringe and a gray suspension was formed. This was followed by addition of (4-
bromo-2-butyn-1-yl)trimethylsilane 2.5 (50 mg, 0.24 mmol). After 30 min, the mixture was 
cooled to 0 °C and acetophenone (23 µL, 0.2 mmol) followed by TMSCl (30 µL, 0.22 mmol) 
HO CH3
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were added. The mixture was stirred at room temperature for 18 h, 1 M HCl was added (1 mL) 
and was extracted with three portions of diethyl ether. The mixed organic phases were washed 
with brine, dried with Mg2SO4 and concentrated under reduced pressure. The residue was 
redissolved in THF (1.5 mL) and 1 M TBAF (1.5 mL) was added. When the reaction was 
completed, as judged by TLC, a saturated solution of NH4Cl (3 mL) was added and the mixture 
was extracted with three portions of EtOAc. The combined organic fractions were washed with 
brine, dried over Mg2SO4 and concentrated under reduced pressure. Enantiomeric excess 
determined by HPLC (250 nm) using a ChiralPAK AS-H column (hexanes : isopropanol = 98:2, 
flow rate = 0.6 mL/min) retention time: = 10.7 min, 11.5 min.  
 
2.5.13 Preparation of imines 
N-benzylideneaniline (2.58a)82: Prepared following the procedure described for 
the synthesis of compound 2.59. Product obtained as a light yellow solid (3 g, 
16.5 mmol, 60%) 1H NMR (CDCl3, 300 MHz) " 8.50 (s, 1 H), 7.99 (m, 2 H), 
7.55-7.49 (m, 3 H), 7.47-7.40 (m, 2 H), 7.28-7.22 (m, 3 H); 13C NMR (75 MHz, CDCl3) 160.4, 
152.0, 136.2, 131.3, 129.1, 128.8, 128.7, 125.9, 120.8.  
 
(4-bromobut-2-yn-1-yl)trimethylsilane (2.58b)83:  
p-(trifluoromethyl)benzaldehyde (1.36 mL, 10 mmol) and aniline (0.8 mL, 
9 mmol) were dissolved in Toluene (100 mL) and stirred under reflux for 
16 h. The solution was cooled to r.t. and toluene was removed under reduced pressure. After 
recrystallization from hexanes the product was obtained as a white solid. (1.93 g, 7.75 mmol, 
77%). 1H NMR (CDCl3, 300 MHz) " 8.54 (s, 1H), 8.06 (d, J = 8.04 Hz, 2 H), 7.77 (d, J = 8.21 
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Hz, 2 H), 7.49-7.41 (m, 2 H), 7.34-7.29 (m, 3 H); 13C NMR (75 MHz, CDCl3) 158.5, 129.2, 
128.9, 126.5, 125.6 (q, J = 4.3), 120.8. 
 
(4-bromobut-2-yn-1-yl)trimethylsilane (2.59)84: A mixture of benzaldehyde 
(2.6 mL, 25.6 mmol), benzylamine (2.8 mL, 25.6 mmol) and MgSO4 (7 g) in 25 
mL of benzene was stirred at r.t. for 24 h. After this time, MgSO4 was removed 
by filtration and rinsed with CH2Cl2. The solution was then concentrated under reduced pressure 
to give a yellow oil. The residue was distilled under reduced pressure  (105-120 °C at 320 
mTorr) to afford a clear oil (2.6 g, 13.3 mmol, 51 %). 1H NMR (CDCl3, 300 MHz) " 8.44 (t, J = 
1.42 Hz, 1 H), 7.85-8.81 (m, 2 H), 7.49-7.44 (m, 3 H), 7.40-7.38 (m, 4 H), 7.32 (m, 1 H), 4.87 
(d, J = 1.37 Hz, 2 H); 13C NMR (75 MHz, CDCl3) 162.0, 139.2, 136.1, 130.7, 128.6, 128.4, 
128.2, 127.9, 126.9, 65.0.  
 
 N-benzylidene-4-methylbenzenesulfonamide (2.60a)85: Following the 
procedure reported by Wynne et al. p-toluenesulfonamide (4.5 g, 26.28 mmol) 
was mixed with dry toluene (70 mL). Next, benzaldehyde (2.4 mL, 26.28 mmol) 
was added via syringe and the mixture was heated to reflux with a Dean-Stark trap for 24 h or 
until completion of the reaction as judged by H1 NMR. After the solution was cooled down, 
toluene was removed under reduced pressure to afford a white solid. The compound was 
recrystallized from diethyl ether to afford the pure imine as white (6.16 g, 23.7 mmol, 90%). 1H 
NMR (CDCl3, 300 MHz) " 9.02 (s, 1 H), 7.91 (m, 4 H), 7.6 (t, J = 7.05 Hz, 1 H), 7.48 (t, J = 
7.56 Hz, 2 H), 7.34 (d, J = 8.33 Hz, 2H), 2.43 (s, 3 H); 13C NMR (75 MHz, CDCl3) " 170.1, 
144.5, 134.4, 132.3, 131.2, 129.7, 129.1, 128.0, 126.2, 21.6. 
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2.5.14 General method for the preparation of N-tosyl imines 
 Following a modification of the procedure reported by Duguet86 et al. p-
toluenesulfonamide (1.4 g, 7.78 mmol) was mixed with dry toluene (70 mL). Next aldehyde 
(7.78 mmol) and BF3·OEt2 (300 µl) were sequentially added to the reaction mixture via syringe. 
Mixture was heated to reflux with a Dean-Stark trap for 24 h or until completion of the reaction 
as judged by H1 NMR. After the solution was cooled down, ethyl acetate was added to 
completely dissolve the newly formed precipitate (if any). The solution was washed with 1 M 
NaOH and brine. The organic phase was dried over Mg2SO4 and concentrated under reduced 
pressure. The solid was recrystallized from a mixture of ethyl acetate and hexanes to afford the 
pure imine.  
 
 N-(4-bromobenzylidene)-4-methylbenzenesulfonamide (2.60b)86: 
Obtained as a white solid (1.4 g, 4.18 mmol, 53%) 1H NMR (CDCl3, 300 
MHz) " 9.98 (s, 1H), 7.89 (d, J = 8.66 Hz, 2H), 7.79 (d, J = 8.66 Hz, 2H), 
7.65 (d, J = 8.28 Hz, 2H), 7.65 (d, J = 8.47 Hz, 2H), 2.45 (s, 3H); 13C NMR (75 MHz, CDCl3) " 
168.8, 144.8, 134.8, 132.5, 132.3, 131.2, 130.2, 129.8, 128.1, 21.6. 
 
4-methyl-N-(4-(trifluoromethyl)benzylidene)benzenesulfonamide 
(2.60c)87: Obtained as a white solid (1.95 g,  5.9  mmol, 31%) 1H NMR 
(CDCl3, 300 MHz) " 9.1 (s, 1H), 8.06 (d, J = 8.5 Hz, 2H), 7.91 (d, J = 8.23 
Hz, 2H), 7.76 (d, J = 8.53 Hz, 2H), 7.38 (d, J = 7.9 Hz, 2H), 2.4 (s, 3H); 13C NMR (75 MHz, 
CDCl3) " 168.4, 145.1, 134.4, 131.3, 129.9, 128.3, 126.2 (q, J = 3.9), 19.4; MS (ESI) calcd for 
C15H12F3NO2S  237.0541, found 237.9835.  
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 N-(4-methoxybenzylidene)-4-methylbenzenesulfonamide 
(2.60d)88: Obtained as white crystals (4.1 g, 14 mmol, 85%) 1H NMR 
(CDCl3, 300 MHz) " 9.95 (s, 1 H), 7.9 (d , J = 8.1 Hz, 2H), 7.8 (d, J = 8.4 
Hz, 2 H), 7.34 (d, J = 8.21 Hz, 2 H), 6.78 (d, J = 9.1 Hz, 2 H), 3.9 (s, 3 H), 2.4 (s, 3H); 13C NMR 
(75 MHz, CDCl3) " 169.2, 165.2, 144.5, 135.8, 133.7, 129.7, 127.9, 125.2, 114.6, 55.6, 21.7; 
HRMS (ESI) calcd for C15H15NO3S (M + H) 290.0851, found 290.0860.  
 
 4-methyl-N-((E)-3-phenylallylidene)benzenesulfonamide (2.60e)86:  
Obtained as light brown crystals (0.83 g, 1.33, 25%). 1H NMR (CDCl3, 
300 MHz) " 9.78 (d, J = 9.42 Hz, 1H), 7.86 (d, J = 8.8 Hz, 2H), 7.58-7.51 
(m, 2 H), 7.47-7.41 (m, 4 H), 7.34 (d, J = 8.0 Hz, 2H) 6.99 (dd, J = 9.36, 15.81 Hz, 2H), 2.43 (s, 
3 H); 13C NMR (75 MHz, CDCl3) " 170.9, 153.8, 144.5, 135.3, 134.1, 131.7, 129.8, 129.2, 
128.6, 128.0, 124.7, 21.7; HRMS (ESI) calcd for C16H15NO2S (M + H) 286.0902, found 
286.0913. 
 
 N-(2-bromobenzylidene)-4-methylbenzenesulfonamide (2.60h)89: Obtained 
as a white needles (1.4 g, 4.15 mmol, 81%) 1H NMR (CDCl3, 300 MHz) " 9.43 
(s, 1 H), 8.14 (dd, J = 2.03, 7.52 Hz, 1H), 7.90 (d, J = 8.51 Hz, 2 H), 7.65 (dd, J 
= 1.38, 7.74 Hz, 1 H), 7.47-7.44 (m, 4 H), 2.45 (s, 3H); 13C NMR (75 MHz, CDCl3) " 169.1, 
144.8, 135.7, 134.6, 133.7, 131.1, 130.6, 129.8, 128.8, 128.3, 127.9, 21.6; HRMS (ESI) calcd for 
C14H12BrNO2S 337.9850 found 337.9853.  
 
4-methyl-N-(3-phenylpropylidene)benzenesulfonamide (2.60f)90: Prepared 
following the procedure describer for the preparation of compound 2.60g as 
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previously described by Wipf.90 Obtained as a white solid after recrystallization from hexanes 
(1.4 g, 4.9 mmol, 49%). 1H NMR (CDCl3, 300 MHz) " 8.62 (t, J = 4.06 Hz, 1 H), 7.77 (d, J = 
8.53 Hz, 2H), 7.33 (J = 8.13 Hz, 2H), 7.28-7.10 (m, 5 H), 2.98-2.92 (m, 2 H), 2.88-2.80 (m, 2 
H), 2.4 (s, 3 H); 177.4, 144.7, 139.6, 134.3, 129.8, 128.6, 128.3, 128.1, 126.4, 37.3, 30.6, 21.6; 
IR (thin film) 2924.9, 1628.6, 1453.4, 1089.6 cm-1; HRMS (ESI) calcd for C16H17NO2S (M + Li) 
294.1140, found 294.1127. 
 
4-methyl-N-(2-methylbenzylidene)benzenesulfonamide (2.60g)91: Prepared 
following the procedure described by Chemla et al.71 Sodium p-toluenesulfinate 
-methylbenzaldehyde (1.15 mL, 10 mmol) were dissolved in a 1:1 solution of 
formic acid/H2O (30 mL). The mixture was stirred at r.t. for 1 week until the aldehyde was 
consumed as judged by TLC. After this time, the white precipitate was collected by filtration and 
rinsed with water and hexanes. The white solid was dissolved in CH2Cl2 (50 mL), a saturated 
solution of NaHCO3 (50 mL) was added and the mixture was stirred for 2 h.  The aqueous layer 
was extracted with CH2Cl2. The combined organic phases were washed with brine dried over 
MgSO4 and concentrated under reduced pressure. The desired imine was obtained as a white 
solid and was used without further purification (2.02 g, 7.4 mmol, 74%) 1H NMR (CDCl3, 300 
MHz) " 9.95 (s, 1 H), 7.9 (d, J = 8.1 Hz, 2H), 7.8 (d, J = 8.4 Hz, 2 H), 7.34 (d, J = 8.21 Hz, 2 H), 
6.78 (d, J = 9.1 Hz, 2 H), 3.9 (s, 3 H), 2.4 (s, 3H); 13C NMR (75 MHz, CDCl3) " 168.6, 144.4, 
142.2, 135.4, 134.5, 131.4, 130.46 130.4, 129.7, 128.0, 126.5, 21.5, 19.6. 
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2.5.15 4-methyl-N-(1-phenylbut-3-en-1-yl)benzenesulfonamide (2.62)67  
 Inside a Nitrogen atmosphene Drybox, a mixture of CrCl3 (4.5 mg, 
0.03 mmol) and Mn powder 325-mesh (33mg, 0.66 mmol) were added to a 
2-dram vial. The vial was capped with a Teflon lid and it was removed from 
the drybox. Tosylimine 2.60a (77mg, 0.3 mmol) was added to the mixture and the vial was 
flushed with argon. Dry THF (2 mL) was added via syringe and a brown suspension was formed. 
This was followed by addition of TMSCl (42 µl, 0.33 mmol) and freshly distilled allyl bromide 
(40 µl, 0.45 mmol). The mixture was stirred at room temperature for 16 h. ethyl acetate (1 -2 
mL) was added to the gray suspension and the mixture was filtered trough a path of silica to 
remove solids. The resulting clear solution was concentrated under reduced pressure and the 
residue was redisolved in THF (3 mL). TBAF (1 M in THF, 0.3 mL, 0.3 mmol) was added and 
the mixture was stirred for 10 min. A saturated solution of NH4Cl was added and the mixture 
was extracted with ethyl acetate. The organic phases were dried over Mg2SO4, filtered though a 
path of silica and concentrated under reduced pressure. The residue was purified by flash 
chromatography using a gradient of ethyl acetate in hexanes (15 to 20%) to afford the desired 
product as a clear oil (80 mg, 0.27 mmol, 88%) 1H NMR (CDCl3, 300 MHz) " 7.57 (d, J = 7.57 
Hz, 2 H), 7.20-7.05 (m, 7 H), 5.51 (m, 1 H), 5.23 (d, J = 6.98 Hz, 1 H), 5.13 (m, 2 H), 4.46 (q, J 
= 6.84 Hz, 1H), 2.46 (q, J = 6.24 Hz, 2 H), 2.37 (s, 3H); 13C NMR (75 MHz, CDCl3) " 143.0, 
140.3, 137.5, 133.1, 129.2, 128.3, 127.3, 127.1, 126.5, 119.1, 57.2, 41.8, 21.4. 
 
2.5.16 General Method for the preparation of (silylmethyl)allenic amines 
 Inside a Nitrogen atmosphene Drybox, a mixture of CrCl2 (11 mg, 0.09 mmol) and Mn 
powder 325-mesh (33mg, 0.66 mmol) were added to a 2-dram vial. The vial was capped with a 
Teflon lid and it was removed from the drybox. The tosylimine  (0.3 mmol) was added to the 
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mixture and the vial was flushed with argon. Dry THF (2 mL) was added via syringe and a 
brown suspension was formed. This was followed by addition of TMSCl (42 µl, 0.33 mmol) and 
(4-bromo-2-butyn-1-yl)trimethyl-silane (120 mg, 0.6 mmol). The mixture was stirred at room 
temperature for 48 h. Et3N (1 mL) and ethyl acetate (1 -2 mL) were added to the gray suspension 
and the brown mixture was filtered trough a path of silica using ethyl acetate as eluent.  The 
resulting clear solution was concentrated under reduced pressure and the residue was redisolved 
in THF (3 mL). TBAF (1 M in THF, 0.45 mL, 0.45 mmol) was added to the solution in two parts 
over 10 minutes. The mixture was stirred for a maximum of 30 min or until the majority of 
propargylamine is consumed to afford the corresponding homoallenic amine as judged by TLC 
(eluent 20% ethyl acetate in hexanes). The yellow solution was again filtered through a path of 
silica using ethyl acetate as eluent. The resulting solution was concentrated under reduced 
pressure to give a yellow oil. The residue was purified by flash chromatography using a gradient 
of ethyl acetate in hexanes (0 to 10%). 
 
 4-methyl-N-(1-phenyl-2-((trimethylsilyl)methyl)buta-2,3-dien-1-
yl)benzenesulfonamide (2.63a): Obtained as a white solid (83 mg, 22 
mmol, 73%). 1H NMR (CDCl3, 300 MHz) " 7.60 (d, 2 H), 7.25-7.13 (m, 7 
H), 5.06 (d, J = 7.99 Hz, 1 H), 4.95-4.88 (dq, J = 2.84, 9.77 Hz, 1 H), 4.84-4.77 (dq, J = 2.99, 
9.77 Hz, 1 H), 4.64 (dt, J = 2.5, 7.67 Hz, 1H), 2.39 (s, 3 H), 1.07 (dt, J = 3.03, 15.05 Hz, 1 H), 
0.99 (dt, J = 2.99, 15.05 Hz, 1 H),  – 0.07 (s, 9H); 13C NMR (75 MHz, CDCl3) " 204.9, 142.99, 
139.3, 137.7, 129.2, 128.4, 127.7, 127.6, 127.1, 102.7, 80.5, 59.3, 21.4, 18.3, -1.3; IR (thin film) 
3276.5, 2953.6, 1955.4, 1329.6, 1161.7 cm-1; HRMS (MALDI) calcd for C21H27NO2SSi (M + 
Na) 408.1429, found 408.1439. 
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N-(1-(4-bromophenyl)-2-((trimethylsilyl)methyl)buta-2,3-dien-1-yl)-
4-methylbenzenesulfonamide (2.63b): Obtained as a clear oil (81 mg, 
0.17 mmol, 58%) 1H NMR (CDCl3, 300 MHz) " 1H NMR (CDCl3, 300 
MHz) " 7.55 (d, J = 8.42 Hz, 2 H), 7.31 (d, J = 8.42 Hz, 2 H), 7.17 (d, J = 8.01 Hz, 2 H),  7.06 
(d, J = 8.43 Hz, 2 H), 5.14 (d, J = 8.09 Hz, 1 H), 4.9 (dq, J = 2.87, 10.03 Hz, 1 H), 4.8 (dq, J = 
2.93, 10.09 Hz, 1 H), 4.59 (dt, J = 3.19, 7.36 Hz, 1H), 2.39 (s, 3 H), 1.15 (dt, J = 3.16, 15.01 Hz, 
1 H), 0.9 (dt, J = 2.9, 15.1 Hz, 1 H), -0.7 (s, 9 H); 13C NMR (75 MHz, CDCl3) " 204.7, 143.2, 
138.3, 137.5, 131.4, 129.4, 129.3, 127.1, 121.7, 102.3, 80.9, 58.8, 21.4, 18.3, -1.2;  IR (thin film) 
3276.6, 1957.5, 1334.0, 1163.3 cm-1; HRMS (MALDI) calcd for C21H26NO2SSi (M + Na) 
486.0535, found 486.0552. 
 
4-methyl-N-(1-(4-(trifluoromethyl)phenyl)-2-((trimethylsilyl) 
methyl)buta-2,3-dien-1-yl)benzenesulfonamide (2.63c): Obtained as 
a clear oil (27 mg, 0.06 mmol, 20%); 1H NMR (CDCl3, 300 MHz) " 
7.50 (d, J = 8.28 Hz, 2 H), 7.48 (d, J = 7.87 Hz, 2 H), 7.21 (d, J = 8.14 Hz, 2 H), 7.11 (d, J = 
8.14 Hz, 2 H), 5.16 (d, J = 7.17 Hz, 1 H), 4.93 (dq, J = 2.95, 10.15 Hz, 1 H), 4.87 (dq, J = 3.0, 
10.15 Hz, 1 H), 4.67 (dt, J =3.02, 7.26 Hz, 1H), 2.34 (s, 3 H), 1.16 (dt, J = 2.93, 15.06 Hz, 1 H), 
0.96 (dt, J = 2.70, 15.13 Hz, 1 H), -0.06 (s, 9 H); 13C NMR (75 MHz, CDCl3) " 204.6, 143.2, 
137.3, 129.2, 128.0, 127.0, 125.1 (q, J = 3.62) 102.2, 81.0, 58.9, 21.3, 18.3, -1.3; IR (thin film) 
2955.94, 1955.69, 1325.9, 1162.1 cm-1; HRMS (MALDI) calcd for C22H26F3NO2SSi (M + Na) 
476.1303, found 476.1292. 
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N-(1-(4-methoxyphenyl)-2-((trimethylsilyl)methyl)buta-2,3-dien-1-
yl)-4-methyl benzenesulfonamide (2.63d): Obtained as a clear oil 
(66 mg, 0.16 mmol, 53%) 1H NMR (CDCl3, 300 MHz) " 7.59 (d, J = 
8.45 Hz, 2 H), 7.18 (d, J = 7.74 Hz, 2 H),  7.06 (d, J = 9.45 Hz, 2 H),  6.47 (d, J = 8.80 Hz, 2 H), 
5.09 (d, J = 7.60 Hz, 1 H), 4.9 (dq, J = 3.0, 9.71 Hz, 1 H), 4.7 (dq, J = 3.0, 9.78 Hz, 1 H), 4.59 
(dt, J = 3.18, 7.54 Hz, 1H), 3.77 (s, 3H), 2.38 (s, 3 H), 1.16 (dt, J = 2.95, 15.21 Hz, 1 H), 0.89 
(dt, J = 2.71, 15.2 Hz, 1 H), -0.06 (s, 9 H); 13C NMR (75 MHz, CDCl3) " 201.8, 159.1, 142.8, 
137.8, 131.4, 129.2, 128.8, 127.2, 113.7, 102.7, 80.4, 58.8, 55.2, 21.4, 18.4, -1.2; IR (thin film) 
3277.4, 3032.9, 2897.9, 1955.6, 1327.6, 1160.6 cm-1; HRMS (MALDI) calcd for C22H29NO2SSi 
(M + Na) 438.1535, found 438.1555. 
 
 4-methyl-N-(1-phenyl-4-((trimethylsilyl)methyl)hexa-1,4,5-trien-3-
yl)benzenesulfon-amide (2.53e): Obtained as a clear oil (20 mg, 0.05 
mmol, 16%) 1H NMR (CDCl3, 300 MHz) " 7.71 (d, J = 8.45 Hz, 2 H), 
7.30-7.14 (m, 7 H), 6.33 (d, J = 15.74 Hz, 1 H), 5.76 (dd, J = 7.75, 15.56 Hz, 1 H), 4.83 (m, 2 
H), 4.77 (d, J = 8.07 Hz, 1 H), 4.21 (m, 1H), 2.34 (s, 3 H), 1.29 (dt, J = 1.29, 15.0 Hz, 1 H), 1.16 
(dt, J = 2.71, 15.12 Hz, 1 H), -0.02 (s, 9 H); 13C NMR (75 MHz, CDCl3) " 205.07, 143.2, 136.1, 
132.2, 129.4, 128.4, 127.8, 127.3, 127.2, 126.4, 101.1, 80.1, 58.0, 21.3, 18.07, -1.2; IR (thin 
film) 3271.9, 2953.05, 1953.8, 1328.9, 1160.6 cm-1 ; HRMS (-ESI) calcd for C23H29NO2SSi (M - 
H) 440.1610, found 410.1623. 
 
 4-methyl-N-(1-phenyl-4-((trimethylsilyl)methyl)hexa-4,5-dien-3-
yl)benzene-sulfonamide (2.63f): Obtained as a clear oil (103 mg, 0.25 
mmol, 84%) 1H NMR (CDCl3, 300 MHz) " 7.74 (d, J = 8.26 Hz, 2 H), 
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7.32-7.08 (m, 7 H), 4.82-4.63 (m, 3 H), 3.6 (m, 1H), 2.63 (dt, J = 5.84, 9.64 Hz, 2 H), 2.42 (s, 3 
H), 1.96 (m, 1 H), 1.73 (m, 1H), 1.14 (dt, J = 3.13, 15.27 Hz, 1 H), 0.9 (dt, J = 2.97, 15.22 Hz, 1 
H), -0.1 (s, 9 H); 13C NMR (75 MHz, CDCl3) " 205.4, 143.2, 141.4, 137.9, 129.4, 128.4, 128.3, 
127.3, 125.8, 101.7, 79.3, 55.9, 36.1, 31.6, 21.4, 17.6, -1.3;  IR (thin film) 3278.3, 1955.9, 
1332.7, 1162.5 cm-1; HRMS (MALDI) calcd for C23H31NO2SSi (M + Na) 436.1743, found 
436.1750. 
 
4-methyl-N-(1-(o-tolyl)-2-((trimethylsilyl)methyl)buta-2,3-dien-1-
yl)benzenesulfon-amide (2.63g): Obtained as a white solid (35 mg, 0.09 
mmol, 30%)  1H NMR (CDCl3, 300 MHz) " 7.59 (d, J = 8.43 Hz, 2 H), 7.16 
(J = 8.28 Hz, 2 H), 7.13-7.03 (m, 4 H), 4.96 (s, 2 H), 4.86 (m, 1H) 4.62 (m, 1 H), 2.38 (s, 3 H), 
2.33 (s, 3H), 1.16 (dt, J = 3.02, 15.13 Hz, 1 H), 0.89 (dt, J = 2.77, 15.16 Hz, 1 H), -0.05 (s, 0 H); 
13C NMR (75 MHz, CDCl3) " 205.3, 142.8, 137.9, 137.1, 136.4, 130.6, 129.1, 127.6, 127.3, 
127.1, 126.0, 102.5, 80.3, 56.1, 21.4, 19.1, 18.2, -1.3; IR (thin film) 3279.5, 1955.4, 1599.1, 
1330.9, 1161.2.8 cm-1; HRMS (+ESI) calcd for C19H21NO2S (M + Na) 422.1586, found 
422.1598. 
 
4-methyl-N-(1-(o-tolyl)penta-3,4-dien-1-yl)benzenesulfonamide 
(2.69g): Obtained as a white solid (34 mg, 0.10 mmol, 35%) 1H NMR 
(CDCl3, 300 MHz) " 7.53 (d, J = 8.28 Hz, 2H), 7.12 (d, J = 7.95 Hz, 2 
H), 7.09-6.98 (m, 4 H), 4.87 (d, J = 6.30 Hz, 1 H), 4.85 (quint, J = 7.02 Hz, 1H), 4.65 (m, 3 H), 
2.38 (m, 2H), 2.36 (s, 3H), 2.21 (s, 3 H); 13C NMR (75 MHz, CDCl3) " 209.7, 143.1, 138.2, 
137.4, 134.8, 130.3, 129.2, 127.2, 127.0, 126.1, 124.9, 85.1, 75.3, 53.5, 36.0, 21.4, 19.1; IR (thin 
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film) 3276.1, 1955.5, 1330.8, 1157.8 cm-1; HRMS (+ESI) calcd for C19H21NO2S (M + H) 
328.1371, found 328.1360. 
 
 4-methyl-N-(1-phenyl-5-(trimethylsilyl)pent-3-yn-1-
yl)benzenesulfon-amide (2.64): Obtained as a white solid. 1H 
NMR (CDCl3, 300 MHz) " 7.61 (d, J = 8.3 Hz, 2 H), 7.22-7.14 (m, 
7 H), 5.15 (d, J = 7.11 Hz, 1 H), 4.42 (q, J = 6.05 Hz, 1 H), 2.58 (dt, J = 2.69, 5.89 Hz, 2 H), 
2.39 (s, 3 H), 1.38 (t, J = 2.69 Hz, 2 H), – 0.03 (s, 9 H); 13C NMR (75 MHz, CDCl3) " 143.1, 
139.7, 137.3, 129.3, 128.3, 128.2, 127.6, 127.5, 127.1, 126.6, 82.1, 72.8, 56.0, 27.6, 21.4, 6.9, -
2.1; IR (thin film) 3257.4, 3031.8, 2223.0, 1330.0, 1161.1 cm-1; HRMS (ESI) calcd for 
C21H27NO2SSi (M + Na) 408.1429, found 408.1204. 
 
 N-(2-((dimethyl(phenyl)silyl)methyl)-1-phenylbuta-2,3-dien-1-yl)-4-
methylbenzenesulfonamide (2.66): Following the procedure described 
for the general synthesis of (silylmethyl)allenic amines. After the reaction 
mixture was stirred for 48 h as described in the general procedure, 2 M HCl (1 mL) and ethyl 
acetate (1 -2 mL) were added to the gray suspension and the green mixture was stirred for 1 h. 
The resulting mixture was extracted with 3 portions of ethyl acetate. Combined organic phases 
were washed with brine, dried over MgSO4 and concentrated under reduced pressure. The 
residue was purified by flash chromatography using a gradient of ethyl acetate in hexanes (0 to 
10%) to give the desired product as a white solid (69 mg, 0.15 mmol, 52%). 1H NMR (CDCl3, 
300 MHz) " 7.52 (d, J = 8.39 Hz, 2 H), 7.42-7.31 (m, 5H), 7.20-7.12 (m, 5 H), 7.01 (m, 2 H), 
4.99 (d, J = 7.6 Hz, 1 H), 4.83 (dq, J = 2.6, 9.86 Hz, 1 H), 4.7 (dq, J = 2.96, 9.97 Hz, 1 H), 4.57 
(dt, J =3.20, 7.66 Hz, 1H), 2.38 (s, 3 H), 1.43 (dt, J = 2.71, 15.2 Hz, 1 H), 1.17 (dt, J = 2.82, 
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15.1 Hz, 1 H), 0.23 (s, 3 H), 0.19 (s, 3 H); 13C NMR (75 MHz, CDCl3) " 205.03, 142.8, 139.1, 
138.2, 137.6, 133.5, 129.17, 129.11, 128.3, 127.7, 127.6, 127.5, 127.1, 102.2, 80.5, 59.1, 21.4, 
17.5, -2.7, -3.0; IR (thin film) 3774.3, 2954.6, 1955.4, 1329.2, 1161.3 cm-1; HRMS (MALDI) 
calcd for C26H29NO2SSi (M + Na) 470.1586, found 470.1601. 
 
 N-(5-(dimethyl(phenyl)silyl)-1-phenylpent-3-yn-1-yl)-4-
methyl-benzenesulfonamide (2.67): Inside a Nitrogen 
atmosphene Drybox, a mixture of CrCl2 (3.6 mg, 0.03 mmol) and 
Mn powder 325-mesh (33mg, 0.66 mmol) were added to a 2-dram vial. The vial was capped 
with a Teflon lid and it was removed from the drybox. The tosylimine  (0.3 mmol) was added to 
the mixture and the vial was flushed with argon. Dry THF (2 mL) was added via syringe and a 
brown suspension was formed. This was followed of (4-bromobut-2-yn-1-
yl)dimethyl(phenyl)silane (120 mg, 0.45 mmol). The mixture was stirred at room temperature 
for 48 h. 2 M HCl (1 mL) and ethyl acetate (1 -2 mL) were added to the gray suspension and the 
green mixture was stirred for 1 h. The resulting mixture was extracted with 3 portions of ethyl 
acetate. Combined organic phases were washed with brine, dried over MgSO4 and concentrated 
under reduced pressure to give a tan oil. The residue was purified by flash chromatography using 
a gradient of ethyl acetate in hexanes (0 to 10%) to give the desired product as a yellow oil (56 
mg, 0.12 mmol, 42%). 1H NMR (CDCl3, 300 MHz) " 7.58 (d, J = 8.15 Hz, 2 H), 7.49 (m, 2 H), 
7.39 (m, 3 H), 7.20-7.15 (m, 5 H), 7.09-7.05 (m, 2 H), 5.05 (d, J = 7.1 Hz, 1 H), 4.42 (q, J = 
5.65, 11.83 Hz, 1 H), 2.57 (dt, J = 2.6, 2.6, 5.6 Hz, 2 H), 2.39 (s, 3 H), 1.63 (t, J = 2.5 Hz, 2 H), 
0.29 (s, 3H), 0.27 (s, 3 H); 13C NMR (75 MHz, CDCl3) " 146.6, 143.1, 140.9, 136.9, 133.0, 
132.9, 132.8, 131.7, 131.4, 130.9, 130.5, 130.1; IR (thin film) 3276.6, 3067.6, 2223.2, 1330.6, 
1161.1 cm-1; HRMS (MALDI) calcd for C26H29NO2SSi (M + Na) ) 470.1586, found 470.3550. 
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(5-vinylidenehex-2-yne-1,6-diyl)bis(trimethylsilane) (2.5b):  
Obtained as a clear oil 1H NMR (CDCl3, 300 MHz) " 4.69 (q, J = 
2.82 Hz, 2 H), 2.87 (q, J = 2.93 Hz, 2 H), 1.46 (t, J = 2.72 Hz, 2 H), 
1.42 (t, J = 2.56 Hz, 2 H), 0.10 (s, 9 H), 0.05 (s, 9H); 13C NMR (75 MHz, CDCl3) " 206.4, 101.8, 
97.8, 79.2, 75.5, 25.6, 20.1, 7.0, -1.1, -2.0; IR (thin film) 2955.5, 2895.8, 2220.5, 1957.9, 1416.6 
cm-1; HRMS (MALDI) calcd for C14H26Si2 (M - H) 449.1489, found 249.1482. 
 
2.5.17 General Method for the preparation of 2-aminomethyl-1,3-dienes 
 Allene (0.21mmol) was dissolved in THF (2 mL). TBAF (1M in THF, 0.21 mL, 0.21 
mmol) was added and the solution. After 3h an extra equivalent of TBAF (1M in THF, 0.21 mL, 
0.21 mmol) was added and the mixture was stirred for 21 hours at r.t. The yellow solution was 
filtered though a path of silica using ethyl acetate as eluent. The filtrate was concentrated under 
reduced pressure and the residue was purified by column chromatography using a gradient of 
ethyl acetate in hexanes (0 to 12%) to afford the desired diene. 
 
4-methyl-N-(2-methylene-1-phenylbut-3-en-1-yl)benzenesulfonamide 
(2.70a): Obtained as a white solid (53 mg, 0.17 mmol, 81%). 1H NMR 
(CDCl3, 300 MHz) " 7.68 (d, J = 8.43 Hz, 2 H), 7.23  (m, 5 H) 7.16 (m, 2 
H), 6.18 (dd,  J = 11.42, 17.72 Hz, 1 H), 5.26-5.22 (m, 3 H), 5.13 (d, J = 0.78 Hz, 1 H), 5.08 (d, 
J = 17.96 Hz, 1 H), 5.02 (d, J = 11.46 Hz, 1 H), 4.84 (d, J = 7.91 Hz, 1H) 2.4 (s, 3 H); 13C NMR 
(75 MHz, CDCl3) " 144.4, 143.2, 139.0, 137.4, 135.5, 129.4, 128.5, 127.7, 127.2, 127.1, 118.2, 
116.0, 58.6, 21.5; IR (thin film) 3283.1, 1636.9, 1598.7, 1326.1, 1159.8 cm-1; ; HRMS (ESI) 
calcd for C18H19NO2S (M + Na) 336.1034, found 336.1028. 
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N-(1-(4-bromophenyl)-2-methylenebut-3-en-1-yl)-4-methylbenzene-
sulfonamide (2.70b): Obtained as a white solid (49 mg, 0.13 mmol, 
65%, 74% conversion). 1H NMR (CDCl3, 300 MHz) " 7.61 (d, J = 8.30 
Hz, 2 H), 7.33 (d, J = 8.56 Hz, 2 H), 7.21 (d, J = 8.56 Hz, 2 H), 7.02 (d, J = 8.56 Hz, 2 H), 6.18 
(dd, J = 11.27, 17.66 Hz, 1 H), 5.24-4.99 (m, 6 H), 2.42 (s, 3H); 13C NMR (75 MHz, CDCl3) " 
144.1, 143.5, 138.0, 135.2, 131.5, 129.4, 128.9, 127.2, 121.6, 118.6, 116.3, 58.0, 21.5; IR (thin 
film) 3277.0, 1597.1, 1327.8, 1184.3 cm-1; HRMS (-ESI) calcd for C18H18BrNO2S (M - H) 
390.0163, found 390.0175. 
 
 N-(1-(4-methoxyphenyl)-2-methylenebut-3-en-1-yl)-4-
methyl 
benzene-sulfonamide (2.70d): Obtained as a white solid (53 mg, 0.16 
mmol, 84%). 1H NMR (CDCl3, 300 MHz) " 7.64 (d, J = 8.53 Hz, 2 H), 7.21 (d, J = 8.14 Hz, 2 
H), 7.02 (d, J = 9.31 Hz, 2 H), 6.72 (d, J = 8.53 Hz, 2 H), 6.19 (dd, J = 11.33, 18.03 Hz, 1 H), 
5.22 (s, 1 H), 5.17 (d, J = 7.69 Hz, 1 H), 5.15 (s, 1 H), 5.05 (d, J = 17.94 Hz, 1H), 5.00 (d, J = 
11.35 Hz, 1 H) 4.88 (d, J = 6.96 Hz, 1 H), 3.79 (s, 3 H), 2.41 (s, 3H); 13C NMR (75 MHz, 
CDCl3) " 159.1, 144.5, 143.2, 137.5, 135.6, 131.1, 129.3, 128.4, 127.2, 117.8, 115.8, 113.9, 
58.0, 55.2, 21.5; IR (thin film) 3434.6, 1610.8, 1510.6, 1323.0, 1158.2 cm-1; HRMS (-ESI) calcd 
for C19H21NO3S (M + Li) 350.1402, found 350.1408. 
 
4-methyl-N-(4-methylene-1-phenylhex-5-en-3-yl)benzenesulfonamide 
(2.70f): Obtained as a white solid (78 mg, 0.23 mmol, 92%). 1H NMR 
(CDCl3, 300 MHz) " 7.73 (d, J = 8.30 Hz, 2 H), 7.31-7.20 (m, 5H), 7.11 
(d, J = 6.84 Hz, 2 H), 6.15 (dd, J = 10.93, 17.77 Hz, 1 H), 5.17 (d, J = 8.10 Hz, 1 H), 5.05 (d, J = 
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17.96 Hz, 1H), 5.03 (s, 1 H), 5.0 (d, J = 11.99 Hz, 1 H), 4.89 (s, 1H), 4.09 (q, J = 7.24 Hz,  1H), 
2.62 (m, 2 H), 2.44 (s, 3 H), 1.92 (m, 2 H); 13C NMR (75 MHz, CDCl3) " 145.4, 142.2, 141.0, 
137.7, 135.5, 129.4, 128.5, 128.4, 127.2, 126.0, 115.7, 114.8, 54.4, 37.1, 31.9, 21.5; IR (thin 
film) 3276.2, 2864.0, 1597.1, 1318.1, 1162.2 cm-1; HRMS (+ESI) calcd for C20H2NO2S (M + H) 
342.1528, found 342.1537.  
 
4-methyl-N-(2-methylene-1-(o-tolyl)but-3-en-1-yl)benzenesulfonamide 
(2.70g): Obtained as a white solid (24 mg, 0.073 mmol, 73%). 1H NMR 
(CDCl3, 300 MHz) " 7.59 (d, J = 8.47 Hz, 2 H), 7.16 (d, J = 8.28 Hz, 2 H), 
7.11-6.94 (m, 4 H), 6.26 (dd, J = 11.18, 17.89 Hz, 1 H), 5.52 (d, J = 6.96 Hz, 1 H), 5.19 (d, J = 
17.57 Hz, 1 H), 5.19 (s, 1 H), 5.04 (d, J = 11.10 Hz, 1H), 4.88 (s, 1 H), 4.74 (d, J = 7.12 Hz, 1 
H), 2.37 (s, 3 H), 2.22 (s, 3H); 13C NMR (75 MHz, CDCl3) " 144.4, 143.1, 137.7, 136.7, 135.9, 
135.7, 130.6, 129.6, 127.6, 127.1, 126.6, 125.9, 118.6, 115.3, 54.6, 21.4, 18.9; IR (thin film) 
3271.0, 3064.0, 1595.5, 1318.8, 1185.6 cm-1; HRMS (+ESI) calcd for C19H21NO3S (M + H) 
328.1371, found 328.1379. 
 
2.5.18 General Method for the preparation of functionalized 1,3-dienes  
 The allene (0.15 mmol) was dissolved in CH2Cl2 (1 mL) and cooled to –78°C. Then, a 
solution of dimethylacetal benzaldehyde (0.16 mmol) and BF3·Et2O (0.16 mmol) in CH2Cl2 (1 
mL) was added to the allene solution dropwise followed by one extra mL of CH2Cl2. The 
mixture was stirred at –78°C for one hour. After this time, one more portion of dimethylacetal 
benzaldehyde (0.8 mmol) and BF3·Et2O (0.8 mmol) were added to the reaction mixture.  More 
acid and acetal (1 equiv) may be added to accelerate the reaction. Reaction was monitored by 
TLC and after completion, a saturated solution of NaHCO3 (1 mL) and ethyl acetate (1 mL) were 
HN
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CH3
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added to the red solution.  The mixture was extracted with three portions of ethyl acetate. The 
combined organic phased were washed with brine, dried over MgSO4 and concentrated under 
reduced pressure. The residue was purified by column chromatography  (0 to 12 % ethyl acetate 
in hexanes) to give the desired diene.  
 
N-(3-(methoxy(phenyl)methyl)-2-methylene-1-phenylbut-3-en-1-yl)-
4-methylbenzenesulfonamide (2.73a):  Obtained as a clear oil (60 mg, 
0.13 mmol, 92%). 1H NMR (CDCl3, 300 MHz) " 7.53 (d, J = 7.53 Hz, 
2H), 2.33- 7.12 (m, 10 H), 7.01 (m, 2H), 5.19-4.85 (m, 6H), 4.70 (s, 1 H), 3.24 (d, J = 0.56 Hz, 3 
H), 2.38 (s, 3 H); 13C NMR (75 MHz, CDCl3) " 145. 4, 145.0, 143.0, 139.0, 139.1, 137.4, 129.3, 
128.3, 127.8, 127.5, 127.4, 127.3, 117.4, 116.5, 85.0, 60.4, 56.9, 21.5; IR (thin film) 3278.0, 
3062.0, 1598.7, 1327.5, 1185.7 cm-1; HRMS (+ESI) calcd for C26H27NO3S (M + Li) 440.1872, 
found 440.1861. 
 
N-(1-(4-bromophenyl)-3-(methoxy(phenyl)methyl)-2-methylene 
but-3-en-1-yl)-4-methylbenzenesulfonamide (2.73b): Obtained as 
a clear oil (43 mg, 0.084 mmol, 93%). 1H NMR (CDCl3, 300 MHz) 
" 7.5 (d, J = 8.21 Hz, 2 H),  7.33-7.12 (m, 10 H), 6.88 (d, J = 8.41 Hz, 2 H), 5.17-5.91 (m, 5 H), 
4.81 (s, 1 H), 4.70 (s, 1H), 3.26 (s, 3H), 2.40 (s, 2 H); 13C NMR (75 MHz, CDCl3) " 145.3, 
144.8, 143.33, 139.1, 138.1, 137.2, 131.3, 129.3, 129.2, 129.0, 128.3, 127.9, 127.2, 127.1, 117.8, 
116.9, 85.2, 60.0, 56.9, 21.5; IR (thin film) 3278.3, 3088.8, 1599.5, 1332.3, 1187.4 cm-1; HRMS 
(+ESI) calcd for C26H26BrNO3S (M + Li) 518.0977 found 518.0971. 
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N-(3-(methoxy(phenyl)methyl)-1-(4-methoxyphenyl)-2-
methylenebut-3-en-1-yl)-4-methylbenzenesulfonamide (2.73c): 
 Obtained as a clear oil (49 mg, 0.10 mmol, 95%). 1H NMR 
(CDCl3, 300 MHz) " 7.56 (d, J = 8.21 Hz, 2 H), 7.39-7.15 (m, 8 H), 6.95 (d, J = 8.7 Hz, 2H), 
6.72 (d, J = 8.7 Hz, 2 H), 5.20-4.93 (m, 6 H), 4.73 (s, 1H), 3.78 (s, 3H), 3.28 (s, 3H), 2.42 (s, 3 
H); 13C NMR (75 MHz, CDCl3) " 159.0, 145.4, 145.4, 145.1, 143.0, 139.5, 139.5, 137.5,  131.2, 
129.3, 128.3, 127.8, 127.3, 127.2, 116.5, 113.7, 85.1, 59.8, 56.9, 55.2, 21.5; IR (thin film) 
3279.6, 3062.0, 1599.4, 1325.4, 1159.7 cm-1; HRMS (+ESI) calcd for C27H29NO4S (M + Li) 
470.1977 found 470.1971. 
 
N-(5-(methoxy(phenyl)methyl)-4-methylene-1-phenylhex-5-en-3-
yl)-4-methylbenzenesulfonamide: Obtained as a clear oil (79 mg, 
0.17 mmol, 78%). 1H NMR (CDCl3, 300 MHz) " 7.62 (d, J = 8.32 Hz, 2 H), 7.35-7.18 (m, 10 
H), 7.07 (d, J = 8.9 Hz, 2H), 5.30 (d, J = 7.85 Hz, 1H), 5.16 (s, 1H), 5.04 (s, 1H), 4.9 (s, 1H), 
4.83 (s, 1H), 4.7 (s, 1H), 4.0 (q, J = 7.15 Hz, 1H), 3.3 (s, 3H), 2.51 (m, 2H), 2.43 (s, 3H), 1.77 
(m, 2H); 13C NMR (75 MHz, CDCl3) " 146.7, 146.1, 143.0, 141.2, 139.2, 137.8, 129.4, 128.5, 
128.3, 128.2, 127.8, 127.3, 127.2, 125.9, 115.7, 115.3, 84.7, 56.9, 56.2, 36.7, 31.8, 21.5; IR (thin 
film) 3282.7, 3085.7, 1599.5, 1323.5, 1158.4 cm-1; HRMS (+ESI) calcd for C28H31NO3S (M + 
Li) 468.2185 found 468.2177. 
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3.  SUMMARY AND CONCLUSIONS 
 
 In summary, we have developed a highly regioselective, efficient method for the 
synthesis of (trimethylsilyl)methylallenic alcohols and shown their further transformation into 
1,3-butadien-2-ylcarbinols. Allenic alcohols were obtained from the chromium-catalyzed 
nucleophilic addition of (4-bromobut-2-yn-1-yl)trimethylsilane to aldehydes in a Nozaky-
Hiyama-Kishi type reaction. The use of (4-bromobut-2-yn-1-yl)trimethylsilane as a diene 
equivalent, strongly favors the formation of homoallenyl alcohols over their propargylic isomers.  
Several analogues of the bis(oxazoline) carbazole compounds were synthesized the coupling of 
di-halocarbazoles and a variety of boronic acids, followed by halogenation, carbonylative 
amidation and cyclization. Bis(oxazoline) carbazoles are good ligands for this chromium-
catalyzed addition reaction, affording chiral alcohols in generally good yields and 
enantioselectivities. Versatile allenic alcohol adducts can be succesfully converted to 1,3-
butadien-2-ylcarbinols by desilylation using TBAF or iodinated for further functionalization.  
In addition, we have developed a method for the synthesis of 3° 1,3-butadien-2-ylcarbinols from 
the chromium-catalyzed addition of (4-bromobut-2-ynyl)trimethylsilane to ketones. This is, to 
the best of our knowledge, the first chromium-catalyzed nucleophilic addition to ketones to 
afford 3° allenylalcohols.   
 Finally, the scope of this method was expanded of the synthesis 2-aminomethyl-1,3-
dienes from tosyl-imines. The presence of an electron withdrawing tosyl group is fundamental to 
increase the reactivity of the imines towards nucleophilic additions. Interestingly, the 
regioselectivity of the allenylation reaction was drastically affected by the presence of a bulky 
tosyl group in the substrate leading to the formation of regioisomeric mixtures not observed 
previously.  The nature of the substituent in the imine affects the isomer ratio, with smaller 
substituents favoring the formation of the desired allenic amine. Allenic imines were desilylated 
 131 
for the synthesis of 2-aminomethyl-1,3-dienes and furthermore, other electrophiles such as 
(dimethoxymethyl)benzene can be used in the preparation of more complex 1,2-dienes.  
 The development of this methodology provided a novel route for the preparation of a 
variety of highly functionalized 1,3-dienes. Thus, making this transformation a valuable tool for 
the synthesis of more complex organic compounds.  
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